Ocular device delivery methods and systems

Abstract

The present disclosure provides an ophthalmic article. The ophthalmic article may comprise a biocompatible matrix comprising a copolymer derived from a caprolactone monomer and at least one other monomer. The ophthalmic article may also comprise an active agent or a diagnostic agent. The ophthalmic article may be configured to associate to a haptic of an intraocular lens (IOL).

Description

CROSS-REFERENCE

[0001] This application claims priority to and the benefit of U.S. Provisional Patent Application Serial No. 62 / 867,233, filed June 27, 2019 and U.S. Provisional Patent Application Serial No. 63 / 012,994, filed April 21, 2020, each of which is entirely incorporated herein by reference. BACKGROUND

[0002] Cataract surgery is the second most common outpatient surgical procedure in the United States. Patients who undergo cataract surgery may receive a postoperative regimen of topical eye drops to be self-administered for many weeks following cataract surgery. These eye drops usually consist of an antibiotic agent to prevent infection and a corticosteroid and / or nonsteroidal anti-inflammatory drug (NSAID) to prevent inflammation.

[0003] Compliance with postoperative eye drop regimens among patients (e.g., elderly patients) undergoing cataract surgery may be difficult. Typical postoperative prophylaxis for cataract surgery can comprise a complex and lengthy regimen of corticosteroid, non-steroidal anti-inflammatory drugs (NSAIDs) and antibiotic eye drops. In addition to their visual impairment, patients, especially the elderly population, may have physical and cognitive deficits that limit their ability to read labels, follow directions and physically instill eye drops into their own eyes. Furthermore, many elderly patients live alone and cannot rely on a caregiver to administer their medications. There is therefore a need to develop systems that automatically deliver drug to the eye and eliminate the issue of patient non-compliance.

[0004] Drug penetration into the eye by topical eye drops may be inefficient. It is estimated that only 1-3% of any drop actually penetrates the eye, and once inside the eye, such drugs are cleared very rapidly. This can result in a pulsatile delivery profile that does not provide continuous coverage by the dispensed medication. A more efficient approach may be to release a drug inside the eye closer to the target tissue and with continuous release kinetics.

[0005] A cataract is an opacification of the crystalline lens inside of the eye that interferes with visual function. Cataracts occur as a normal part of aging, and also as a side effect of some medications, systemic diseases and hereditary conditions. However, cataracts may also be related to eye trauma, long-term diabetes, corticosteroid medications or radiation treatments. The standard treatment for cataracts may be a surgical procedure in which the opacified lens is removed and replaced with an artificial lens (e.g., an intraocular lens) made of transparent acrylic or other synthetic material.

[0006] Intraocular lens (IOL) devices are comprised of two parts, the central optic and the haptics. The optic is the lens portion in the center of the IOL. Haptics are flexible arms that stabilize the IOL inside the lens capsule of the eye. The cataract surgery employs foldable IOLs, which can be injected into the eye using very small incisions (2.2 to 2.8 mm). As a result, sutures are not usually required to close the eye after cataract surgery.

[0007] lOL-based drug delivery strategies have been investigated previously, but none have succeeded in engineering such a system without significantly modifying the IOL design, requiring changes to the usual surgical technique or adding additional steps to manufacturing process. For example, one prior IOL comprised two dexamethasone-PLGA pellets embedded in the optic, but implantation required a 6 mm wound with two sutures, which is three times the size of the current standard for sutureless corneal incisions. Thus, this approach is not practical for modem cataract surgery.

[0008] Prior ring-shaped drug-release devices were attached to haptics of a 3-piece IOL, but its size and rigidity were not compatible with standard cataract surgery technique because the device required delivery through a larger comeal incision than is currently used. Thus, this approach was also not ideal.

[0009] Other prior approaches required soaking IOLs in drug solutions prior to surgery but this approach is limited by compatibility of specific drugs with specific IOL matrix materials (e.g., water soluble antibiotics with acrylic lenses; corticosteroids with silicone lenses). Furthermore, this approach does not offer controlled release; rather, it is purely diffusion limited burst release.

[0010] In another example, a system was previously proposed, in which an ultra-thin transparent film that releases a drug is manufactured on the surface of the IOL without disrupting the optical properties of the lens. While it is plausible that this device could provide adequate drug release function and not require changes to the usual cataract surgical procedure, this system adds additional steps to the manufacturing process which has implications for the overall cost of goods. Furthermore, it is not readily applied to IOLs of varying sizes, shapes and refractive powers or material, and to do so would require the manufacturers to add this feature to each individual make and model of IOL separately.

[0011] Improved ophthalmic articles, devices, methods, systems, and kits for delivery or administration of active agents and / or diagnostic agents from an ocular device to an eye and / or that address at least some of the above disadvantages would be desirable. SUMMARY

[0012] Embodiments of the present disclosure provide articles, methods, devices, systems, and kits for intraocular agent (e.g., active agent and / or diagnostic agent) delivery. The present disclosure provides articles, methods, systems, and kits for delivery or administration of active agents and / or diagnostic agents from an ocular device to an eye. The present disclosure also provides articles, methods, systems, and kits for diagnosis and / or treatment of ocular diseases, conditions, and / or complications.

[0013] In an aspect, the present disclosure provides an ophthalmic article. In one embodiment, the ophthalmic article comprises: (a) a biocompatible matrix comprising a copolymer derived from a caprolactone monomer and at least one other monomer; and (b) an active agent or a diagnostic agent; wherein the ophthalmic article is configured to associate to a haptic of an intraocular lens (IOL). In some embodiments, the copolymer is derived from about 20 wt% to about 60 wt% of the caprolactone monomer and from about 40 wt% to 80 wt% of the at least one other monomer. In some embodiments, the copolymer is derived from about 40 wt% of the caprolactone monomer and about 60 wt% of the at least one other monomer. In some embodiments, the at least one other monomer is lactide, glycolide, or trimethylene carbonate. In some embodiments, the copolymer is a random copolymer, a block copolymer, or a gradient copolymer. In some embodiments, the biocompatible matrix is a random copolymer, a block copolymer, or a gradient copolymer. In some embodiments, the copolymer comprises a random copolymer. In some embodiments, the biocompatible matrix is biodegradable. In some embodiments, ophthalmic article has a tensile strength of at least about 0.5 megapascal (MPa). In some embodiments, ophthalmic article has a tensile strength from about 25 MPa to 35 MPa. In some embodiments, the ophthalmic article has a glass transition temperature of at most about 24°C as measured by differential scanning calorimetry. In some embodiments, the ophthalmic article has a glass transition temperature from about -20°C to 24°C as measured by differential scanning calorimetry. In some embodiments, the ophthalmic article has an elasticity modulus of at most about 3 MPa. In some embodiments, the ophthalmic article has an elasticity modulus from about 0.5 MPa to 3 MPa. In some embodiments, the ophthalmic article has an elongation at break of at least about 100% as measured by tensile testing. In some embodiments, the ophthalmic article has an elongation at break from about 500% to 1500% at from about 18 °C to 24 °C. In some embodiments, the shape of the ophthalmic article is an annulus, an extruded annulus, a torus, or a prism with a hole in the center. In some embodiments, the prism is a round prism, rectangular prism, a prism with three or more sides, or a prism with another shape. In some embodiments, the ophthalmic article comprises an internal structure for associating around the haptic of the IOL. In some embodiments, a perimeter or widest dimension of the internal structure is less than or equal to a perimeter or widest dimension of the haptic of the IOL. In some embodiments, a perimeter of the internal structure is less than or equal to a perimeter of the haptic of the IOL. In some embodiments, a widest dimension of the internal structure is less than or equal to a widest dimension of the haptic of the IOL. In some embodiments, the ophthalmic article extends no more than about 0.32 mm beyond the haptic of the IOL once the ophthalmic article is associated to the haptic of the IOL. In some embodiments, a shape of the internal structure is the same as a shape of the haptic of the IOL. In some embodiments, the ophthalmic article comprises an internal structure for securing around a notched region of the haptic of the IOL. In some embodiments, the ophthalmic article comprises an outer diameter of at most 1.5 mm. In some embodiments, the ophthalmic article comprises an internal hole with a diameter of at most 0.7 mm. In some embodiments, the active agent is an interocular pressure (IOP) lowering agent, corticosteroid, non-steroidal anti-inflammatory drug, antibiotic, antiviral, antimetabolite, antifungal, antifibrotic agent, or angiogenesis inhibitor. In some embodiments, the active agent is dexamethasone, ketorolac, diclofenac, moxifloxacin, travoprost, 5-fluorouracil, or methotrexate. In some embodiments, the ophthalmic article is configured such that the active agent or diagnostic agent is released from the biocompatible matrix. In some embodiments, the active agent or diagnostic agent is released from the biocompatible matrix over at least about 7 days. In some embodiments, active agent or diagnostic agent is released from the biocompatible matrix over from about 5-30 days, 5-21 days, 5-14 days, 5-10 days, 7-30 days, 7-21 days, 7-14 days, or 7-10 days. In some embodiments, the active agent or diagnostic agent is released from the biocompatible matrix through degradation of the biocompatible matrix. In some embodiments, the biocompatible matrix is sufficiently compressible such that it is compatible with injection through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is sufficiently flexible such that it is compatible with injection through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, biocompatible matrix is sufficiently elastic such that it recovers its original shape after injection through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, biocompatible matrix is sufficiently elastic such that the ophthalmic article recovers its shape once implanted inside an eye. In some embodiments, ophthalmic article is sufficiently physically stable in a physiologic environment such that it does not significantly change shape within at least 7 days after implantation of the ophthalmic article in an eye of a subject. In some embodiments, the ophthalmic article comprises from about 1 pg to 800 pg of the one or more active agents and / or diagnostic agent.

[0014] In another aspect, the present disclosure provides an ophthalmic article. In one embodiment, the ophthalmic article comprises (a) a biocompatible material; and (b) an active agent or a diagnostic agent, wherein the ophthalmic article has an equivalent elasticity, compressibility, tensile strength, shape recovery, or reshapability to another article comprising a biocompatible matrix comprising a copolymer derived from about 40 wt% of a caprolactone monomer and about 60 wt% of a lactide monomer, and wherein the ophthalmic article is configured to associate to a haptic of an intraocular lens (IOL). In some embodiments, the biocompatible material comprises a copolymer matrix. In some embodiments, the biocompatible material comprises a copolymer derived from about 20 wt% to about 60 wt% of a caprolactone monomer and from about 40 wt% to 80 wt% of at least one other monomer. In some embodiments, the at least one other monomer is lactide, glycolide, or trimethylene carbonate. In some embodiments, the biocompatible material or the another article comprising the biocompatible matrix comprises a random copolymer, a block copolymer, or a gradient copolymer. In some embodiments, the biocompatible material or the another article comprising the biocompatible matrix comprises a random copolymer. In some embodiments, the biocompatible material or the another article comprising the biocompatible matrix is biodegradable. In some embodiments, the another article comprises another active agent or diagnostic agent. In some embodiments, the another article comprising the biocompatible matrix has a tensile strength of at least about 0.5 megapascal (MPa). In some embodiments, the another article comprising the biocompatible matrix has a tensile strength from about 25 MPa to 35 MPa. In some embodiments, the another article comprising the biocompatible matrix has a glass transition temperature of at most about 24°C as measured by differential scanning calorimetry. In some embodiments, the another article comprising the biocompatible matrix has a glass transition temperature from about -20°C to 24°C as measured by differential scanning calorimetry. In some embodiments, the another article comprising the biocompatible matrix has an elasticity modulus of at most about 3 MPa. In some embodiments, the another article comprising the biocompatible matrix has an elasticity modulus from about 0.5 MPa to 3 MPa. In some embodiments, the another article comprising the biocompatible matrix has an elongation at break of at least about 100% as measured at from about 18 °C to 24 °C. In some embodiments, the another article comprising the biocompatible matrix has an elongation at break from about 500% to 1500% at from about 18 °C to 24 °C. In some embodiments, a shape of the ophthalmic article is an annulus, an extruded annulus, a torus, or a prism with a hole in the center. In some embodiments, the prism is a round prism, rectangular prism, a prism with three or more sides, or a prism with another shape. In some embodiments, the ophthalmic article comprises an internal structure for associating around the haptic of the IOL. In some embodiments, a perimeter or widest dimension of the internal structure is less than or equal to a perimeter or widest dimension of the haptic of the IOL. In some embodiments, a perimeter of the internal structure is less than or equal to a perimeter of the haptic of the IOL. In some embodiments, a widest dimension of the internal structure is less than or equal to a widest dimension of the haptic of the IOL. In some embodiments, the ophthalmic article extends no more than about 0.32 mm beyond the haptic of the IOL once the ophthalmic article is associated to the haptic of the IOL. In some embodiments, a shape of the internal structure is the same as a shape of the haptic of the IOL. In some embodiments, the ophthalmic article comprises an internal structure for securing around a notched region of the haptic of the IOL. In some embodiments, the ophthalmic article comprises an outer diameter of at most 1.5 mm. In some embodiments, the ophthalmic article comprises an internal hole with a diameter of at most 0.7 mm. In some embodiments, the active agent is an interocular pressure (IOP) lowering agent, corticosteroid, non-steroidal anti-inflammatory drug, antibiotic, antiviral, antimetabolite, antifungal, antifibrotic agent, or angiogenesis inhibitor. In some embodiments, the active agent is dexamethasone, ketorolac, diclofenac, moxifloxacin, travoprost, 5-fluorouracil, or methotrexate. In some embodiments, the ophthalmic article is configured such that the active agent or diagnostic agent is released from the biocompatible material. In some embodiments, the active agent or diagnostic agent is released from the biocompatible material over at least about 7 days. In some embodiments, the active agent or diagnostic agent is released from the biocompatible material over from about 5-30 days, 5-21 days, 5-14 days, 5-10 days, 7-30 days, 7-21 days, 7-14 days, or 7-10 days. In some embodiments, the active agent or diagnostic agent is released from the biocompatible material through degradation of the biocompatible material. In some embodiments, the ophthalmic article or the another article comprising the biocompatible matrix is sufficiently compressible such that it is compatible with injection through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, ophthalmic article or the another article comprising the biocompatible matrix is sufficiently flexible such that it is compatible with injection through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the ophthalmic article or the another article comprising the biocompatible matrix is sufficiently elastic such that it recovers its original shape after injection through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is sufficiently elastic such that the ophthalmic article recovers its shape once implanted inside an eye. In some embodiments, the ophthalmic article is sufficiently physically stable in a physiologic environment such that it does not significantly change shape within at least 7 days after implantation of the ophthalmic article in an eye of a subject. In some embodiments, the ophthalmic article comprises from about 1 pg to 800 pg of the one or more active agents and / or diagnostic agents.

[0015] In an aspect, the present disclosure provides an ophthalmic system. In one embodiment, the ophthalmic delivery system comprises (a) one or more ophthalmic articles comprising (1) a biocompatible matrix comprising a copolymer derived from a caprolactone monomer and at least one other monomer, and (2) one or more active agents or diagnostic agents; and (b) one or more intraocular lenses (IOL) comprising one or more haptics, wherein the one or more ophthalmic articles is associated to the one or more haptics of the IOL. In some embodiments, about one of the one or more ophthalmic articles is associated with the one or more haptics of the IOL. In some embodiments, about two of the one or more ophthalmic articles are associated with the one or more haptics of the IOL. In some embodiments, about 3, 4, 5, 6, 7, 8, 9, or 10 of the one or more ophthalmic articles are associated with the one or more haptics of the IOL. In some embodiments, about one of the one or more ophthalmic articles is associated with one of the one or more haptics of the IOL. In some embodiments, two of the one or more ophthalmic articles are associated with one of the one or more haptics of the IOL. In some embodiments, about 3, 4, 5, 6, 7, 8, 9, or 10 of the one or more ophthalmic articles are associated with one of the one or more haptics of the IOL. In some embodiments, the copolymer is derived from about 20 wt% to about 60 wt% of the caprolactone monomer and from about 40 wt% to 80 wt% of the at least one other monomer. In some embodiments, the copolymer is derived from about 40 wt% of the caprolactone monomer and about 60 wt% of the at least one other monomer. In some embodiments, the at least one other monomer is lactide, glycolide, or trimethylene carbonate. In some embodiments, the copolymer is a random copolymer, a block copolymer, or a gradient copolymer. In some embodiments, copolymer is a random copolymer. In some embodiments, the biocompatible matrix is biodegradable. In some embodiments, the one or more ophthalmic articles has a tensile strength of at least about 0.5 megapascal (MPa). In some embodiments, the one or more ophthalmic articles has a tensile strength from about 25 MPa to 35 MPa. In some embodiments, the one or more ophthalmic articles has a glass transition temperature of at most about 24°C as measured by differential scanning calorimetry. In some embodiments, the one or more ophthalmic articles has a glass transition temperature from about - 20°C to 24°C as measured by differential scanning calorimetry. In some embodiments, the one or more ophthalmic articles has an elasticity modulus of at most about 3 MPa. In some embodiments, the one or more ophthalmic articles has an elasticity modulus from about 0.5 MPa to 3 MPa. In some embodiments, the one or more ophthalmic articles has an elongation at break of at least about 100% as measured by tensile testing. In some embodiments, the one or more ophthalmic articles has an elongation at break from about 500% to 1500% at from about 18 °C to 24 °C. In some embodiments, a shape of the one or more ophthalmic articles is an annulus, an extruded annulus, a torus, or a prism with a hole in the center. In some embodiments, the prism is a round prism, rectangular prism, a prism with three or more sides, or a prism with another shape. In some embodiments, the active agent is an interocular pressure (IOP) lowering agent, corticosteroid, non-steroidal anti-inflammatory drug, antibiotic, antiviral, antimetabolite, antifungal, antifibrotic agent, or angiogenesis inhibitor. In some embodiments, the active agent is dexamethasone, ketorolac, diclofenac, moxifloxacin, travoprost, 5-fluorouracil, or methotrexate. In some embodiments, the one or more ophthalmic articles comprises an internal structure for associating around the one or more haptics of the IOL. In some embodiments, a perimeter or widest dimension of the internal structure is less than or equal to a perimeter or widest dimension of the haptic of the IOL. In some embodiments, a perimeter of the internal structure is less than or equal to a perimeter of the one or more haptics of the IOL. In some embodiments, a widest dimension of the internal structure is less than or equal to a widest dimension of the one or more haptics of the IOL. In some embodiments, the one or more ophthalmic articles extends no more than about 0.32 mm beyond the one or more haptics of the IOL once the one or more ophthalmic articles is associated to the one or more haptics of the IOL. In some embodiments, a shape of the internal structure is the same as a shape of the one or more haptics of the IOL. In some embodiments, the one or more ophthalmic articles comprises an internal structure for securing around a notched region of the one or more haptics of the IOL. In some embodiments, the one or more ophthalmic articles comprises an outer diameter of at most 1.5 mm. In some embodiments, the one or more ophthalmic articles comprises an inner diameter of at most 0.7 mm. In some embodiments, the one or more ophthalmic articles is configured such that the active agent or diagnostic agent is released from the biocompatible matrix. In some embodiments, the active agent or diagnostic agent is released from the biocompatible matrix over at least about 7 days. In some embodiments, the active agent or diagnostic agent is released from the biocompatible matrix over from about 5-30 days, 5-21 days, 5-14 days, 5-10 days, 7-30 days, 7-21 days, 7-14 days, or 7-10 days. In some embodiments, the active agent or diagnostic agent is released from the biocompatible matrix through degradation of the biocompatible matrix. In some embodiments, the biocompatible matrix is sufficiently compressible such that it is compatible with injection through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is sufficiently flexible such that it is compatible with injection through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is sufficiently elastic such that it recovers its original shape after injection through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is sufficiently elastic such that the ophthalmic article recovers its shape once implanted inside an eye. In some embodiments, the ophthalmic article is sufficiently physically stable in a physiologic environment such that it does not significantly change shape within at least 7 days after implantation of the ophthalmic article in an eye of a subject. In some embodiments, the ophthalmic article comprises from about 1 pg to 800 pg of the one or more active agents and / or diagnostic agents.

[0016] In another aspect, the present disclosure provides a method of treating or preventing a disease. In one embodiment, the method comprises implanting into an eye of a subject in need thereof an intraocular lens (IOL) for sustained intraocular drug delivery, which IOL comprises one or more drug release articles associated thereto, wherein the one or more drug release articles comprises one or more active agents, wherein within 7 days after implantation the one or more drug release articles releases the one or more active agents and results in an inflammation score of at most 1 as measured by an anterior chamber cell score using slit lamp biomicroscopy or absence of eye pain as measured by a 10-point visual analog scale. In some embodiments, within 7 days after implantation the one or more drug release articles releases the one or more active agents and results in an inflammation score of at most 1 as measured by an anterior chamber cell score using slit lamp biomicroscopy. In some embodiments, within 7 days after implantation the one or more drug release articles releases the one or more active agents and results in an absence of eye pain as measured by a 10-point visual analog scale. In some embodiments, the one or more drug release articles is associated to one or more haptics of the IOL. In some embodiments, about one of the one or more drug release articles is associated with the one or more haptics of the IOL. In some embodiments, about two of the one or more drug release articles are associated with the one or more haptics of the IOL. In some embodiments, about 3, 4, 5, 6, 7, 8, 9, or 10 of the one or more drug release articles are associated with the one or more haptics of the IOL. In some embodiments, about one of the one or more drug release articles is associated with one of the one or more haptics of the IOL. In some embodiments, about two of the one or more drug release articles are associated with one of the one or more haptics of the IOL. In some embodiments, about 3, 4, 5, 6, 7, 8, 9, or 10 of the one or more drug release articles are associated with one of the one or more haptics of the IOL. In some embodiments, the one or more drug release articles comprises a biocompatible matrix. In some embodiments, the biocompatible matrix comprises a copolymer derived from about 20 wt% to about 60 wt% of a caprolactone monomer and from about 40 wt% to 80 wt% of at least one other monomer. In some embodiments, the biocompatible matrix comprises a copolymer derived from about 40 wt% of the caprolactone monomer and about 60 wt% of the at least one other monomer. In some embodiments, the at least one other monomer is lactide, glycolide, or trimethylene carbonate. In some embodiments, the copolymer is a random copolymer, a block copolymer, or a gradient copolymer. In some embodiments, the copolymer is a random copolymer. In some embodiments, the biocompatible matrix is biodegradable. In some embodiments, the one or more drug release articles is configured such that the active agent is released from the biocompatible matrix. In some embodiments, the active agent is released from the biocompatible matrix over at least about 7 days. In some embodiments, the active agent is released from the biocompatible matrix over from about 5-30 days, 5-21 days, 5-14 days, 5-10 days, 7-30 days, 7-21 days, 7-14 days, or 7-10 days. In some embodiments, the active agent is released from the biocompatible matrix through degradation of the biocompatible matrix. In some embodiments, the biocompatible matrix is sufficiently compressible such that it is compatible with injection through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is sufficiently flexible such that it is compatible with injection through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is sufficiently elastic such that it recovers its original shape after injection through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the one or more drug release articles has a tensile strength of at least about 0.5 megapascal (MPa). In some embodiments, the one or more drug release articles has a tensile strength from about 25 MPa to 35 MPa. In some embodiments, the one or more drug release articles has a glass transition temperature of at most about 24°C as measured by differential scanning calorimetry. In some embodiments, the one or more drug release articles has a glass transition temperature from about -20°C to 24°C as measured by differential scanning calorimetry. In some embodiments, the one or more drug release articles has an elasticity modulus of at most about 3 MPa. In some embodiments, the one or more drug release articles has an elasticity modulus from about 0.5 MPa to 3 MPa. In some embodiments, the one or more drug release articles has an elongation at break of at least about 100% as measured by tensile testing. In some embodiments, the one or more drug release articles has an elongation at break from about 500% to 1500% at from about 18 °C to 24 °C. In some embodiments, a shape of the one or more drug release articles is an annulus, an extruded annulus, a torus, or a prism with a hole in the center. In some embodiments, the prism is a round prism, rectangular prism, a prism with three or more sides, or a prism with another shape. In some embodiments, the active agent is an interocular pressure (IOP) lowering agent, corticosteroid, non-steroidal anti-inflammatory drug, antibiotic, antiviral, antimetabolite, antifungal, antifibrotic agent, or angiogenesis inhibitor. In some embodiments, the active agent is dexamethasone, ketorolac, diclofenac, moxifloxacin, travoprost, 5-fluorouracil, or methotrexate. In some embodiments, the one or more drug release articles comprises an internal structure for associating around one or more haptics of the IOL. In some embodiments, a perimeter or widest dimension of the internal structure is less than or equal to a perimeter or widest dimension of the haptic of the IOL. In some embodiments, a perimeter of the internal structure is less than or equal to a perimeter of the one or more haptics. In some embodiments, a widest dimension of the internal structure is less than or equal to a widest dimension of the one or more haptics. In some embodiments, the one or more drug release articles extends no more than about 0.32 mm beyond the one or more haptics once the one or more drug release articles is associated to the one or more haptics. In some embodiments, a shape of the internal structure is the same as a shape of the one or more haptics. In some embodiments, the one or more drug release articles comprises an internal structure for securing around a notched region of the one or more haptics. In some embodiments, the one or more drug release articles comprises an outer diameter of at most 1.5 mm. In some embodiments, the internal structure comprises a diameter of at most 0.7 mm. In some embodiments, the one or more drug release articles is compressively associated to an outward surface of the one or more haptics. In some embodiments, the one or more drug release articles is associated to the one or more haptics of the IOL. In some embodiments, prior to implanting into the eye of the subject, compressing the IOL having the one or more drug release articles associated thereto through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the compressing comprises folding the IOL having the one or more drug release articles associated thereto into a tubular shape through the IOL injector that comprises the injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the subject is concurrently undergoing or has undergone ophthalmic surgery. In some embodiments, the subject is concurrently undergoing or has undergone cataract surgery. In some embodiments, the biocompatible matrix is sufficiently elastic such that the ophthalmic article recovers its shape once implanted inside an eye. In some embodiments, the ophthalmic article is sufficiently physically stable in a physiologic environment such that it does not significantly change shape within at least 7 days after implantation of the ophthalmic article in an eye of a subject. In some embodiments, the ophthalmic article comprises from about 1 pg to 800 pg of the one or more active agents and / or diagnostic agents.

[0017] In another aspect, the present disclosure provides a method of treating or preventing a disease. In one embodiment, the method comprises (a) associating one or more ophthalmic articles to one or more haptics of at least one intraocular lens (IOL), thereby generating at least one active agent-releasing intraocular lens; (b) implanting the at least one active agent-releasing intraocular lens into an eye of a subject in need thereof for sustained intraocular active agent delivery, wherein within 7 days after implantation the one or more ophthalmic articles releases the one or more active agents and results in an inflammation score of at most 1 as measured by an anterior chamber cell score using slit lamp biomicroscopy or absence of eye pain as measured by a 10-point visual analog scale. In some embodiments, within 7 days after implantation the one or more ophthalmic articles releases the one or more active agents and results in an inflammation score of at most 1 as measured by an anterior chamber cell score using slit lamp biomicroscopy. In some embodiments, within 7 days after implantation the one or more ophthalmic articles releases the one or more active agents and results in an absence of eye pain as measured by a 10-point visual analog scale. In some embodiments, about one of the one or more ophthalmic articles is associated with the one or more haptics. In some embodiments, about two of the one or more ophthalmic articles are associated with the one or more haptics. In some embodiments, about 3, 4, 5, 6, 7, 8, 9, or 10 of the one or more ophthalmic articles are associated with the one or more haptics. In some embodiments, about one of the one or more ophthalmic articles is associated with one of the one or more haptics. In some embodiments, about two of the one or more ophthalmic articles are associated with one of the one or more haptics. In some embodiments, about 3, 4, 5, 6, 7, 8, 9, or 10 of the one or more ophthalmic articles are associated with one of the one or more haptics. In some embodiments, one or more ophthalmic articles comprises a biocompatible matrix. In some embodiments, the biocompatible matrix comprises a copolymer derived from about 20 wt% to about 60 wt% of a caprolactone monomer and from about 40 wt% to 80 wt% of at least one other monomer. In some embodiments, the biocompatible matrix comprises a copolymer derived from about 40 wt% of the caprolactone monomer and about 60 wt% of the at least one other monomer. In some embodiments, the at least one other monomer is lactide, glycolide, or trimethylene carbonate. In some embodiments, the copolymer is a random copolymer, a block copolymer, or a gradient copolymer. In some embodiments, the copolymer is a random copolymer. In some embodiments, the biocompatible matrix is biodegradable. In some embodiments, the one or more ophthalmic articles is configured such that the active agent is released from the biocompatible matrix. In some embodiments, the active agent is released from the biocompatible matrix over at least about 7 days. In some embodiments, the active agent is released from the biocompatible matrix over from about 5-30 days, 5-21 days, 5-14 days, 5-10 days, 7-30 days, 7-21 days, 7-14 days, or 7-10 days. In some embodiments, the active agent is released from the biocompatible matrix through degradation of the biocompatible matrix. In some embodiments, the biocompatible matrix is sufficiently compressible such that it is compatible with injection through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is sufficiently flexible such that it is compatible with injection through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is sufficiently elastic such that it recovers its original shape after injection through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the one or more ophthalmic articles has a tensile strength of at least about 0.5 megapascal (MPa). In some embodiments, the one or more ophthalmic articles has a tensile strength from about 25 MPa to 35 MPa. In some embodiments, the one or more ophthalmic articles has a glass transition temperature of at most about 24°C as measured by differential scanning calorimetry. In some embodiments, the one or more ophthalmic articles has a glass transition temperature from about -20°C to 24°C as measured by differential scanning calorimetry. In some embodiments, the one or more ophthalmic articles has an elasticity modulus of at most about 3 MPa. In some embodiments, the one or more ophthalmic articles has an elasticity modulus from about 0.5 MPa to 3 MPa. In some embodiments, the one or more ophthalmic articles has an elongation at break of at least about 100% as measured by tensile testing. In some embodiments, the one or more ophthalmic articles has an elongation at break from about 500% to 1500% at from about 18 °C to 24 °C. In some embodiments, a shape of the one or more ophthalmic articles is an annulus, an extruded annulus, a torus, or a prism with a hole in the center. In some embodiments, the prism is a round prism, rectangular prism, a prism with three or more sides, or a prism with another shape. In some embodiments, the active agent is an interocular pressure (IOP) lowering agent, corticosteroid, non-steroidal anti-inflammatory drug, antibiotic, antiviral, antimetabolite, antifungal, antifibrotic agent, or angiogenesis inhibitor. In some embodiments, the active agent is dexamethasone, ketorolac, diclofenac, moxifloxacin, travoprost, 5-fluorouracil, or methotrexate. In some embodiments, the associating comprises indirect association between the one or more ophthalmic articles and the one or more haptics. In some embodiments, the one or more ophthalmic articles comprises an internal structure for associating around the one or more haptics. In some embodiments, a perimeter or widest dimension of the internal structure is less than or equal to a perimeter or widest dimension of the one or more haptics. In some embodiments, a perimeter of the internal structure is less than or equal to a perimeter of the one or more haptics. In some embodiments, a widest dimension of the internal structure is less than or equal to a widest dimension of the one or more haptics. In some embodiments, the one or more ophthalmic articles extends no more than about 0.32 mm beyond the one or more haptics once the one or more ophthalmic articles is associated to the one or more haptics. In some embodiments, a shape of the internal structure is the same as a shape of the one or more haptics. In some embodiments, one or more ophthalmic articles comprises an internal structure for securing around a notched region of the one or more haptics. In some embodiments, the one or more ophthalmic articles comprises an outer diameter of at most 1.5 mm. In some embodiments, the internal structure comprises a diameter of at most 0.7 mm. In some embodiments, the one or more ophthalmic articles is compressively associated to an outward surface of the one or more haptics. In some embodiments, prior to implanting into the eye of the subject, compressing the at least one active agent-releasing intraocular lens through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the compressing comprises folding the at least one active agent-releasing intraocular lens into a tubular shape through the IOL injector that comprises the injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the subject is concurrently undergoing or has undergone ophthalmic surgery. In some embodiments, the subject is concurrently undergoing or has undergone cataract surgery. In some embodiments, the associating comprises direct association between the one or more ophthalmic articles and the one or more haptics through a chemical bond, physical bond, compressive forces, or contractile forces. In some embodiments, the biocompatible matrix is sufficiently elastic such that the ophthalmic article recovers its shape once implanted inside an eye. In some embodiments, the ophthalmic article is sufficiently physically stable in a physiologic environment such that it does not significantly change shape within at least 7 days after implantation of the ophthalmic article in an eye of a subject. In some embodiments, the ophthalmic article comprises from about 1 pg to 800 pg of the one or more active agents and / or diagnostic agents.

[0018] In another aspect, the present disclosure provides method of treating or preventing a disease. In one embodiments, the method comprises (a) combining one or more active agents with a biocompatible matrix, thereby generating one or more ophthalmic articles; (b) associating the one or more ophthalmic articles to one or more haptics of at least one intraocular lens, thereby generating at least one active agent-releasing intraocular lens; (c) implanting the at least one active agent-releasing intraocular lens into an eye of a subject in need thereof for sustained intraocular active agent delivery, wherein within 7 days after implantation the one or more ophthalmic articles releases the one or more active agents and results in an inflammation score of at most 1 as measured by an anterior chamber cell score using slit lamp biomicroscopy or absence of eye pain as measured by a 10-point visual analog scale. In some embodiments, within 7 days after implantation the one or more ophthalmic articles releases the one or more active agents and results in an inflammation score of at most 1 as measured by an anterior chamber cell score using slit lamp biomicroscopy. In some embodiments, within 7 days after implantation the one or more ophthalmic articles releases the one or more active agents and results in an absence of eye pain as measured by a 10-point visual analog scale. In some embodiments, about one of the one or more ophthalmic articles is associated with the one or more haptics. In some embodiments, about two of the one or more ophthalmic articles are associated with the one or more haptics. In some embodiments, about 3, 4, 5, 6, 7, 8, 9, or 10 of the one or more ophthalmic articles are associated with the one or more haptics. In some embodiments, about one of the one or more ophthalmic articles is associated with one of the one or more haptics. In some embodiments, about two of the one or more ophthalmic articles are associated with one of the one or more haptics. In some embodiments, about 3, 4, 5, 6, 7, 8, 9, or 10 of the one or more ophthalmic articles are associated with one of the one or more haptics. In some embodiments, the biocompatible matrix comprises a copolymer derived from about 20 wt% to about 60 wt% of a caprolactone monomer and from about 40 wt% to 80 wt% of at least one other monomer. In some embodiments, the biocompatible matrix comprises a copolymer derived from about 40 wt% of the caprolactone monomer and about 60 wt% of the at least one other monomer. In some embodiments, the at least one other monomer is lactide, glycolide, or trimethylene carbonate. In some embodiments, the copolymer is a random copolymer, a block copolymer, or a gradient copolymer. In some embodiments, the copolymer is a random copolymer. In some embodiments, the biocompatible matrix is biodegradable. In some embodiments, the one or more ophthalmic articles has a tensile strength of at least about 0.5 megapascal (MPa). In some embodiments, the one or more ophthalmic articles has a tensile strength from about 25 MPa to 35 MPa. In some embodiments, the one or more ophthalmic articles has a glass transition temperature of at most about 24°C as measured by differential scanning calorimetry. In some embodiments, the one or more ophthalmic articles has a glass transition temperature from about -20°C to 24°C as measured by differential scanning calorimetry. In some embodiments, the one or more ophthalmic articles has an elasticity modulus of at most about 3 MPa. In some embodiments, the one or more ophthalmic articles has an elasticity modulus from about 0.5 MPa to 3 MPa. In some embodiments, the one or more ophthalmic articles has an elongation at break of at least about 100% as measured by tensile testing. In some embodiments, the one or more ophthalmic articles has an elongation at break from about 500% to 1500% at from about 18 °C to 24 °C. In some embodiments, a shape of the one or more ophthalmic articles is an annulus, an extruded annulus, a torus, or a prism with a hole in the center. In some embodiments, the prism is a round prism, rectangular prism, a prism with three or more sides, or a prism with another shape. In some embodiments, the one or more active agents is an interocular pressure (IOP) lowering agent, corticosteroid, non-steroidal anti-inflammatory drug, antibiotic, antiviral, antimetabolite, antifungal, antifibrotic agent, or angiogenesis inhibitor. In some embodiments, the one or more active agents is dexamethasone, ketorolac, diclofenac, moxifloxacin, travoprost, 5-fluorouracil, or methotrexate. In some embodiments, the associating comprises indirect association between the one or more ophthalmic articles and the one or more haptics. In some embodiments, the one or more ophthalmic articles comprises an internal structure for associating around the one or more haptics. In some embodiments, a perimeter or widest dimension of the internal structure is less than or equal to a perimeter or widest dimension of the one or more haptics. In some embodiments, a perimeter of the internal structure is less than or equal to a perimeter of the one or more haptics. In some embodiments, a widest dimension of the internal structure is less than or equal to a widest dimension of the one or more haptics. In some embodiments, the one or more ophthalmic articles extends no more than about 0.32 mm beyond the one or more haptics once the one or more ophthalmic articles is associated to the one or more haptics. In some embodiments, a shape of the internal structure is the same as a shape of the one or more haptics. In some embodiments, the one or more ophthalmic articles comprises an internal structure for securing around a notched region of the one or more haptics. In some embodiments, the one or more ophthalmic articles comprises an outer diameter of at most 1.5 mm. In some embodiments, the internal structure comprises a diameter of at most 0.7 mm. In some embodiments, the one or more ophthalmic articles is configured such that the active agent is released from the biocompatible copolymer matrix. In some embodiments, the active agent is released from the biocompatible matrix over at least about 7 days. In some embodiments, the active agent is released from the biocompatible matrix over from about 5-30 days, 5-21 days, 5-14 days, 5-10 days, 7-30 days, 7-21 days, 7-14 days, or 7-10 days. In some embodiments, the active agent is released from the biocompatible matrix through degradation of the biocompatible matrix. In some embodiments, the biocompatible matrix is sufficiently compressible such that it is compatible with injection through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is sufficiently flexible such that it is compatible with injection through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is sufficiently elastic such that it recovers its original shape after injection through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm wherein the one or more ophthalmic articles is compressively associated to an outward surface of the one or more haptics. In some embodiments, prior to implanting the at least one active agent-releasing intraocular lens into the eye of the subject, compressing the at least one active agent-releasing intraocular lens through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the compressing comprises folding the at least one active agent-releasing intraocular lens into a tubular shape through the IOL injector that comprises the injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the subject is concurrently undergoing or has undergone ophthalmic surgery. In some embodiments, the subject is concurrently undergoing or has undergone cataract surgery. In some embodiments, the associating comprises direct association between the one or more ophthalmic articles and the one or more haptics through a chemical bond, physical bond, compressive forces, or contractile forces. In some embodiments, the biocompatible matrix is sufficiently elastic such that the ophthalmic article recovers its shape once implanted inside an eye. In some embodiments, the ophthalmic article is sufficiently physically stable in a physiologic environment such that it does not significantly change shape within at least 7 days after implantation of the ophthalmic article in an eye of a subject. In some embodiments, the ophthalmic article comprises from about 1 pg to 800 pg of the one or more active agents and / or diagnostic agents.

[0019] In another aspect, the present disclosure provides a method of preparing at least one ophthalmic article. In one embodiment, the method comprises (a) combining one or more active agents or diagnostic agents in a solvent with a biocompatible matrix in the solvent, thereby generating a combined mixture in the solvent; (b) removing the solvent from the combined mixture, thereby generating an evaporated mixture; (c) using a weighted tool to compress the evaporated mixture, thereby generating a compressed mixture; and (d) using a shaping tool and an orifice tool to extract the at least one ophthalmic article from the compressed mixture. In some embodiments, the biocompatible matrix comprises a copolymer derived from about 20 wt% to about 60 wt% of a caprolactone monomer and from about 40 wt% to 80 wt% of at least one other monomer. In some embodiments, the biocompatible matrix comprises a copolymer derived from about 40 wt% of the caprolactone monomer and about 60 wt% of the at least one other monomer. In some embodiments, the at least one other monomer is lactide, glycolide, or trimethylene carbonate. In some embodiments, the copolymer is a random copolymer, a block copolymer, or a gradient copolymer. In some embodiments, the copolymer is a random copolymer. In some embodiments, biocompatible matrix is biodegradable. In some embodiments, the at least one ophthalmic article has a tensile strength of at least about 0.5 megapascal (MPa). In some embodiments, the at least one ophthalmic article has a tensile strength from about 25 MPa to 35 MPa. In some embodiments, the at least one ophthalmic article has a glass transition temperature of at most about 24°C as measured by differential scanning calorimetry. In some embodiments, the at least one ophthalmic article has a glass transition temperature from about -20°C to 24°C as measured by differential scanning calorimetry. In some embodiments, the at least one ophthalmic article has an elasticity modulus of at most about 3 MPa. In some embodiments, the at least one ophthalmic article has an elasticity modulus from about 0.5 MPa to 3 MPa. In some embodiments, the at least one ophthalmic article has an elongation at break of at least about 100% as measured by tensile testing. In some embodiments, the at least one ophthalmic article has an elongation at break from about 500% to 1500% at from about 18 °C to 24 °C. In some embodiments, a shape of the at least one ophthalmic article is an annulus, an extruded annulus, a torus, or a prism with a hole in the center. In some embodiments, the prism is a round prism, rectangular prism, a prism with three or more sides, or a prism with another shape. In some embodiments, the one or more active agents is an interocular pressure (IOP) lowering agent, corticosteroid, non-steroidal anti-inflammatory drug, antibiotic, antiviral, antimetabolite, antifungal, antifibrotic agent, or angiogenesis inhibitor. In some embodiments, the one or more active agents is dexamethasone, ketorolac, diclofenac, moxifloxacin, travoprost, 5-fluorouracil, or methotrexate. In some embodiments, the at least one ophthalmic article comprises an internal structure for associating around one or more haptics of an intraocular lens. In some embodiments, the at least one ophthalmic article comprises an outer diameter of at most 1.5 mm. In some embodiments, the internal structure comprises a diameter of at most 0.7 mm. In some embodiments, the at least one ophthalmic article is configured such that the one or more active agents or diagnostic agents is released from the biocompatible matrix. In some embodiments, the one or more active agents or diagnostic agents is released from the biocompatible matrix through degradation of the biocompatible matrix. In some embodiments, the biocompatible matrix is sufficiently compressible such that it is compatible with injection through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is sufficiently flexible such that it is compatible with injection through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is sufficiently elastic such that it recovers its original shape after injection through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, prior to the combining in (a), suspending the one or more active agents or diagnostic agents in the solvent, thereby generating a suspension. In some embodiments, the weighted tool is a steel plate. In some embodiments, the weighted tool is a heated steel plate. In some embodiments, the weighted tool is a heated steel plate with Teflon. In some embodiments, the weighted tool compresses the evaporated mixture into a sheet. In some embodiments, the biocompatible matrix is sufficiently elastic such that the ophthalmic article recovers its shape once implanted inside an eye. In some embodiments, the ophthalmic article is sufficiently physically stable in a physiologic environment such that it does not significantly change shape within at least 7 days after implantation of the ophthalmic article in an eye of a subject. In some embodiments, the ophthalmic article comprises from about 1 pg to 800 pg of the one or more active agents and / or diagnostic agents.

[0020] In another aspect, the present disclosure provides a method of preparing at least one agent-releasing intraocular lens. In one embodiment, the method comprises (a) combining one or more active agents or diagnostic agents with a biocompatible matrix comprising a copolymer derived from a caprolactone monomer and at least one other monomer, thereby generating one or more ophthalmic articles; (b) associating the one or more ophthalmic articles to one or more haptics of at least one intraocular lens (IOL). In some embodiments, about one of the one or more ophthalmic articles is associated with the one or more haptics of the IOL. In some embodiments, about two of the one or more ophthalmic articles are associated with the one or more haptics of the IOL. In some embodiments, about 3, 4, 5, 6, 7, 8, 9, or 10 of the one or more ophthalmic articles are associated with the one or more haptics of the IOL. In some embodiments, about one of the one or more ophthalmic articles is associated with one of the one or more haptics of the IOL. In some embodiments, about two of the one or more ophthalmic articles are associated with one of the one or more haptics of the IOL. In some embodiments, about 3, 4, 5, 6, 7, 8, 9, or 10 of the one or more ophthalmic articles are associated with one of the one or more haptics of the IOL. In some embodiments, the biocompatible matrix comprises a copolymer derived from about 20 wt% to about 60 wt% of a caprolactone monomer and from about 40 wt% to 80 wt% of at least one other monomer. In some embodiments, the biocompatible matrix comprises a copolymer derived from about 40 wt% of the caprolactone monomer and about 60 wt% of the at least one other monomer. In some embodiments, the at least one other monomer is lactide, glycolide, or trimethylene carbonate. In some embodiments, the copolymer is a random copolymer, a block copolymer, or a gradient copolymer. In some embodiments, the copolymer is a random copolymer. In some embodiments, the biocompatible matrix is biodegradable. In some embodiments, the one or more ophthalmic articles has a tensile strength of at least about 0.5 megapascal (MPa). In some embodiments, the one or more ophthalmic articles has a tensile strength from about 25 MPa to 35 MPa. In some embodiments, the one or more ophthalmic articles has a glass transition temperature of at most about 24°C as measured by differential scanning calorimetry. In some embodiments, the one or more ophthalmic articles has a glass transition temperature from about -20°C to 24°C as measured by differential scanning calorimetry. In some embodiments, the one or more ophthalmic articles has an elasticity modulus of at most about 3 MPa. In some embodiments, the one or more ophthalmic articles has an elasticity modulus from about 0.5 MPa to 3 MPa. In some embodiments, the one or more ophthalmic articles has an elongation at break of at least about 100% as measured by tensile testing. In some embodiments, the one or more ophthalmic articles has an elongation at break from about 500% to 1500% at from about 18 °C to 24 °C. In some embodiments, a shape of the one or more ophthalmic articles is an annulus, an extruded annulus, a torus, or a prism with a hole in the center. In some embodiments, the prism is a round prism, rectangular prism, a prism with three or more sides, or a prism with another shape. In some embodiments, the active agent is an interocular pressure (IOP) lowering agent, corticosteroid, non-steroidal anti-inflammatory drug, antibiotic, antiviral, antimetabolite, antifungal, antifibrotic agent, or angiogenesis inhibitor. In some embodiments, the active agent is dexamethasone, ketorolac, diclofenac, moxifloxacin, travoprost, 5-fluorouracil, or methotrexate. In some embodiments, the associating comprises indirect association between the one or more ophthalmic articles and the one or more haptics. In some embodiments, the one or more ophthalmic articles comprises an internal structure for associating around the one or more haptics. In some embodiments, a perimeter or widest dimension of the internal structure is less than or equal to a perimeter or widest dimension of the one or more haptics. In some embodiments, a perimeter of the internal structure is less than or equal to a perimeter of the one or more haptics. In some embodiments, a perimeter or widest dimension of the internal structure is less than or equal to a perimeter or widest dimension of the one or more haptics. In some embodiments, a widest dimension of the internal structure is less than or equal to a widest dimension of the one or more haptics. In some embodiments, the one or more ophthalmic articles extends no more than about 0.32 mm beyond the one or more haptics once the one or more ophthalmic articles is associated to the one or more haptics. In some embodiments, a shape of the internal structure is the same as a shape of the one or more haptics. In some embodiments, the one or more ophthalmic articles comprises an internal structure for securing around a notched region of the one or more haptics. In some embodiments, the one or more ophthalmic articles comprises an outer diameter of at most 1.5 mm. In some embodiments, the internal structure comprises a diameter of at most 0.7 mm. In some embodiments, the one or more ophthalmic articles is configured such that the one or more active agents or diagnostic agents is released from the biocompatible matrix. In some embodiments, the active agent or diagnostic agent is released from the biocompatible matrix over at least about 7 days. In some embodiments, the active agent or diagnostic agent is released from the biocompatible matrix over from about 5-30 days, 5-21 days, 5-14 days, 5-10 days, 7-30 days, 7-21 days, 7-14 days, or 7-10 days. In some embodiments, the active agent or diagnostic agent is released from the biocompatible matrix through degradation of the biocompatible copolymer matrix. In some embodiments, the biocompatible matrix is sufficiently compressible such that it is compatible with injection through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is sufficiently flexible such that it is compatible with injection through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is sufficiently elastic such that it recovers its original shape after injection through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the one or more ophthalmic articles is compressively associated to an outward surface of the one or more haptics. In some embodiments, prior to implanting into the eye of the subject, compressing the IOL having the one or more ophthalmic articles associated thereto through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the compressing comprises folding the IOL having the one or more ophthalmic articles associated thereto into a tubular shape through the IOL injector that comprises the injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the associating comprises direct association between the one or more ophthalmic articles and the one or more haptics through a chemical bond, physical bond, compressive forces, or contractile forces. In some embodiments, the biocompatible matrix is sufficiently elastic such that the ophthalmic article recovers its shape once implanted inside an eye. In some embodiments, the ophthalmic article is sufficiently physically stable in a physiologic environment such that it does not significantly change shape within at least 7 days after implantation of the ophthalmic article in an eye of a subject. In some embodiments, the ophthalmic article comprises from about 1 pg to 800 pg of the one or more active agents and / or diagnostic agents.

[0021] In another aspect, the present disclosure provides a method of administering an active agent or diagnostic agent. In one embodiment, the method comprises (a) associating one or more ophthalmic articles to one or more haptics of at least one intraocular lens, thereby generating at least one agent-releasing intraocular lens; (b) compressing the at least one agent-releasing intraocular lens through an intraocular lens injector comprising an injector tip inner diameter from about 0.5 mm to 3 mm; and (c) implanting the at least one agent-releasing intraocular lens into an eye of a subject in need thereof for sustained intraocular active agent or diagnostic agent delivery. In some embodiments, about one of the one or more ophthalmic articles is associated with the one or more haptics of the IOL. In some embodiments, about two of the one or more ophthalmic articles are associated with the one or more haptics of the IOL. In some embodiments, about 3, 4, 5, 6, 7, 8, 9, or 10 of the one or more ophthalmic articles are associated with the one or more haptics of the IOL. In some embodiments, about one of the one or more ophthalmic articles is associated with one of the one or more haptics of the IOL. In some embodiments, about two of the one or more ophthalmic articles are associated with one of the one or more haptics of the IOL. In some embodiments, about 3, 4, 5, 6, 7, 8, 9, or 10 of the one or more ophthalmic articles are associated with one of the one or more haptics of the IOL. In some embodiments, the one or more ophthalmic articles comprises a biocompatible matrix. In some embodiments, the biocompatible matrix comprises a copolymer derived from about 20 wt% to about 60 wt% of a caprolactone monomer and from about 40 wt% to 80 wt% of at least one other monomer. In some embodiments, the biocompatible matrix comprises a copolymer derived from about 40 wt% of the caprolactone monomer and about 60 wt% of the at least one other monomer. In some embodiments, the at least one other monomer is lactide, glycolide, or trimethylene carbonate. In some embodiments, the copolymer is a random copolymer, a block copolymer, or a gradient copolymer. In some embodiments, the copolymer is a random copolymer. In some embodiments, the biocompatible matrix is biodegradable. In some embodiments, the one or more ophthalmic articles is configured such that the active agent or diagnostic agent is released from the biocompatible matrix. In some embodiments, the active agent or diagnostic agent is released from the biocompatible matrix over at least about 7 days. In some embodiments, the active agent or diagnostic agent is released from the biocompatible matrix over from about 5-30 days, 5-21 days, 5-14 days, 5-10 days, 7-30 days, 7-21 days, 7-14 days, or 7-10 days. In some embodiments, the active agent or diagnostic agent is released from the biocompatible matrix through degradation of the biocompatible matrix. In some embodiments, the biocompatible matrix is sufficiently compressible such that it is compatible with injection through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is sufficiently flexible such that it is compatible with injection through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is sufficiently elastic such that it recovers its original shape after injection through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the one or more ophthalmic articles has a tensile strength of at least about 0.5 megapascal (MPa). In some embodiments, the one or more ophthalmic articles has a tensile strength from about 25 MPa to 35 MPa. In some embodiments, the one or more ophthalmic articles has a glass transition temperature of at most about 24°C as measured by differential scanning calorimetry. In some embodiments, the one or more ophthalmic articles has a glass transition temperature from about -20°C to 24°C as measured by differential scanning calorimetry. In some embodiments, the one or more ophthalmic articles has an elasticity modulus of at most about 3 MPa. In some embodiments, the one or more ophthalmic articles has an elasticity modulus from about 0.5 MPa to 3 MPa. In some embodiments, the one or more ophthalmic articles has an elongation at break of at least about 100% as measured by tensile testing. In some embodiments, the one or more ophthalmic articles has an elongation at break from about 500% to 1500% at from about 18 °C to 24 °C. In some embodiments, a shape of the one or more ophthalmic articles is an annulus, an extruded annulus, a torus, or a prism with a hole in the center. In some embodiments, the prism is a round prism, rectangular prism, a prism with three or more sides, or a prism with another shape. In some embodiments, the active agent is an interocular pressure (IOP) lowering agent, corticosteroid, non-steroidal anti-inflammatory drug, antibiotic, antiviral, antimetabolite, antifungal, antifibrotic agent, or angiogenesis inhibitor. In some embodiments, the active agent is dexamethasone, ketorolac, diclofenac, moxifloxacin, travoprost, 5-fluorouracil, or methotrexate. In some embodiments, the associating comprises indirect association between the one or more ophthalmic articles and the one or more haptics. In some embodiments, the one or more ophthalmic articles comprises an internal structure for associating around the one or more haptics. In some embodiments, a perimeter or widest dimension of the internal structure is less than or equal to a perimeter or widest dimension of the one or more haptics. In some embodiments, a perimeter of the internal structure is less than or equal to a perimeter of the one or more haptics. In some embodiments, a widest dimension of the internal structure is less than or equal to a widest dimension of the one or more haptics. In some embodiments, the one or more ophthalmic articles extends no more than about 0.32 mm beyond the one or more haptics once the one or more ophthalmic articles is associated to the one or more haptics. In some embodiments, a shape of the internal structure is the same as a shape of the one or more haptics. In some embodiments, the one or more ophthalmic articles comprises an internal structure for securing around a notched region of the one or more haptics. In some embodiments, the one or more ophthalmic articles comprises an outer diameter of at most 1.5 mm. In some embodiments, the one or more ophthalmic articles comprises an inner diameter of at most 0.7 mm. In some embodiments, the one or more ophthalmic articles is compressively associated to an outward surface of the one or more haptics. In some embodiments, the compressing comprises folding the at least one agentreleasing intraocular lens into a tubular shape through the IOL injector that comprises the injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the subject is concurrently undergoing or has undergone ophthalmic surgery. In some embodiments, the subject is concurrently undergoing or has undergone cataract surgery. In some embodiments, the associating comprises direct association between the one or more ophthalmic articles and the one or more haptics through a chemical bond, physical bond, compressive forces, or contractile forces. In some embodiments, the biocompatible matrix is sufficiently elastic such that the ophthalmic article recovers its shape once implanted inside an eye. In some embodiments, the ophthalmic article is sufficiently physically stable in a physiologic environment such that it does not significantly change shape within at least 7 days after implantation of the ophthalmic article in an eye of a subject. In some embodiments, the ophthalmic article comprises from about 1 pg to 800 pg of the one or more active agents and / or diagnostic agents.

[0022] In another aspect, the present disclosure provides a method of administering an active agent or diagnostic agent. In one embodiment, the method comprises (a) compressing an intraocular lens (IOL) having one or more ophthalmic articles associated thereto through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm, thereby generating a compressed IOL having one or more ophthalmic articles associated thereto, which one or more ophthalmic articles comprises one or more active agents or diagnostic agents; and (b) implanting the compressed IOL having one or more ophthalmic articles associated thereto into an eye of a subject in need thereof for sustained intraocular active agent or diagnostic agent delivery. In some embodiments, about one of the one or more ophthalmic articles is associated with one or more haptics of the IOL. In some embodiments, about two of the one or more ophthalmic articles are associated with one or more haptics of the IOL. In some embodiments, about 3, 4, 5, 6, 7, 8, 9, or 10 of the one or more ophthalmic articles are associated with one or more haptics of the IOL. In some embodiments, about one of the one or more ophthalmic articles is associated with one of one or more haptics of the IOL. In some embodiments, about two of the one or more ophthalmic articles are associated with one of one or more haptics of the IOL. In some embodiments, about 3, 4, 5, 6, 7, 8, 9, or 10 of the one or more ophthalmic articles are associated with one of one or more haptics of the IOL. In some embodiments, the one or more ophthalmic articles comprises a biocompatible matrix. In some embodiments, the biocompatible matrix comprises a copolymer derived from about 20 wt% to about 60 wt% of a caprolactone monomer and from about 40 wt% to 80 wt% of at least one other monomer. In some embodiments, the biocompatible matrix comprises a copolymer derived from about 40 wt% of the caprolactone monomer and about 60 wt% of the at least one other monomer. In some embodiments, the at least one other monomer is lactide, glycolide, or trimethylene carbonate. In some embodiments, the copolymer is a random copolymer, a block copolymer, or a gradient copolymer. In some embodiments, the copolymer is a random copolymer. In some embodiments, the biocompatible matrix is biodegradable. In some embodiments, the one or more ophthalmic articles is configured such that the one or more active agents or diagnostic agents is released from the biocompatible matrix. In some embodiments, the one or more active agents or diagnostic agents is released from the biocompatible matrix over at least about 7 days. In some embodiments, the one or more active agents or diagnostic agents is released from the biocompatible matrix over from about 5-30 days, 5-21 days, 5-14 days, 5-10 days, 7-30 days, 721 days, 7-14 days, or 7-10 days. In some embodiments, the one or more active agents or diagnostic agents is released from the biocompatible matrix through degradation of the biocompatible matrix. In some embodiments, the biocompatible matrix is sufficiently compressible such that it is compatible with injection through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is sufficiently flexible such that it is compatible with injection through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is sufficiently elastic such that it recovers its original shape after injection through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the one or more ophthalmic articles has a tensile strength of at least about 0.5 megapascal (MPa). In some embodiments, the one or more ophthalmic articles has a tensile strength from about 25 MPa to 35 MPa. In some embodiments, the one or more ophthalmic articles has a glass transition temperature of at most about 24°C as measured by differential scanning calorimetry. In some embodiments, the one or more ophthalmic articles has a glass transition temperature from about -20°C to 24°C as measured by differential scanning calorimetry. In some embodiments, the one or more ophthalmic articles has an elasticity modulus of at most about 3 MPa. In some embodiments, the one or more ophthalmic articles has an elasticity modulus from about 0.5 MPa to 3 MPa. In some embodiments, the one or more ophthalmic articles has an elongation at break of at least about 100% as measured by tensile testing. In some embodiments, the one or more ophthalmic articles has an elongation at break from about 500% to 1500% at from about 18 °C to 24 °C. In some embodiments, a shape of the one or more ophthalmic articles is an annulus, an extruded annulus, a torus, or a prism with a hole in the center. In some embodiments, the prism is a round prism, rectangular prism, a prism with three or more sides, or a prism with another shape. In some embodiments, the active agent is an interocular pressure (IOP) lowering agent, corticosteroid, non-steroidal anti-inflammatory drug, antibiotic, antiviral, antimetabolite, antifungal, antifibrotic agent, or angiogenesis inhibitor. In some embodiments, the active agent is dexamethasone, ketorolac, diclofenac, moxifloxacin, travoprost, 5-fluorouracil, or methotrexate. In some embodiments, the one or more ophthalmic articles is indirectly associated with one or more haptics of the IOL. In some embodiments, the one or more ophthalmic articles comprises an internal structure for associating around one or more haptics of the intraocular lens. In some embodiments, a perimeter or widest dimension of the internal structure is less than or equal to a perimeter or widest dimension of the one or more haptics of the IOL. In some embodiments, a perimeter dimension of the internal structure is less than or equal to a perimeter of the one or more haptics of the IOL. In some embodiments, a widest dimension of the internal structure is less than or equal to a widest dimension of the one or more haptics of the IOL. In some embodiments, the one or more ophthalmic articles extends no more than about 0.32 mm beyond the one or more haptics of the IOL once the one or more ophthalmic articles is associated to the one or more haptics of the IOL. In some embodiments, a shape of the internal structure is the same as a shape of the one or more haptics of the IOL. In some embodiments, the one or more ophthalmic articles comprises an internal structure for securing around a notched region of one or more haptics of the IOL. In some embodiments, the one or more ophthalmic articles comprises an outer diameter of at most 1.5 mm. In some embodiments, the internal structure comprises a diameter of at most 0.7 mm. In some embodiment, the one or more ophthalmic articles is associated to one or more haptics of the IOL. In some embodiments, the one or more ophthalmic articles is compressively associated to an outward surface of the one or more haptics of the IOL. In some embodiments, the one or more ophthalmic articles is directly associated between the one or more ophthalmic articles and the one or more haptics through a chemical bond, physical bond, compressive forces, or contractile forces. In some embodiments, the compressing comprises folding the IOL having the one or more ophthalmic articles associated thereto into a tubular shape through the IOL injector that comprises the injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the subject is concurrently undergoing or has undergone ophthalmic surgery. In some embodiments, the subject is concurrently undergoing or has undergone cataract surgery. In some embodiments, the biocompatible matrix is sufficiently elastic such that the ophthalmic article recovers its shape once implanted inside an eye. In some embodiments, the ophthalmic article is sufficiently physically stable in a physiologic environment such that it does not significantly change shape within at least 7 days after implantation of the ophthalmic article in an eye of a subject. In some embodiments, the ophthalmic article comprises from about 1 pg to 800 pg of the one or more active agents and / or diagnostic agents.

[0023] In another aspect, the present disclosure provides kit. In one embodiment, the kit comprises a container comprising one or more ophthalmic articles comprising (1) a biocompatible matrix comprising a copolymer derived from a caprolactone monomer and at least one other monomer, and (2) one or more active agents or diagnostic agents; and instructions for use. In some embodiments, the kit further comprises another container comprising one or more intraocular lenses, which each of the one or more intraocular lenses comprises one or more haptics. In some embodiments, the container further comprises one or more intraocular lenses comprising one or more haptics associated with the one or more ophthalmic articles. In some embodiments, the one or more ophthalmic articles is associated with the one or more haptics of the one or more IOLs. In some embodiments, about one of the one or more ophthalmic articles is associated with the one or more haptics. In some embodiments, about two of the one or more ophthalmic articles are associated with the one or more haptics. In some embodiments, about 3, 4, 5, 6, 7, 8, 9, or 10 of the one or more ophthalmic articles are associated with the one or more haptics. In some embodiments, about one of the one or more ophthalmic articles is associated with one of the one or more haptics. In some embodiments, about two of the one or more ophthalmic articles are associated with one of the one or more haptics. In some embodiments, about 3, 4, 5, 6, 7, 8, 9, or 10 of the one or more ophthalmic articles are associated with one of the one or more haptics. In some embodiments, the biocompatible matrix comprises a copolymer derived from about 20 wt% to about 60 wt% of the caprolactone monomer and from about 40 wt% to 80 wt% of the at least one other monomer. In some embodiments, the biocompatible matrix comprises a copolymer derived from about 40 wt% of the caprolactone monomer and about 60 wt% of the at least one other monomer. In some embodiments, the at least one other monomer is lactide, glycolide, or trimethylene carbonate. In some embodiments, the copolymer is a random copolymer, a block copolymer, or a gradient copolymer. In some embodiments, the copolymer is a random copolymer. In some embodiments, the biocompatible matrix is biodegradable. In some embodiments, the one or more ophthalmic articles has a tensile strength of at least about 0.5 megapascal (MPa). In some embodiments, the one or more ophthalmic articles has a tensile strength from about 25 MPa to 35 MPa. In some embodiments, the one or more ophthalmic articles has a glass transition temperature of at most about 24°C as measured by differential scanning calorimetry. In some embodiments, the one or more ophthalmic articles has a glass transition temperature from about -20°C to 24°C as measured by differential scanning calorimetry. In some embodiments, the one or more ophthalmic articles has an elasticity modulus of at most about 3 MPa. In some embodiments, the one or more ophthalmic articles has an elasticity modulus from about 0.5 MPa to 3 MPa. In some embodiments, the one or more ophthalmic articles has an elongation at break of at least about 100% as measured by tensile testing. In some embodiments, the one or more ophthalmic articles has an elongation at break from about 500% to 1500% at from about 18 °C to 24 °C. In some embodiments, a shape of the one or more ophthalmic articles is an annulus, an extruded annulus, a torus, or a prism with a hole in the center. In some embodiments, the prism is a round prism, rectangular prism, a prism with three or more sides, or a prism with another shape. In some embodiments, the one or more active agents is an interocular pressure (IOP) lowering agent, corticosteroid, non-steroidal antiinflammatory drug, antibiotic, antiviral, antimetabolite, antifungal, antifibrotic agent, or angiogenesis inhibitor. In some embodiments, the one or more active agents is dexamethasone, ketorolac, diclofenac, moxifloxacin, travoprost, 5-fluorouracil, or methotrexate. In some embodiments, the one or more ophthalmic articles comprises an internal structure for associating around the one or more haptics. In some embodiments, a perimeter or widest dimension of the internal structure is less than or equal to a perimeter or widest dimension of the one or more haptics. In some embodiments, a perimeter of the internal structure is less than or equal to a perimeter of the one or more haptics. In some embodiments, a widest dimension of the internal structure is less than or equal to a widest dimension of the one or more haptics. In some embodiments, the one or more ophthalmic articles extends no more than about 0.32 mm beyond the one or more haptics once the one or more ophthalmic articles is associated to the one or more haptics. In some embodiments, a shape of the internal structure is the same as a shape of the one or more haptics. In some embodiments, the one or more ophthalmic articles comprises an internal structure for securing around a notched region of the one or more haptics. In some embodiments, the one or more ophthalmic articles comprises an outer diameter of at most 1.5 mm. In some embodiments, the internal structure comprises a diameter of at most 0.7 mm. In some embodiments, the one or more ophthalmic articles is configured such that the active agent or diagnostic agent is released from the biocompatible matrix. In some embodiments, the active agent or diagnostic agent is released from the biocompatible matrix over at least about 7 days. In some embodiments, the active agent or diagnostic agent is released from the biocompatible matrix over from about 5-30 days, 5-21 days, 5-14 days, 5-10 days, 7-30 days, 7-21 days, 7-14 days, or 7-10 days. In some embodiments, the active agent or diagnostic agent is released from the biocompatible matrix through degradation of the biocompatible matrix. In some embodiments, the biocompatible matrix is sufficiently compressible such that it is compatible with injection through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is sufficiently flexible such that it is compatible with injection through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is sufficiently elastic such that it recovers its original shape after injection through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is sufficiently elastic such that the ophthalmic article recovers its shape once implanted inside an eye. In some embodiments, the ophthalmic article is sufficiently physically stable in a physiologic environment such that it does not significantly change shape within at least 7 days after implantation of the ophthalmic article in an eye of a subject. In some embodiments, the ophthalmic article comprises from about 1 pg to 800 pg of the one or more active agents and / or diagnostic agents.

[0024] In another aspect, the present disclosure provides a method of diagnosing a disease or condition of an eye. In one embodiment, the method comprises administering into an eye of a subject in need thereof an intraocular lens (IOL) for delivery of one or more diagnostic agents to the eye of the subject, which IOL comprises one or more ophthalmic articles associated thereto, wherein the one or more ophthalmic articles comprises the one or more diagnostic agents selected from the group consisting of paramagnetic molecules, fluorescent compounds, magnetic molecules, radionuclides, x-ray imaging agents, and contrast media. In some embodiments, the method further comprises capturing an image in which the one or more diagnostic agents indicate the disease or condition. In some embodiments, prior to administering the IOL comprising one or more ophthalmic articles associated thereto, associating the one or more ophthalmic articles to one or more haptics of the IOL. In some embodiments, prior to administering the IOL comprising one or more ophthalmic articles associated thereto, combining one or more diagnostic agents with a biocompatible copolymer matrix, thereby generating one or more ophthalmic articles. In some embodiments, prior to administering the IOL comprising one or more ophthalmic articles associated thereto, compressing the IOL comprising one or more ophthalmic articles associated thereto through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the one or more diagnostic agents is a fluorescent compound. In some embodiments, the one or more ophthalmic articles comprises a biocompatible matrix. In some embodiments, the one or more ophthalmic articles is associated to one or more haptics of the IOL. In some embodiments, about one of the one or more ophthalmic articles is associated with the one or more haptics of the IOL. In some embodiments, about two of the one or more ophthalmic articles are associated with the one or more haptics of the IOL. In some embodiments, about 3, 4, 5, 6, 7, 8, 9, or 10 of the one or more ophthalmic articles are associated with the one or more haptics of the IOL. In some embodiments, about one of the one or more ophthalmic articles is associated with one of the one or more haptics of the IOL. In some embodiments, about two of the one or more ophthalmic articles are associated with one of the one or more haptics of the IOL. In some embodiments, about 3, 4, 5, 6, 7, 8, 9, or 10 of the one or more ophthalmic articles are associated with one of the one or more haptics of the IOL. In some embodiments, the one or more ophthalmic articles comprises a biocompatible matrix. In some embodiments, the biocompatible matrix comprises a copolymer derived from about 20 wt% to about 60 wt% of a caprolactone monomer and from about 40 wt% to 80 wt% of at least one other monomer. In some embodiments, the biocompatible matrix comprises a copolymer derived from about 40 wt% of the caprolactone monomer and about 60 wt% of the at least one other monomer. In some embodiments, the at least one other monomer is lactide, glycolide, or trimethylene carbonate. In some embodiments, the copolymer is a random copolymer, a block copolymer, or a gradient copolymer. In some embodiments, the copolymer is a random copolymer. In some embodiments, the biocompatible matrix is biodegradable. In some embodiments, the one or more ophthalmic articles is configured such that the diagnostic agent is released from the biocompatible matrix. In some embodiments, the diagnostic agent is released from the biocompatible matrix through degradation of the biocompatible matrix. In some embodiments, the biocompatible matrix is sufficiently compressible such that it is compatible with injection through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is sufficiently flexible such that it is compatible with injection through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is sufficiently elastic such that it recovers its original shape after injection through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the one or more ophthalmic articles has a tensile strength of at least about 0.5 megapascal (MPa). In some embodiments, the one or more ophthalmic articles has a tensile strength from about 25 MPa to 35 MPa. In some embodiments, the one or more ophthalmic articles has a glass transition temperature of at most about 24°C as measured by differential scanning calorimetry. In some embodiments, the one or more ophthalmic articles has a glass transition temperature from about -20°C to 24°C as measured by differential scanning calorimetry. In some embodiments, the one or more ophthalmic articles has an elasticity modulus of at most about 3 MPa. In some embodiments, the one or more ophthalmic articles has an elasticity modulus from about 0.5 MPa to 3 MPa. In some embodiments, the one or more ophthalmic articles has an elongation at break of at least about 100% as measured by tensile testing. In some embodiments, the one or more ophthalmic articles has an elongation at break from about 500% to 1500% at from about 18 °C to 24 °C. In some embodiments, a shape of one or more ophthalmic articles is an annulus, an extruded annulus, a torus, or a prism with a hole in the center. In some embodiments, the prism is a round prism, rectangular prism, a prism with three or more sides, or a prism with another shape. In some embodiments, wherein the one or more ophthalmic articles comprises an internal structure for associating around one or more haptics of the IOL. In some embodiments, a perimeter or widest dimension of the internal structure is less than or equal to a perimeter or widest dimension of the one or more haptics. In some embodiments, a perimeter of the internal structure is less than or equal to a perimeter of the one or more haptics. In some embodiments, a widest dimension of the internal structure is less than or equal to a widest dimension of the one or more haptics. In some embodiments, the one or more ophthalmic articles extends no more than about 0.32 mm beyond the one or more haptics once the one or more ophthalmic articles is associated to the one or more haptics. In some embodiments, a shape of the internal structure is the same as a shape of the one or more haptics. In some embodiments, the one or more ophthalmic articles comprises an internal structure for securing around a notched region of the one or more haptics. In some embodiments, the one or more ophthalmic articles comprises an outer diameter of at most 1.5 mm. In some embodiments, the internal structure comprises a diameter of at most 0.7 mm. In some embodiments, the one or more ophthalmic articles is compressively associated to an outward surface of the one or more haptics. In some embodiments, the one or more ophthalmic articles is associated to the one or more haptics of the IOL. In some embodiments, the compressing comprises folding the IOL having the one or more ophthalmic articles associated thereto into a tubular shape through the IOL injector that comprises the injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is sufficiently elastic such that the ophthalmic article recovers its shape once implanted inside an eye. In some embodiments, the ophthalmic article is sufficiently physically stable in a physiologic environment such that it does not significantly change shape within at least 7 days after implantation of the ophthalmic article in an eye of a subject. In some embodiments, the ophthalmic article comprises from about 1 pg to 800 pg of the one or more active agents and / or diagnostic agents.

[0025] In another aspect, the present disclosure provides a method of administering an active agent or diagnostic agent. In one embodiment, the method comprises (a) combining one or more active agents or diagnostic agents with a biocompatible matrix, thereby generating one or more ophthalmic articles; (b) associating the one or more ophthalmic articles to one or more haptics of at least one intraocular lens, thereby generating at least one agent-releasing intraocular lens; (c) compressing the at least one agent-releasing intraocular lens through an intraocular lens injector comprising an injector tip inner diameter from about 0.5 mm to 3 mm; and (d) implanting the at least one agent-releasing intraocular lens into an eye of a subject in need thereof for sustained intraocular active agent or diagnostic agent delivery. In some embodiments, about one of the one or more ophthalmic articles is associated with the one or more haptics. In some embodiments, about two of the one or more ophthalmic articles are associated with the one or more haptics. In some embodiments, about 3, 4, 5, 6, 7, 8, 9, or 10 of the one or more ophthalmic articles are associated with the one or more haptics. In some embodiments, about one of the one or more ophthalmic articles is associated with one of the one or more haptics. In some embodiments, about two of the one or more ophthalmic articles are associated with one of the one or more haptics. In some embodiments, about 3, 4, 5, 6, 7, 8, 9, or 10 of the one or more ophthalmic articles are associated with one of the one or more haptics. In some embodiments, the biocompatible matrix comprises a copolymer derived from about 20 wt% to about 60 wt% of a caprolactone monomer and from about 40 wt% to 80 wt% of at least one other monomer. In some embodiments, the biocompatible matrix comprises a copolymer derived from about 40 wt% of the caprolactone monomer and about 60 wt% of the at least one other monomer. In some embodiments, the at least one other monomer is lactide, glycolide, or trimethylene carbonate. In some embodiments, the copolymer is a random copolymer, a block copolymer, or a gradient copolymer. In some embodiments, the copolymer is a random copolymer. In some embodiments, the biocompatible matrix is biodegradable. In some embodiments, the one or more ophthalmic article has a tensile strength of at least about 0.5 megapascal (MPa). In some embodiments, the one or more ophthalmic article has a tensile strength from about 25 MPa to 35 MPa. In some embodiments, the one or more ophthalmic article has a glass transition temperature of at most about 24°C as measured by differential scanning calorimetry. In some embodiments, the one or more ophthalmic article has a glass transition temperature from about -20°C to 24°C as measured by differential scanning calorimetry. In some embodiments, the one or more ophthalmic article has an elasticity modulus of at most about 3 MPa. In some embodiments, the one or more ophthalmic article has an elasticity modulus from about 0.5 MPa to 3 MPa. In some embodiments, the one or more ophthalmic article has an elongation at break of at least about 100% as measured by tensile testing. In some embodiments, the one or more ophthalmic article has an elongation at break from about 500% to 1500% at from about 18 °C to 24 °C. In some embodiments, a shape of the one or more ophthalmic article is an annulus, an extruded annulus, a torus, or a prism with a hole in the center. In some embodiments, the prism is a round prism, rectangular prism, a prism with three or more sides, or a prism with another shape. In some embodiments, the active agent is an interocular pressure (IOP) lowering agent, corticosteroid, non-steroidal anti-inflammatory drug, antibiotic, antiviral, antimetabolite, antifungal, antifibrotic agent, or angiogenesis inhibitor. In some embodiments, the active agent is dexamethasone, ketorolac, diclofenac, moxifloxacin, travoprost, 5-fluorouracil, or methotrexate. In some embodiments, the associating comprises indirect association between the one or more ophthalmic articles and the one or more haptics. In some embodiments, the one or more ophthalmic articles comprises an internal structure for associating around the one or more haptics. In some embodiments, a perimeter or widest dimension of the internal structure is less than or equal to a perimeter or widest dimension of the one or more haptics. In some embodiments, a perimeter of the internal structure is less than or equal to a perimeter of the one or more haptics. In some embodiments, a widest dimension of the internal structure is less than or equal to a widest dimension of the one or more haptics. In some embodiments, the one or more ophthalmic articles extends no more than about 0.32 mm beyond the one or more haptics once the one or more ophthalmic articles is associated to the one or more haptics. In some embodiments, a shape of the internal structure is the same as a shape of the one or more haptics. In some embodiments, the one or more ophthalmic articles comprises an internal structure for securing around a notched region of the one or more haptics. In some embodiments, the one or more ophthalmic articles comprises an outer diameter of at most 1.5 mm. In some embodiments, the one or more ophthalmic articles comprises an inner diameter of at most 0.7 mm. In some embodiments, the one or more ophthalmic articles is configured such that the active agent or diagnostic agent is released from the biocompatible copolymer matrix. In some embodiments, the one or more active agents or diagnostic agents is released from the biocompatible matrix over at least about 7 days. In some embodiments, the one or more active agents or diagnostic agents is released from the biocompatible matrix over from about 5-30 days, 5-21 days, 5-14 days, 5-10 days, 7-30 days, 721 days, 7-14 days, or 7-10 days. In some embodiments, the one or more active agents or diagnostic agents is released from the biocompatible matrix through degradation of the biocompatible copolymer matrix. In some embodiments, the biocompatible matrix is sufficiently compressible such that it is compatible with injection through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is sufficiently flexible such that it is compatible with injection through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is sufficiently elastic such that it recovers its original shape after injection through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the one or more ophthalmic articles is compressively associated to an outward surface of the one or more haptics. In some embodiments, the compressing comprises folding the at least one agent-releasing intraocular lens into a tubular shape through the IOL injector that comprises the injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the subject is concurrently undergoing or has undergone ophthalmic surgery. In some embodiments, the subject is concurrently undergoing or has undergone cataract surgery. In some embodiments, the associating comprises direct association between the one or more ophthalmic articles and the one or more haptics through a chemical bond, physical bond, compressive forces, or contractile forces. In some embodiments, the biocompatible matrix is sufficiently elastic such that the ophthalmic article recovers its shape once implanted inside an eye. In some embodiments, the ophthalmic article is sufficiently physically stable in a physiologic environment such that it does not significantly change shape within at least 7 days after implantation of the ophthalmic article in an eye of a subject. In some embodiments, the ophthalmic article comprises from about 1 pg to 800 pg of the one or more active agents and / or diagnostic agents.

[0026] In another aspect, the present disclosure provides an ophthalmic drug delivery system. In one embodiment, the ophthalmic drug delivery system comprises (a) one or more ophthalmic articles comprising (1) one or more active agents or diagnostic agents, and (2) a biocompatible copolymer matrix derived from about 40 wt% of a caprolactone monomer and 60 wt% of a lactide monomer, which biocompatible copolymer matrix comprises at least one of the following characteristics: (i) the biocompatible copolymer matrix comprises a random copolymer; (ii) the one or more ophthalmic articles has a tensile strength from about 25 Megapascal (MPa) to 35 MPa; (iii) the one or more ophthalmic articles has a glass transition temperature of at most about 24°C as measured by differential scanning calorimetry; (iv) the one or more ophthalmic articles has an elasticity modulus from about 0.5 MPa to 3 MPa; (v) the one or more ophthalmic articles has an elongation at break from about 500% to 1500% at from about 18°C to 24 °C; and (b) one or more intraocular lenses (IOLs) comprising one or more haptics; wherein the one or more ophthalmic articles comprises an outer diameter of at most 1.5 mm and is configured to associate to an outward surface of the one or more haptics of the one or more IOLs to secure the one or more ophthalmic articles to the one or more haptics of the one or more IOLs. In some embodiments, about one of the one or more ophthalmic articles are associated with the one or more haptics. In some embodiments, about two of the one or more ophthalmic articles are associated with the one or more haptics. In some embodiments, about 3, 4, 5, 6, 7, 8, 9, or 10 of the one or more ophthalmic articles are associated with the one or more haptics. In some embodiments, about one of the one or more ophthalmic articles is associated with one of the one or more haptics of the IOL. In some embodiments, about two of the one or more ophthalmic articles are associated with one of the one or more haptics of the IOL. In some embodiments, about 3, 4, 5, 6, 7, 8, 9, or 10 of the one or more ophthalmic articles are associated with one of the one or more haptics of the IOL. In some embodiments, the biocompatible copolymer matrix is biodegradable. In some embodiments, a shape of the one or more ophthalmic articles is an annulus, an extruded annulus, a torus, or a prism with a hole in the center. In some embodiments, the prism is a round prism, rectangular prism, a prism with three or more sides, or a prism with another shape. In some embodiments, the active agent is an interocular pressure (IOP) lowering agent, corticosteroid, non-steroidal anti-inflammatory drug, antibiotic, antiviral, antimetabolite, antifungal, antifibrotic agent, or angiogenesis inhibitor. In some embodiments, the active agent is dexamethasone, ketorolac, diclofenac, moxifloxacin, travoprost, 5-fluorouracil, or methotrexate. In some embodiments, the one or more ophthalmic articles comprises an internal structure for associating around the one or more haptics. In some embodiments, a perimeter or widest dimension of the internal structure is less than or equal to a perimeter or widest dimension of the one or more haptics. In some embodiments, a perimeter of the internal structure is less than or equal to a perimeter of the one or more haptics. In some embodiments, a widest dimension of the internal structure is less than or equal to a widest dimension of the one or more haptics. In some embodiments, the one or more ophthalmic articles extends no more than about 0.32 mm beyond the one or more haptics once the one or more ophthalmic articles is associated to the one or more haptics. In some embodiments, a shape of the internal structure of the one or more ophthalmic articles is the same as a shape of the one or more haptic. In some embodiments, the one or more ophthalmic articles comprises an internal structure for securing around a notched region of the one or more haptics. In some embodiments, the one or more ophthalmic articles comprises an inner diameter of at most 0.7 mm. In some embodiments, the one or more ophthalmic articles is configured such that the active agent or diagnostic agent is released from the biocompatible copolymer matrix. In some embodiments, the active agent or diagnostic agent is released from the biocompatible copolymer matrix over at least about 7 days. In some embodiments, the active agent or diagnostic agent is released from the biocompatible copolymer matrix over from about 5-30 days, 5-21 days, 5-14 days, 5-10 days, 7-30 days, 7-21 days, 7-14 days, or 7-10 days. In some embodiments, the active agent or diagnostic agent is released from the biocompatible copolymer matrix through degradation of the biocompatible copolymer matrix. In some embodiments, the biocompatible copolymer matrix is sufficiently compressible such that it is compatible with injection through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the biocompatible copolymer matrix is sufficiently flexible such that it is compatible with injection through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the biocompatible copolymer matrix is sufficiently elastic such that it recovers its original shape after injection through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the biocompatible copolymer matrix is sufficiently elastic such that the ophthalmic article recovers its shape once implanted inside an eye. In some embodiments, the ophthalmic article is sufficiently physically stable in a physiologic environment such that it does not significantly change shape within at least 7 days after implantation of the ophthalmic article in an eye of a subject. In some embodiments, the ophthalmic article comprises from about 1 pg to 800 pg of the one or more active agents and / or diagnostic agents.

[0027] In another aspect, the present disclosure provides an ophthalmic article. In one embodiment, the ophthalmic article comprises (a) a biocompatible copolymer matrix derived from about 40 wt% of a caprolactone monomer and 60 wt% of a lactide monomer, which biocompatible copolymer matrix comprises at least one of the following characteristics: (i) the biocompatible copolymer matrix comprises a random copolymer; (ii) the ophthalmic article has a tensile strength from about 25 Megapascal (MPa) to 35 MPa; (iii) the ophthalmic article has a glass transition temperature of at most about 24°C as measured by differential scanning calorimetry; (iv) the ophthalmic article has an elasticity modulus from about 0.5 MPa to 3 MPa; (v) the ophthalmic article has an elongation at break from about 500% to 1500% at 18-24 °C; and (b) an active agent or diagnostic agent; wherein the ophthalmic article comprises an outer diameter of at most 1.5 mm and is configured to associate to an outward surface of a haptic of an intraocular lens (IOL) to secure the ophthalmic article to the haptic of the IOL. In some embodiments, the biocompatible copolymer matrix is biodegradable. In some embodiments, a shape of the ophthalmic article is an annulus, an extruded annulus, a torus, or a prism with a hole in the center, which may be round, rectangular or other another shape. In some embodiments, the prism is a round prism, rectangular prism, a prism with three or more sides, or a prism with another shape. In some embodiments, the ophthalmic article comprises an internal structure for associating around the outward surface of the haptic of the IOL. In some embodiments, a perimeter or widest dimension of the internal structure is less than or equal to a perimeter or widest dimension of the haptic of the IOL. In some embodiments, a perimeter of the internal structure is less than or equal to a perimeter of the haptic of the IOL. In some embodiments, a widest dimension of the internal structure is less than or equal to a widest dimension of the haptic of the IOL. In some embodiments, the ophthalmic article extends no more than about 0.32 mm beyond the haptic of the IOL once the ophthalmic article is associated to the haptic of the IOL. In some embodiments, a shape of the internal structure is the same as a shape of the haptic of the IOL. In some embodiments, the ophthalmic article comprises an internal structure for securing around a notched region of the haptic of the IOL. In some embodiments, the ophthalmic article comprises an internal hole with a diameter of at most 0.7 mm. In some embodiments, the active agent is an interocular pressure (IOP) lowering agent, corticosteroid, non-steroidal antiinflammatory drug, antibiotic, antiviral, antimetabolite, antifungal, antifibrotic agent, or angiogenesis inhibitor. In some embodiments, the active agent is dexamethasone, ketorolac, diclofenac, moxifloxacin, travoprost, 5-fluorouracil, or methotrexate. In some embodiments, the ophthalmic article is configured such that the active agent or the diagnostic agent is released from the biocompatible copolymer matrix. In some embodiments, the active agent or diagnostic agent is released from the biocompatible copolymer matrix over at least about 7 days. In some embodiments, the active agent or diagnostic agent is released from the biocompatible copolymer matrix over from about 5-30 days, 5-21 days, 5-14 days, 5-10 days, 7-30 days, 7-21 days, 7-14 days, or 7-10 days. In some embodiments, the active agent or diagnostic agent is released from the biocompatible copolymer matrix through degradation of the biocompatible copolymer matrix. In some embodiments, the biocompatible copolymer matrix is sufficiently compressible such that it is compatible with injection through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the biocompatible copolymer matrix is sufficiently flexible such that it is compatible with injection through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the biocompatible copolymer matrix is sufficiently elastic such that it recovers its original shape after injection through an IOL injector that comprises an injector tip inner diameter from about 0.5 mm to 3 mm. In some embodiments, the biocompatible matrix is sufficiently elastic such that the ophthalmic article recovers its shape once implanted inside an eye. In some embodiments, the ophthalmic article is sufficiently physically stable in a physiologic environment such that it does not significantly change shape within at least 7 days after implantation of the ophthalmic article in an eye of a subject. In some embodiments, the ophthalmic article comprises from about 1 pg to 800 pg of the one or more active agents and / or diagnostic agent.

[0028] Additional aspects and advantages of the present disclosure will become readily apparent to those skilled in this art from the following detailed description, wherein only illustrative embodiments of the present disclosure are shown and described. As will be realized, the present disclosure is capable of other and different embodiments, and its several details are capable of modifications in various obvious respects, all without departing from the disclosure. Accordingly, the drawings and description are to be regarded as illustrative in nature, and not as restrictive.

[0029] Specification, the specification is intended to supersede and / or take precedence over any such contradictory material. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings (also “Figure” and “FIG.” herein), of which:

[0031] Fig. 1A illustrates a perspective view of an ophthalmic article, in accordance with many embodiments;

[0032] Fig. IB illustrates another perspective view of an ophthalmic article, in accordance with many embodiments;

[0033] Fig. 2A illustrates a plan view of an annulus shaped ophthalmic article, in accordance with many embodiments;

[0034] Fig. 2B illustrates a cross-sectional view of the annulus shaped ophthalmic article, in accordance with many embodiments;

[0035] Fig. 2C illustrates a plan view of a toroid shaped ophthalmic article, in accordance with many embodiments;

[0036] Fig. 2D illustrates a cross-sectional view of the toroid shaped ophthalmic article, in accordance with many embodiments;

[0037] Fig. 2E illustrates a plan view of a square shaped ophthalmic article, in accordance with many embodiments;

[0038] Fig. 2F illustrates a cross-sectional view of a square shaped ophthalmic article, in accordance with many embodiments;

[0039] Fig. 2G illustrates a plan view of an octagon shaped ophthalmic article, in accordance with many embodiments;

[0040] Fig. 2H illustrates a cross-sectional view of an octagon shaped ophthalmic article, in accordance with many embodiments;

[0041] Fig. 3 A illustrates a plan view of an intraocular lens with an ophthalmic article, in accordance with many embodiments;

[0042] Fig. 3B illustrates a side view of an intraocular lens (IOL) with an ophthalmic article, in accordance with many embodiments;

[0043] Fig. 4A illustrates a plan view of an IOL with ophthalmic articles, in accordance with many embodiments;

[0044] Fig. 4B illustrates a side view of an IOL with ophthalmic articles, in accordance with many embodiments;

[0045] Fig. 5A schematically illustrates an example of a loading method, in accordance with many embodiments;

[0046] Fig. 5B schematically illustrates an example of an implanting method, in accordance with many embodiments;

[0047] Fig. 5C schematically illustrates another example of an intraocular lens with an ophthalmic article associated thereto;

[0048] Fig. 6 schematically illustrates an example of an administration, treatment, and / or diagnosis method, in accordance with many embodiments;

[0049] Fig. 7A illustrates an example of an ophthalmic article;

[0050] Fig. 7B illustrates an example of an ophthalmic article placed on an ocular device;

[0051] Fig. 7C illustrates a side view of an exemplary ophthalmic article;

[0052] Fig. 7D illustrates plan view of an exemplary ophthalmic article;

[0053] Fig. 8A illustrates an example of an ophthalmic article positioned on a haptic of an IOL;

[0054] Fig. 8B schematically illustrates an ophthalmic article;

[0055] Fig. 9A illustrates a pre-stretched state of an ophthalmic article;

[0056] Fig. 9B illustrates a stretched state of the ophthalmic article;

[0057] Fig. 9C illustrates a recovered state of the ophthalmic article;

[0058] Fig. 10 illustrates elongation at break test performed on an ophthalmic article;

[0059] Fig. 11 illustrates a stretched state of the ophthalmic article;

[0060] Fig. 12 shows an illustrative embodiment of an ophthalmic article;

[0061] Fig. 13 shows another illustrative embodiment of an ophthalmic article;

[0062] Fig. 14A shows an exemplary appearance of the ophthalmic article and IOL before an in vitro IOL injection;

[0063] Fig. 14B shows the exemplary appearance of the ophthalmic article and the IOL after the in vitro IOL injection was performed;

[0064] Fig. 15A shows an exemplary appearance of the ophthalmic article and IOL before an in vitro IOL injection was performed;

[0065] Fig. 15B shows the exemplary appearance of the ophthalmic article and IOL after the in vitro IOL injection was performed;

[0066] Fig. 16A shows an exemplary appearance of the ophthalmic article and IOL before an in vitro IOL injection was performed;

[0067] Fig. 16B shows the exemplary appearance of the ophthalmic article and IOL after the in vitro IOL injection was performed;

[0068] Fig. 17A shows an exemplary appearance of the ophthalmic article and IOL before an in vitro IOL injection was performed;

[0069] Fig. 17B shows the appearance of ophthalmic article and IOL after the in vitro IOL injection is performed;

[0070] Figs. 18A, 18C and 18E show the appearances of coated IOLs before in vitro IOL injections are performed;

[0071] Figs. 18B, 18D and 18F show the appearances of the coated IOL after in vitro IOL injections are performed;

[0072] Figs. 19A, 19C and 19E show the appearances of coated IOLs before in vitro IOL injections are performed;

[0073] Figs. 19B, 19D and 19F show the appearances of the coated IOL after in vitro IOL injections are performed;

[0074] Figs. 20A-20F show an example of a qualitative testing of a copolymer;

[0075] Figs. 21A-21E show an example of a qualitative testing of another copolymer;

[0076] Figs. 22A-22F show an example of a qualitative testing of another copolymer;

[0077] Figs. 23 A-D show an annulus-shaped ring made from a copolymer;

[0078] Fig. 24A shows an annulus shaped ring comprised of copolymer;

[0079] Fig. 24B shows an ophthalmic article in a post stretched state;

[0080] Fig. 24C shows the appearance of the polymer ring and IOL before the in vitro IOL injection was performed;

[0081] Fig. 24D shows an ophthalmic article’s state post injection;

[0082] Fig. 25A shows cumulative amounts of dexamethasone released from the ophthalmic articles;

[0083] Fig. 25B shows cumulative amounts of ketorolac released from the ophthalmic articles;

[0084] Fig. 26 shows cumulative amounts of moxifloxacin released from the ophthalmic articles;

[0085] Fig. 27 illustrates an example of antibiotic activity of a drug (e.g., moxifloxacin) released from the ophthalmic article;

[0086] Fig. 28 A illustrates the diameter of the zone of inhibition at day 0, 1,2, 7, and 9;

[0087] Fig. 28B illustrates the diameter of the zone of inhibition at day 0, 1,2, 7, and 9;

[0088] Fig. 29 shows an example of a position of an IOL in a subject’s eye that received cataract surgery.;

[0089] Figs. 30A-30C schematically illustrates a representative surgical implantation;

[0090] Figs. 31 A-31H illustrate examples of digital planar photographs of rabbit eyes at day 1 and 7;

[0091] Fig. 32 shows average ocular examination scores at day 0 (baseline), day 1, day 2, day 4, and day 7;

[0092] Fig. 33 shows the average intraocular pressure measured at day 0 (baseline), 1, 2, 4 and 7;

[0093] Fig. 34 shows ocular examination scores for a group that received implants comprising vehicle or ketorolac;

[0094] Fig. 35 shows ocular examination scores for a group that received implants comprising vehicle or dexamethasone;

[0095] Figs. 36A-F illustrates digital planar photographs associated with the ocular examination of rabbit’s eyes in one group;

[0096] Figs. 36G-L illustrates digital planar photographs associated with the ocular examination of rabbit’s eyes in another group;

[0097] Fig. 37A shows average intraocular pressure measured at day 0, 1, 3, 7, 14, 21, and 29 for a group;

[0098] Fig. 37B shows average intraocular pressure measured at day 0, 1, 3, 7, 14, 21, and 29 for another group;

[0099] Figs. 38A-38D shows representative images of histopathology sections of the eyes of the animals in a group;

[0100] Figs. 39A-38D shows representative images of histopathology sections of the eyes of the animals in another group;

[0101] Fig. 40 illustrates tissue concentrations of ketorolac in aqueous humor;

[0102] Fig. 41 illustrates tissue concentrations of dexamethasone in aqueous humor;

[0103] Fig. 42 illustrates an area under the curve analyses for ketorolac concentrations in aqueous humor;

[0104] Fig. 43 illustrates an area under the curve analyses for dexamethasone concentrations in aqueous humor;

[0105] Fig. 44 illustrates average total ocular examination scores for treatment groups at days 0, 1, 3, 7, 14, 21, 30, 60 and 90;

[0106] Fig. 45 shows PCO subscores on days 0, 1, 3, 7 ,14, 21, 30, 60 and day 90 following the surgery;

[0107] Fig. 46 illustrates total ocular examination scores assessed by the modified Hackett-MacDonald scale;

[0108] Fig. 47 illustrates intraocular pressure measurements at day 0, 30, 60, and 90 post surgery;

[0109] Fig. 48 illustrates anterior chamber cell (ACC) scores;

[0110] Fig. 49 shows pain scores for subjects at day 0, 1, 7 and 28;

[0111] Figs. 50A-50D illustrate a loading process of an IOL with an associated ophthalmic article into an IOL injector cartridge;

[0112] Figs. 51 A-5 ID illustrate surgical implantation of an IOL with an associated ophthalmic article into an eye of a human subject;

[0113] Figs. 52A-52B illustrate slit lamp photographs for a subject;

[0114] Fig. 53 illustrates differential scanning calorimetry of an ophthalmic article; and

[0115] Fig. 54 illustrates a storage modulus curve, a loss modulus, and a tan delta curve for an ophthalmic article. DETAILED DESCRIPTION

[0116] While various embodiments of the invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions may occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed.

[0117] As used herein, the singular forms “a,” “an,” and “the” include plural references unless the context clearly dictates otherwise. Any reference to “or” herein is intended to encompass “and / or” unless otherwise stated.

[0118] As used herein, “substantial” or “substantially” can refer to the complete or nearly complete extent or degree of an action, characteristic, property, state, structure, item, or result. For example, an object that is substantially enclosed would mean that the object is either completely enclosed or nearly completely enclosed. The exact allowable degree of deviation from absolute completeness may in some cases depend on the specific context. However, generally speaking the nearness of completion will be so as to have the same overall result as if absolute and total completion were obtained. The use of “substantially” is equally applicable when used in a negative connotation to refer to the complete or near complete lack of an action, characteristic, property, state, structure, item, or result.

[0119] As used herein, “effective amount” refers to an amount of an ingredient which, when included in a composition, is sufficient to achieve an intended compositional or physiological effect. Thus, a “therapeutically effective amount” refers to a substantially non-toxic, but sufficient amount of an active agent, to achieve therapeutic results in treating or preventing a condition for which the active agent is known to be effective. It is understood that various biological factors may affect the ability of a substance to perform its intended task. Therefore, an “effective amount” or a “therapeutically effective amount” may be dependent in some instances on such biological factors. Further, while the achievement of therapeutic effects may be measured by a physician or other qualified medical personnel using evaluations known in the art, it is recognized that individual variation and response to treatments may make the achievement of therapeutic effects a subjective decision. However, the determination of an effective amount may be within the ordinary skill in the art of pharmaceutical and nutritional sciences as well as medicine.

[0120] As used herein, “reshape” can refer to the act of reducing the overall dimensions of an object (e.g., an ophthalmic article), for instance by bending, folding, rolling or otherwise collapsing the object to a desired configuration (shape), physically or chemically. To that end, the terms, “collapsing”, “bending”, “folding”, “rolling” can refer to the reshaping of the ophthalmic article and / or ocular device of the present invention to allow the ophthalmic article to fit in an intraocular injector tip’s inner diameter that is smaller in at least one dimension than that of the ophthalmic article in its original shape (e.g. prior to reshaping).

[0121] As used herein, “subject” refers to a mammal that may benefit from the administration of a composition or method as recited herein. Examples of subjects include humans, and can also include other animals such as horses, pigs, cattle, dogs, cats, rabbits, or aquatic mammals.

[0122] Whenever the term “at least,” “greater than,” or “greater than or equal to” precedes the first numerical value in a series of two or more numerical values, the term “at least,” “greater than” or “greater than or equal to” applies to each of the numerical values in that series of numerical values. For example, greater than or equal to 1, 2, or 3 is equivalent to greater than or equal to 1, greater than or equal to 2, or greater than or equal to 3.

[0123] Whenever the term “at most”, “no more than,” “up to,” “less than,” or “less than or equal to” precedes the first numerical value in a series of two or more numerical values, the term “no more than,” “less than,” or “less than or equal to” applies to each of the numerical values in that series of numerical values. For example, less than or equal to 3, 2, or 1 is equivalent to less than or equal to 3, less than or equal to 2, or less than or equal to 1.

[0124] Cataract surgery has evolved significantly over the past 30 to 40 years. The advent of new biomaterials (e.g., soft acrylic polymers) has enabled development of deformable, elastic IOLs with capacity to be folded, rolled or otherwise deformed into narrower profiles for injection through smaller incisions. Advancements in surgical instruments (e.g., IOL injector cartridges and injectors) have improved the efficiency of IOL folding and rolling with greater consistency and reliability than traditional methods (e.g., IOL forceps). Such innovations have reduced the invasiveness and duration of cataract surgery resulting in fewer complications, better refractive outcomes and faster recovery for patients.

[0125] In designing an ophthalmic article (e.g., drug delivery device) intended for implantation inside the eye, the ophthalmic article’s physical, chemical and / or biologic properties may affect its safety profile. The ophthalmic article can be sufficiently soft and / or flexible so as not to deform, abrade, pierce, occlude or otherwise physically injure internal structures of an eye. The inactive materials that comprise the drug delivery device, and any degradants thereof, may be biocompatible and not cause untoward effects within the eye. The active agents (e.g., active ingredients) and / or diagnostic agents that comprise the ophthalmic article may be present in quantities sufficient to achieve their intended function but not exceed levels known to cause toxicity within the eye.

[0126] Surgical procedures may be optimized to achieve the maximum benefit to a subject (e.g., patient) with the lowest possible risk of complications. Any modifications to the standard surgical technique may alter the risk benefit-ratio for subjects (e.g., patients). In designing an ophthalmic article (e.g., drug delivery device) for association to an ocular device (e.g., an intraocular lens), the ocular device with the ophthalmic article attached thereto may be compatible with standard surgical technique for surgery (e.g., cataract surgery). Furthermore, the usability and human factors aspects of the ocular device with the ophthalmic article attached thereto may be comparable to that of an ocular device alone.

[0127] The present disclosure provides articles, methods, systems, and kits for delivery or administration of active agents and / or diagnostic agents from an ocular device to an eye. The present disclosure also provides articles, methods, systems, and kits for diagnosis and / or treatment of a disease, condition, or complication. For example, the present disclosure provides articles, methods, devices, systems, and kits for delivery of active agents (e.g., medications) from an intraocular lens (IOL) to an eye. In some embodiments, articles, systems, and associated methods of the present disclosure can be positioned within an anterior segment of the eye (e.g. within the lens capsule) of a subject to deliver an active agent and / or diagnostic agent to the posterior segment of an eye of the subject. Non-limiting examples of ocular regions found within the posterior segment of the eye can include at least one of vitreous humor, the choroid, and the retina. In addition to delivering the active agent and / or diagnostic agent to the posterior segment of the eye, the active agent and / or diagnostic agent can also be delivered to the anterior segment of the eye. The anterior segment of the eye can include at least one of the aqueous humor, the iris, and the lens capsule. The delivery may provide sustained release of the active agents and / or diagnostic agents over a period of time (e.g., with continuous release kinetics). The ophthalmic article for delivery or administration of the active agent and / or diagnostic agent to the eye can comprise a polymeric material (e.g., biocompatible polymer matrix), a non polymeric material, and / or an agent (e.g., active agent and / or diagnostic agent, a variety or combination of different active agents and / or diagnostic agents). The ophthalmic article (e.g., a drug delivery device) as described herein can be associated with to the ocular device (e.g., intraocular device) and can provide active agent and / or diagnostic agent delivery by alleviating the methods of multiple injections or complex eyedrop regimens. This allows for automatic active agent delivery to the eye and can eliminate the issue of patient non-compliance.

[0128] In an aspect, the present disclosure provides an ophthalmic article. The ophthalmic article may comprise a biocompatible material (e.g., biocompatible matrix). The biocompatible material may comprise a polymeric material comprising one or more polymers. The polymer may be a copolymer derived from one or more monomers. In some embodiments, the polymer may be a copolymer derived from a caprolactone monomer and at least one other monomer. In some embodiments, the one or more ophthalmic article may comprise at least one active agent and / or diagnostic agent.

[0129] In another aspect, the present disclosure provides an ophthalmic article. The ophthalmic article may comprise a biocompatible material (e.g., a biocompatible matrix). The ophthalmic article may also comprise an active agent and / or a diagnostic agent. The ophthalmic article can comprise an equivalent elasticity, compressibility, tensile strength, shape recovery, or reshapability to another article comprising a biocompatible matrix comprising a copolymer derived from a caprolactone monomer and a lactide monomer. In some embodiments, the ophthalmic article can comprise an equivalent elasticity, compressibility, tensile strength, shape recovery, or reshapability to an article comprising a biocompatible matrix comprising a copolymer derived from about 40 wt% of a caprolactone monomer and about 60 wt% of a lactide monomer. The ophthalmic article may be configured to associate to a portion of an ocular device (e.g., a haptic of an intraocular lens).

[0130] In another aspect, the present disclosure provides an ophthalmic system. The ophthalmic system may comprise one or more ophthalmic articles. The one or more ophthalmic articles may comprise a biocompatible material (e.g., polymer matrix) comprising at least a polymer. The polymer may be a copolymer. The copolymer may be derived from one or more monomers. In some embodiments, the one or more monomers may be lactide, glycolide, caprolactone, ethylene glycol, trimethylene carbonate, or combinations thereof. In some embodiments, the polymer may be a copolymer derived from a caprolactone monomer and at least one other monomer. In some embodiments, the one or more ophthalmic article may comprise at least one active agent and / or diagnostic agent. The ophthalmic system may also comprise one or more ocular devices (e.g., an intraocular lens). The one or more ocular devices may be associated to the one or more ophthalmic articles.

[0131] In any of the various aspects, the one or more ophthalmic articles described herein are engineered in composition, size, shape, and combinations thereof, to provide maximal approximation of the ophthalmic article to a subject’s eye. In some embodiments, the one or more ophthalmic articles may comprise a material. The material may be a biocompatible material (e.g., a biocompatible matrix). The biocompatible matrix may be a polymeric matrix. The material may comprise a polymeric material (e.g., a polymeric matrix) and / or a non-polymeric material. Non-polymeric materials can comprise glass (silica), soda-lime glass, alkali aluminosilicate glass, borosilicate glass, alkali-free glass, crystal glass quartz glass, metals and metal alloys (steel, aluminum, silver, gold, tantalum, titanium, copper, nickel, palladium platinum, zinc tin, antimony, bismuth, zinc, manganese, antimony, molybdenum, vanadium), crystalline materials (diamond, sapphire, graphene), carbon fiber, fiberglass, silicon carbide, alumina, graphite, aluminum oxide, aluminum oxide with chrome, brown fused aluminum oxide (ALOX), low titanium dioxide brown fused aluminum oxide (ALOX), zirconia-alumina, hydrated alumina, ceramic aluminum oxide (ALOX), green silicon carbide, black silicon carbide, boron carbide, cubic boron nitride, and diamond.

[0132] Biocompatible materials may comprise substances that do not elicit an adverse reaction when placed in a biologic environment. Biocompatible materials can be natural or synthetic in origin.

[0133] In some embodiments, the polymeric material can comprise a biocompatible polymer and / or a biodegradable polymer. For example, the polymeric materials or compositions for use in the ophthalmic article may comprise materials which are compatible (e.g., biocompatible) with the eye so as to cause no substantial interference with the functioning or physiology of the eye. Such polymeric materials may also be biodegradable and / or bioerodible. A biodegradable polymer can refer to one or more polymers, which can erode or degrade (e.g., in vivo) under physiological conditions over time due, at least in part, to contact with substances found in the surrounding tissue fluids, or by cellular function. The release of the active agent and / or diagnostic agent can occur concurrent with, or subsequent to, the degradation of a biodegradable polymer over time.

[0134] In some embodiments, the polymeric material may comprise homopolymers (e.g., polymers comprising one type of monomeric repeating unit), copolymers (e.g., polymer comprising two or more types of monomeric repeating units), or a polymer comprising more than two different polymeric units. In some embodiments, the polymeric material (e.g., polymer matrix) can comprise a homogeneous mixture of polymers. For example, the homogeneous mixture of polymers may not include a mixture wherein one portion thereof is different from another portion, (e.g., by ingredient or density). In some embodiments, the polymeric material (e.g., polymer matrix) can comprise a heterogeneous mixture of polymers. In some embodiments, the polymeric material may comprise a mixture of polymers of the same type (e.g. two different polylactic acid polymers) or of different types (e.g. polylactic acid polymers combined with polycaprolactone polymers). In some embodiments, the polymeric material may comprise a copolymer. In other embodiments, the copolymer may comprise one or more of a block copolymer (by way of illustration represented by PPPP-HHHH; wherein P and H are each illustrative monomeric units), alternating copolymer (by way of illustration represented by PHPHPHPH; wherein P and H are each illustrative monomeric units), statistical or random copolymer (by way of illustration represented by PHPPHPHH; wherein P and H are each illustrative monomeric units), a star copolymer, a brush copolymer, a gradient copolymer, or a graft copolymer. In some embodiments, the copolymer may be a random copolymer.

[0135] In some embodiments, the polymeric materials may comprise poly(L-lactide-co-caprolactone) (e.g., different ratios of L-lactide to caprolactone content), poly(D-lactide-co-caprolactone), poly(D,L-lactide-co-caprolactone), poly-(D-lactic acid) (PDLA), poly-(L-lactic acid) (PLLA), poly(D,L-lactic acid) (PLA), polycaprolactone (PCL), polyvinyl alcohol (PVA), poly(ethylene glycol) (PEG), poly(glycolic acid) (PGA), poly(L-lactide-co-glycolide), poly(D-lactide-co-glycolide), poly(D,L-lactide-co-glycolide) (PLGA), poly(L-lactide-co-trimethylene carbonate), poly(D-lactide-co-trimethylene carbonate), poly(D,L-lactide-co-trimethylene carbonate), poly(trimethylene carbonate-co-s-caprolactone), poly(caprolactone-co-glycolide), polyorthoesters, polyanhydrides, polyesters, polyamides, polyesteramides, polycarbonates, polyethylene, polypropylene, polygalactic acid, polyacrylamide, polystyrene, polyurethane, silicone, hydroxypropylmethylcellulose (HPMC), hydroxypropyl cellulose (HPC), polyglycolic acid-polyvinyl alcohol copolymers, polycaprolactone-polyethylene glycol copolymers, collagen, croscarmellose collagen, hyaluronic acid, elastin, polyhydroxybutyrate, polyalkaneanhydrides, gelatin, cellulose, oxidized cellulose, polyphosphazene, poly(sebacic acid), poly(ricenolic acid), poly(fumaric acid), chitin, chitosan, polyvinylpyrrolidone (PVP), synthetic cellulose esters, polyacrylic acids, polybutyric acid; triblock copolymers (e.g., PLGA-PEG-PLGA, PEG-PLGA-PEG), poly(N-isopropylacrylamide, poly(ethylene oxide)- poly(propylene oxide)- poly(ethylene oxide) tri-block copolymers (PEO-PPO-PEO), poly valeric acid, poly(valerolactone), polyhydroxyalkylcellulose; siloxane, polysiloxane; dimethylsiloxane / -methylvinylsiloxane copolymer; poly(dimethylsiloxane / -methylvinylsiloxane / -methylhydrogensiloxane) dimethylvinyl or trimethyl copolymer, polypeptides, poly(amino acids), poly(dioxanones), poly(alkylene alkylates), hydrophobic polyethers, polyetheresters, polyacetals, polycyanoacrylates, polyacrylates, polymethylmethacrylates, polysiloxanes, poly(oxyethylene) / poly(oxypropylene) copolymers, polyketals, polyphosphates, polyhydroxyvalerates, polyalkylene oxalates, polyalkylene succinates, poly(maleic acid), as well as copolymers thereof or derivatives thereof including oxidized, reduced, mono substituted, di substituted, multi-substituted derivatives, or any combinations thereof. In some embodiments, the polymeric materials may comprise one or more elements as described by, for example, Abraham J. Domb et al., Biodegradable Polymers in Clinical Use and Clinical Development (2011), (ISBN: 978-1-118-01580-3), which is incorporated by reference herein in its entirety. In some embodiments, the polymeric material may comprise polymers (e.g., polylactic acid, polycaprolactone, poly(lactide-co-caprolactone) and / or poly(L-lactide-co-caprolactone)) that can provide sustained-release of the active agent and / or diagnostic agent into the eye over time. In some embodiments, the polymeric material can comprise polylactic acid. In other embodiments, the polymeric material can comprise polycaprolactone. In other embodiments, the polymeric material can comprise poly(lactide-co-caprolactone). In other embodiments, the polymeric material can comprise poly(L-lactide-co-caprolactone).

[0136] In some embodiments, the polymeric material includes mixtures of a copolymer with another homopolymer or another copolymer. In some embodiment, the polymer may include a mixture of poly(lactide-co-caprolactone) (PLCL) with another homopolymer or another copolymer. In some embodiment, the polymer may include a mixture of poly(L-lactide-co-caprolactone) with another homopolymer or another copolymer. In some embodiment, the polymer may include a mixture of poly(L-lactide-co-caprolactone) with a PLA. In some embodiment, the polymer may include a mixture of poly(L-lactide-co-caprolactone) with a PGA. In some embodiment, the polymer may include a mixture of poly(L-lactide-co-caprolactone) with a PLGA. In some embodiment, the polymer may include a mixture of poly(L-lactide-co-caprolactone) with a PGA and / or PLGA.

[0137] In some embodiments, examples of polymeric materials comprise materials derived from and / or including organic esters and / or organic ethers, which when degraded results in physiologically acceptable degradation products. In some embodiments, the polymeric materials can comprise materials derived from and / or including, anhydrides, amides, esters, orthoesters and the like, alone or in combination with other monomers. The polymeric materials may be addition or condensation polymers. The polymeric materials may be cross-linked or non-cross-linked.

[0138] In some embodiments, besides carbon and hydrogen, the polymers may include at least one of oxygen and / or nitrogen. The oxygen may be present as oxy (e.g. hydroxy or ether), carbonyl (e.g., non-oxo carbonyl, carboxylic acid, carboxylic acid ester, amide and the like). The nitrogen may be present as part of an amide, cyano, or amino (including substituted amino) moi eties. In some embodiments, polymers of hydroxyaliphatic carboxylic acids, polymers of hydroxalkanoates, either homopolymers or copolymers, and polysaccharides can be used in the ophthalmic articles. In some embodiments, polyesters can also be used in ophthalmic articles and can comprise polymers of D-lactic acid, L-lactic acid, racemic lactic acid (D,L-lactic acid), caproic acid, hydroxybutyric acid, glycolic acid, caprolactone, valerolactone, polymers and copolymers thereof in any ratios, or combinations thereof.

[0139] Some characteristics of the polymers or polymeric materials for use in embodiments of the present disclosure may comprise biocompatibility, compatibility with the active agents and / or diagnostic agents, ease of use of the polymer in making the active agent and / or diagnostic agent delivery systems described herein, a desired half-life in the physiological environment, and hydrophilicity.

[0140] In some embodiments, the polymer matrix used to manufacture the ophthalmic article may be a synthetic aliphatic polyester, for example, a polymer of lactic acid and / or caproic acid, which can comprise poly-(D,L-lactide) (PLA), poly-(D-lactide), poly-(L-lactide), polycaprolactone (PCL), poly(L-lactide-co-caprolactone), poly(D-lactide-co-caprolactone), or mixtures, or copolymers thereof.

[0141] These polymers can degrade via backbone hydrolysis (bulk erosion) and the final degradation products of PLCL are lactic acid (e.g., L-lactic acid) and caproic acid, which are non-toxic and considered natural metabolic compounds. Lactic acid (e.g., L-lactic acid) and caproic acid are eliminated safely via the Krebs cycle by conversion to carbon dioxide and water. The ophthalmic article and / or the biocompatible material can degrade (e.g., non-enzymatic hydrolysis of its ester linkages throughout the polymer matrix, in the presence of water in the surrounding tissues) homogenously at a constant rate throughout the polymer matrix thereby enabling diffusion of the active agent and / or diagnostic agent from the matrix into the surrounding environment. This contrasts with other polymer-drug release systems that degrade through “surface erosion” whereby degradation of the polymer only occurs at outwardly exposure surfaces.

[0142] In bulk erosion, degradation of the matrix occurs throughout the matrix simultaneously with solubilization of oligomers in the surrounding media and drug release occurs by diffusion, which is a concentration-dependent phenomenon. On the other hand, surface erosion occurs from the front of the device, which continuously moves to the core of the device. As these types of polymers are made up of very hydrophobic monomers they do not allow aqueous media to penetrate the core; moreover, the oligomers usually deposit on the device itself and further hinder the release of entrapped bioactives. As a particular volume of the device is exposed to the environment, release occurs in zero-order fashion. These surface-eroding polymers have very labile hydrolytic bonds, thus may not be suitable for sustaining the release in nanoscopic carriers.

[0143] In some embodiments, poly(lactide-co-caprolactone) (PLCL) may be synthesized through random ring-opening co-polymerization of D,L-lactide and 8-caprolactone. Successive monomeric units of D,L-lactide or 8-caprolactone can be linked together by ester linkages. The ratio of lactide to caprolactone can be varied, altering the biodegradation characteristics of the product. By altering the ratio it may be possible to tailor the polymer degradation time. Drug release characteristics can be affected by the rate of biodegradation, molecular weight or molecular mass, and degree of crystallinity in drug delivery systems. By altering and customizing the biodegradable polymer matrix, the drug delivery profile can be changed.

[0144] In some embodiments, poly(L-lactide-co-caprolactone) may be synthesized through random ring-opening co-polymerization of L-lactide and 8-caprolactone. Successive monomeric units of L-lactide or 8-caprolactone are linked together by ester linkages. The ratio of L-lactide to 8-caprolactone can be varied, altering the biodegradation characteristics of the product. By altering the ratio it may be possible to tailor the polymer degradation time. Drug release characteristics can be affected by the rate of biodegradation, molecular weight or molecular mass, and degree of crystallinity in drug delivery systems. By altering and customizing the biodegradable polymer matrix, the drug delivery profile can be changed.

[0145] Alternatively, the synthesis of various molecular weights or molecular mass of PLCL with various D,L-lactide-caprolactone ratios may be possible. For example, the synthesis of various molecular weights or molecular mass of poly(L-lactide-co-caprolactone) with various L-lactide-caprolactone ratios is possible. The polymers used to form the ophthalmic articles of the disclosure have independent properties associated with them that when combined provide the properties needed to provide sustained release of an effective amount (e.g., therapeutically effective amount) of an active agent and / or diagnostic agent. A few of the primary polymer characteristics that control active agent and / or diagnostic agent release rates can be the molecular weight distribution or molecular mass distribution, polymer end group (i.e., carboxylic acid or ester), and the ratio of monomers within a copolymer, and / or the ratio of polymers and / or copolymers in the polymer matrix. The present disclosure provides an example of a polymer matrix that possess desirable active agent and / or diagnostic agent release characteristics by manipulating one or more of the aforementioned properties to develop a suitable ophthalmic article.

[0146] Some polymeric materials can be subject to enzymatic or hydrolytic instability. Water soluble polymers may be cross-linked with hydrolytic or biodegradable unstable cross- links to provide useful water insoluble polymers. Thus, the degree of stability can vary, depending upon the choice of one or more monomers, whether a homopolymer or copolymer is employed, employing mixtures of polymers, and whether the polymer includes terminal acid groups.

[0147] Another factor for controlling the biodegradation of the polymer matrix and hence the extended release profile of the ophthalmic article is the relative average molecular weight or molecular mass of the polymeric composition employed in the ophthalmic article. Different molecular weights or molecular mass of the same or different polymeric compositions may modulate the release profile (e.g., extended release, non-extended release, linear release) of the at least one active agent and / or diagnostic agent. In some embodiments, the polymeric material may be selected from biodegradable polymers, disclosed herein, that do not substantially swell when in the presence of the aqueous humor. For example, PLGA polymers swell when used as the matrix material of drug delivery implants whereas PLA based polymer blends do not appreciably swell in the presence of the aqueous humor.

[0148] Example polymers used in various embodiments of the disclosure may comprise variation in the mole ratio of a first monomer (e.g., L-lactide) to a second monomer (e.g., 8-caprolactone) from approximately 50:50 to approximately 85:15, including, but not limited to, 50:50, 51:49, 52:48, 53:47, 54:46, 55:45, 54:46, 53:47, 52:48, 51:49, 60:40, 61:39, 62:38, 63:37, 64:35, 65:35, 66:34, 67:33, 68:32, 69:31,70:30, 71:29, 72:28, 73:27, 74:26, 75:25, 76:24, 77:23, 78:22, 79:21, 80:20, 81:19, 82:18, 83:17, 84:16, 85:15, 90:10, or 95:5. In some embodiments, the mole ratio of the first monomer (e.g., L-lactide) to the second monomer may be a ratio aside from 50:50 (e.g., 8-caprolactone). In some embodiments, the mole ratio of the first monomer (e.g., L-lactide) to the second monomer (e.g., 8-caprolactone) may be 60:40.

[0149] Example polymers used in various embodiments of the disclosure may comprise variation in the weight ratio of a first monomer (e.g., L-lactide) to a second monomer (e.g., £caprolactone) from approximately 50:50 to approximately 85:15, including, but not limited to, about 5:95, about 10:90, about 15:85, about 20:80, about 25:75, about 30:70, about 35:65, about 40:60, about 45:55, about 50:50, about 51:49, about 52:48, about 53:47, about 54:46, about 55:45, about 54:46, about 53:47, about 52:48, about 51:49, about 60:40, about 61:39, about 62:38, about 63:37, about 64:35, about 65:35, about 66:34, about 67:33, about 68:32, about 69:31, about 70:30, about 71:29, about 72:28, about 73:27, about 74:26, about 75:25, about 76:24, about 77:23, about 78:22, about 79:21, about 80:20, about 81:19, about 82:18, about 83:17, about 84:16, about 85:15, about 90:10, or about 90:15. In some embodiments, the ratio of the first monomer (e.g., L-lactide) to the second monomer may be a ratio aside from 50:50. In some embodiments, the mole ratio of the first monomer (e.g., L-lactide) to the second monomer (e.g., 8-caprolactone) may be 60:40.

[0150] In one example, the polymeric material can comprise poly(lactide-co-caprolactone) having a copolymer ratio from 10:90 to 90:10 and in another case from 52:48 to 90:10. In yet other examples, the copolymer ratio can be from about 60:40 to about 40:60, or from about 55:45 to about 45:55. In some embodiments, the copolymer ratio can be about 60:40. In some embodiments, the copolymer ratio can be about 50:50. In some embodiments, the copolymer ratio can be a ratio aside from about 50:50. In some embodiments, the copolymer ratio can be 5278:48-22 and in another specific example from 60-90:40-10.

[0151] In one example, the polymeric material can comprise poly(L-lactide-co-caprolactone) having a copolymer ratio from 10:90 to 90:10 and in another case from 52:48 to 90:10. In yet other examples, the copolymer ratio can be from about 60:40 to about 40:60, or from about 55:45 to about 45:55. In some embodiments, the copolymer ratio can be about 60:40. In some embodiments, the copolymer ratio can be about 50:50. In some embodiments, the copolymer ratio can be a ratio aside from about 50:50. In some embodiments, the copolymer ratio can be 5278:48-22 and in another specific example from 60-90:40-10. Although degradation rates can be dependent on such proportions, additional alternative approaches can also be useful such as device coatings, particle encapsulation, and the like.

[0152] In one example, the polymeric material can comprise poly(L-lactide-co-caprolactone) having a copolymer ratio from 10:90 to 90:10 and in another case from 52:48 to 90:10. In yet other examples, the copolymer ratio can be from about 60:40 to about 40:60, or from about 55:45 to about 45:55. In some embodiments, the copolymer ratio can be about 60:40. In some embodiments, the copolymer ratio can be about 50:50. In some embodiments, the copolymer ratio can be a ratio aside from about 50:50. In some embodiments, the copolymer ratio can be 5278:48-22 and in another specific example from 60-90:40-10.

[0153] In some embodiments, the polymeric material (e.g., biocompatible copolymer matrix) may be derived from about 20 wt% to about 60 wt% of a caprolactone monomer and from about 40 wt% to 80 wt% of at least one other monomer. In some embodiments, the polymeric material (e.g., biocompatible copolymer matrix) may be derived from about 40 wt% of the caprolactone monomer and about 60 wt% of the at least one other monomer. In some embodiments, the at least one other monomer may be lactide, glycolide, caprolactone, ethylene glycol, trimethylene carbonate, or combinations thereof. In some embodiments, the at least one other monomer is lactide.

[0154] In some embodiments, the polymeric material (e.g., biocompatible matrix) may be derived from about 20 wt% to about 60 wt% of a caprolactone monomer and from about 40 wt% to 80 wt% of lactide. In some embodiments, the polymeric material (e.g., biocompatible matrix) may be derived from about 40 wt% of the caprolactone monomer and about 60 wt% of lactide.

[0155] In some embodiments, the polymeric material (e.g., biocompatible matrix) may be derived from about 20 wt% to about 60 wt% of a caprolactone monomer and from about 40 wt% to 80 wt% of L-lactide. In some embodiments, the polymeric material (e.g., biocompatible matrix) may be derived from about 40 wt% of the caprolactone monomer and about 60 wt% of L-lactide.

[0156] In some embodiments, the ophthalmic article can contain at least about 50 wt% polymeric material and / or at least about 50 wt% active agent and / or diagnostic agent. In some embodiments, the ophthalmic article can contain at least about 55 wt% polymeric material and / or at least about 45 wt% active agent and / or diagnostic agent. In some embodiments, the ophthalmic article can contain at least about 60 wt% polymeric material and / or at least about 40 wt% active agent and / or diagnostic agent. In some embodiments, the ophthalmic article can contain at least about 65 wt% polymeric material and / or at least about 35 wt% active agent and / or diagnostic agent. In some embodiments, the ophthalmic article can contain at least about 70 wt% polymeric material and / or at least about 30 wt% active agent and / or diagnostic agent. In some embodiments, the ophthalmic article can contain at least about 75 wt% polymeric material and / or at least about 25 wt% active agent and / or diagnostic agent. In some embodiments, the ophthalmic article can contain at least about 80wt% polymeric material and / or at least about 20wt% active agent and / or diagnostic agent. In some embodiments, the ophthalmic article can contain at least about 85 wt% polymeric material and / or at least about 15 wt% active agent and / or diagnostic agent. In some embodiments, the ophthalmic article can contain at least about 90 wt% polymeric material and / or at least about 10 wt% active agent and / or diagnostic agent. In some embodiments, the ophthalmic article can contain at least about 95 wt% polymeric material and / or at least about 5 wt% active agent and / or diagnostic agent.

[0157] In some embodiments, the ophthalmic article can contain at most about 50 wt% polymeric material and / or at most about 50 wt% active agent and / or diagnostic agent. In some embodiments, the ophthalmic article can contain at most about 55 wt% polymeric material and / or at most about 45 wt% active agent and / or diagnostic agent. In some embodiments, the ophthalmic article can contain at most about 60 wt% polymeric material and / or at most about 40 wt% active agent and / or diagnostic agent. In some embodiments, the ophthalmic article can contain at most about 65 wt% polymeric material and / or at most about 35 wt% active agent and / or diagnostic agent. In some embodiments, the ophthalmic article can contain at most about 70 wt% polymeric material and / or at most about 30 wt% active agent and / or diagnostic agent. In some embodiments, the ophthalmic article can contain at most about 75 wt% polymeric material and / or at most about 25 wt% active agent and / or diagnostic agent. In some embodiments, the ophthalmic article can contain at most about 80wt% polymeric material and / or at most about 20wt% active agent and / or diagnostic agent. In some embodiments, the ophthalmic article can contain at most about 85 wt% polymeric material and / or at most about 15 wt% active agent and / or diagnostic agent. In some embodiments, the ophthalmic article can contain at most about 90 wt% polymeric material and / or at most about 10 wt% active agent and / or diagnostic agent. In some embodiments, the ophthalmic article can contain at most about 95 wt% polymeric material and / or at most about 5 wt% active agent and / or diagnostic agent.

[0158] In some embodiments, the ophthalmic article can contain about 50wt% to about 55wt% polymeric material and / or about 45wt% to about 50wt% active agent and / or diagnostic agent. In some embodiments, the ophthalmic article can contain about 55wt% to about 60wt% polymeric material and / or about 40wt% to about 45wt% active agent and / or diagnostic agent. In some embodiments, the ophthalmic article can contain about 60wt% to about 65wt% polymeric material and / or about 35wt% to about 40wt% active agent and / or diagnostic agent. In some embodiments, the ophthalmic article can contain about 65wt% to about 70wt% polymeric material and / or about 30wt% to about 35wt% active agent and / or diagnostic agent. In some embodiments, the ophthalmic article can contain about 70wt% to about 75wt% polymeric material and / or about 25wt% to about 30wt% active agent and / or diagnostic agent. In some embodiments, the ophthalmic article can contain about 75wt% to about 80wt% polymeric material and / or about 20wt% to about 25wt% active agent and / or diagnostic agent. In some embodiments, the ophthalmic article can contain about 80wt% to about 85wt% polymeric material and / or about 15wt% to about 20wt% active agent and / or diagnostic agent. In some embodiments, the ophthalmic article can contain about 85wt% to about 90wt% polymeric material and / or about 10wt% to about 15wt% active agent and / or diagnostic agent. In some embodiments, the ophthalmic article can contain about 90wt% to about 95wt% polymeric material and / or about 5wt% to about 10wt% active agent and / or diagnostic agent.

[0159] In some embodiments, the ophthalmic article can contain at least about 50wt% polymeric material, at least about 10wt% active agent and / or diagnostic agent and / or at least about 40wt% pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article can contain at least about 55wt% polymeric material, at least about 10wt% active agent and / or diagnostic agent and / or at least about 35wt% pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article can contain at least about 60wt% polymeric material, at least about 10wt% active agent and / or diagnostic agent and / or at least about 30wt% pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article can contain at least about 65wt% polymeric material, at least about 10wt% active agent and / or diagnostic agent and / or at least about 25wt% pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article can contain at least about 70wt% polymeric material, at least about 10wt% active agent and / or diagnostic agent and / or at least about 20wt% pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article can contain at least about 75wt% polymeric material, at least about 10wt% active agent and / or diagnostic agent and / or at least about 15wt% pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article can contain at least about 80wt% polymeric material, at least about 10wt% active agent and / or diagnostic agent and / or at least about 10wt% pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article can contain at least about 85wt% polymeric material, at least about 10wt% active agent and / or diagnostic agent and / or at least about 5wt% pharmaceutically acceptable excipient.

[0160] In some embodiments, the ophthalmic article can contain at least about 50wt% polymeric material, at least about 20wt% active agent and / or diagnostic agent and / or at least about 30wt% pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article can contain at least about 55wt% polymeric material, at least about 20wt% active agent and / or diagnostic agent and / or at least about 25wt% pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article can contain at least about 60wt% polymeric material, at least about 20wt% active agent and / or diagnostic agent and / or at least about 20wt% pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article can contain at least about 65wt% polymeric material, at least about 20wt% active agent and / or diagnostic agent and / or at least about 15wt% pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article can contain at least about 70wt% polymeric material, at least about 20wt% active agent and / or diagnostic agent and / or at least about 10wt% pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article can contain at least about 75wt% polymeric material, at least about 20wt% active agent and / or diagnostic agent and / or at least about 5wt% pharmaceutically acceptable excipient.

[0161] In some embodiments, the ophthalmic article can contain at most about 50wt% polymeric material, at most about 10wt% active agent and / or diagnostic agent and / or at most about 40wt% pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article can contain at most about 55wt% polymeric material, at most about 10wt% active agent and / or diagnostic agent and / or at most about 35wt% pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article can contain at most about 60wt% polymeric material, at most about 10wt% active agent and / or diagnostic agent and / or at most about 30wt% pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article can contain at most about 65wt% polymeric material, at most about 10wt% active agent and / or diagnostic agent and / or at most about 25wt% pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article can contain at most about 70wt% polymeric material, at most about 10wt% active agent and / or diagnostic agent and / or at most about 20wt% pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article can contain at most about 75wt% polymeric material, at most about 10wt% active agent and / or diagnostic agent and / or at most about 15wt% pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article can contain at most about 80wt% polymeric material, at most about 10wt% active agent and / or diagnostic agent and / or at most about 10wt% pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article can contain at most about 85wt% polymeric material, at most about 10wt% active agent and / or diagnostic agent and / or at most about 5wt% pharmaceutically acceptable excipient.

[0162] In some embodiments, the ophthalmic article can contain at most about 50wt% polymeric material, at most about 20wt% active agent and / or diagnostic agent and / or at most about 30wt% pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article can contain at most about 55wt% polymeric material, at most about 20wt% active agent and / or diagnostic agent and / or at most about 25wt% pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article can contain at most about 60wt% polymeric material, at most about 20wt% active agent and / or diagnostic agent and / or at most about 20wt% pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article can contain at most about 65wt% polymeric material, at most about 20wt% active agent and / or diagnostic agent and / or at most about 15wt% pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article can contain at most about 70wt% polymeric material, at most about 20wt% active agent and / or diagnostic agent and / or at most about 10wt% pharmaceutically acceptable excipient. In some embodiments, the ophthalmic article can contain at most about 75wt% polymeric material, at most about 20wt% active agent and / or diagnostic agent and / or at most about 5wt% pharmaceutically acceptable excipient.

[0163] In some embodiments, at least a first monomer (e.g., first monomer) can be present in the ophthalmic article at a concentration of from about 5 wt% to about 95wt%, or from about 5 wt% to about 90wt%, or from about 5 wt% to about 85wt%, or from about 5 wt% to about 75wt%, or from about 5 wt% to about 70wt%, or from about 5 wt% to about 65wt%, or from about 5 wt% to about 60wt%, or from about 5 wt% to about 55wt%, or from about 5 wt% to about 50wt%, or from about 5 wt% to about 45wt%, or from about 5 wt% to about 40wt%, or from about 5 wt% to about 35wt%, or from about 5 wt% to about 30wt%, or from about 5 wt% to about 25wt%, or from about 5 wt% to about 20wt%, or from about 5 wt% to about 15wt%, or from about 5 wt% to about 10wt%, or from about 10 wt% to about 90 wt%, or from about 10 wt% to about 85wt%, or from about 10 wt% to about 75wt%, or from about 10 wt% to about 70%, or from about 10 wt% to at most about 65wt%, or from about 10 wt% to at most about 60wt%, or from about 10 wt% to about 55wt%, or from about 10 wt% to about 50wt%, or from about 10 wt% to about 45wt%, or from about 10 wt% to about 40wt%, or from about 10 wt% to about 35wt%, or from about 10 wt% to about 30wt%, or from about 10 wt% to about 25wt%, or from 10 wt% to about 20wt% or from about 10 wt% to about 15wt%.

[0164] In some embodiments, at least a second monomer (e.g., second monomer) can be present in the ophthalmic article at a concentration of from about 5 wt% to about 95wt%, or from about 5 wt% to about 90wt%, or from about 5 wt% to about 85wt%, or from about 5 wt% to about 75wt%, or from about 5 wt% to about 70wt%, or from about 5 wt% to about 65wt%, or from about 5 wt% to about 60wt%, or from about 5 wt% to about 55wt%, or from about 5 wt% to about 50wt%, or from about 5 wt% to about 45wt%, or from about 5 wt% to about 40wt%, or from about 5 wt% to about 35wt%, or from about 5 wt% to about 30wt%, or from about 5 wt% to about 25wt%, or from about 5 wt% to about 20wt%, or from about 5 wt% to about 15wt%, or from about 5 wt% to about 10wt%, or from about 10 wt% to about 90 wt%, or from about 10 wt% to about 85wt%, or from about 10 wt% to about 75wt%, or from about 10 wt% to about 70t%, or from about 10 wt% to about 65wt%, or from about 10 wt% to about 60wt%, or from about 10 wt% to about 55wt%, or from about 10 wt% to about 50wt%, or from about 10 wt% to about 45wt%, or from about 10 wt% to about 40wt%, or from about 10 wt% to about 35wt%, or from about 10 wt% to about 30wt%, or from about 10 wt% to about 25wt%, or from about 10 wt% to about 20wt% or from about 10 wt% to about 15wt%.

[0165] Molecular weight (e.g., polymer molecular weight) or molecular mass can be expressed in different ways such as number average molecular weight (Mn) or molecular mass, weight average molecular weight (Mw) or molecular mass, viscosity average molecular weight (Mv) or molecular mass and / or higher average molecular weight (Mz, Mz+i) or molecular mass. Molecular weight or molecular mass can be measured by any method known in the art. By way of illustration, the average molecular weight or molecular mass may be measured by end group analysis (Mn). In another embodiment, the average molecular weight or molecular mass can be determined by Ebullioscopy (boiling point elevation) or Cryoscopy (freezing point depression (Mn). In another embodiment, the average molecular weight or molecular mass can be determined by osmometry (Mn). In another embodiment, the average molecular weight or molecular mass can be determined by gel permeation chromatography (GPC). In another embodiment, the average molecular weight or molecular mass can be determined by light scattering techniques (Mw). In another embodiment, the average molecular weight or molecular mass can be determined by sedimentation equilibrium (Mw, Mz). In another embodiment, the average molecular weight or molecular mass can be determined by viscometry (Mr|).

[0166] In some embodiments, the active agent and / or drug release profile can be controlled by varying the molecular weight or molecular mass of the ophthalmic article’s material (e.g., PLCL). For example, PLCL -co-caprolactone) may have an average molecular weight or molecular mass between 1 kilodalton (kDa) and 200 kDa. In some embodiments, the ophthalmic article’s material can comprise poly(lactide-co-caprolactone) (50:50) with a numerical average molecular weight (Mn) or molecular mass from about 75 kDa to about 85 kDa. In some embodiments, the ophthalmic article’s material can comprise poly(lactide-co-caprolactone) (60:40) with a numerical average molecular weight (Mn) or molecular mass from about 75 kDa to 85 kDa. In some embodiments, the ophthalmic article’s material can comprise poly(lactide-co-caprolactone) (50:50) with a weight average molecular weight (Mw) or molecular mass from about 75 kDa to about 85 kDa. In some embodiments, the ophthalmic article’s material can comprise poly(lactide-co-caprolactone) (60:40) with a weight average molecular weight (Mw) or molecular mass from about 75 kDa to 85 kDa.

[0167] In some embodiments, the active agent and / or drug release profile can be controlled by varying the molecular weight or molecular mass of the ophthalmic article’s material which is exemplarily poly(L-lactide-co-caprolactone). For example, poly(L-lactide-co-caprolactone) may have an average molecular weight or molecular mass between 1 kilodalton (kDa) and 200 kDa. In some embodiments, the ophthalmic article’s material can comprise poly(L-lactide-co-caprolactone) (50:50) with a numerical average molecular weight (Mn) or molecular mass from about 75 kDa to about 85 kDa. In some embodiments, the ophthalmic article’s material can comprise poly(L-lactide-co-caprolactone) (60:40) with a numerical average molecular weight (Mn) or molecular mass from about 75 kDa to 85 kDa. In some embodiments, the ophthalmic article’s material can comprise poly(L-lactide-co-caprolactone) (50:50) with a weight average molecular weight (Mw) or molecular mass from about 75 kDa to about 85 kDa. In some embodiments, the ophthalmic article’s material can comprise poly(L-lactide-co-caprolactone) (60:40) with a weight average molecular weight (Mw) or molecular mass from about 75 kDa to 85 kDa.

[0168] In some embodiments, the ophthalmic article’s material can have an average molecular weight or average molecular mass (e.g., a number average molecular mass) of at least about 1 kDa, at least about 2 kDa, at least about 3 kDa, at least about 4 kDa, at least about 5 kDa, at least about 6 kDa, at least about 7 kDa, at least about 8 kDa, at least about 9 kDa, at least about 10 kDa, at least about 11 kDa, at least about 12 kDa, at least about 13 kDa, at least about 14 kDa, at least about 15 kDa, at least about 16 kDa, at least about 17 kDa, at least about 18 kDa, at least about 19 kDa, at least about 20 kDa, at least about 21 kDa, at least about 22 kDa, at least about 23 kDa, at least about 24 kDa, at least about 25 kDa, at least about 26 kDa, at least about 27 kDa, at least about 28 kDa, at least about 29 kDa, at least about 30 kDa, at least about 31 kDa, at least about 32 kDa, at least about 33 kDa, at least about 34 kDa, at least about 35 kDa, at least about 36 kDa, at least about 37 kDa, at least about 38 kDa, at least about 39 kDa, at least about 40 kDa, at least about 41 kDa, at least about 42 kDa, at least about 43 kDa, at least about 44 kDa, at least about 45 kDa, at least about 46 kDa, at least about 47 kDa, at least about 48 kDa, at least about 49 kDa, at least about 50 kDa, at least about 51 kDa, at least about 52 kDa, at least about 53 kDa, at least about 54 kDa, at least about 55 kDa, at least about 56 kDa, at least about 57 kDa, at least about 58 kDa, at least about 59 kDa, at least about 60 kDa, at least about 65 kDa, at least about 70 kDa, at least about 75 kDa, at least about 80 kDa, at least about 85 kDa, at least about 90 kDa, at least about 95 kDa, at least about 100 kDa, at least about 110 kDa, at least about 120 kDa, at least about 130 kDa, at least about 140 kDa, at least about 150 kDa, at least about 160 kDa, at least about 170 kDa, at least about 180 kDa, at least about 190 kDa, at least about 200 kDa, at least about 250 kDa, at least about 300 kDa, at least about 350 kDa, or at least about 400 kDa. In any of the above possibilities, molecular weight or molecular mass may be determined by any of the methods described herein.

[0169] In some embodiments, the ophthalmic article’s material can have an average molecular weight or average molecular mass (e.g., a number average molecular mass) of at most about 1 kDa, at most about 2 kDa, at most about 3 kDa, at most about 4 kDa, at most about 5 kDa, at most about 6 kDa, at most about 7 kDa, at most about 8 kDa, at most about 9 kDa, at most about 10 kDa, at most about 11 kDa, at most about 12 kDa, at most about 13 kDa, at most about 14 kDa, at most about 15 kDa, at most about 16 kDa, at most about 17 kDa, at most about 18 kDa, at most about 19 kDa, at most about 20 kDa, at most about 21 kDa, at most about 22 kDa, at most about 23 kDa, at most about 24 kDa, at most about 25 kDa, at most about 26 kDa, at most about 27 kDa, at most about 28 kDa, at most about 29 kDa, at most about 30 kDa, at most about 31 kDa, at most about 32 kDa, at most about 33 kDa, at most about 34 kDa, at most about 35 kDa, at most about 36 kDa, at most about 37 kDa, at most about 38 kDa, at most about 39 kDa, at most about 40 kDa, at most about 41 kDa, at most about 42 kDa, at most about 43 kDa, at most about 44 kDa, at most about 45 kDa, at most about 46 kDa, at most about 47 kDa, at most about 48 kDa, at most about 49 kDa, at most about 50 kDa, at most about 51 kDa, at most about 52 kDa, at most about 53 kDa, at most about 54 kDa, at most about 55 kDa, at most about 56 kDa, at most about 57 kDa, at most about 58 kDa, at most about 59 kDa, at most about 60 kDa, at most about 65 kDa, at most about 70 kDa, at most about 75 kDa, at most about 80 kDa, at most about 85 kDa, at most about 90 kDa, at most about 95 kDa, at most about 100 kDa, at most about 110 kDa, at most about 120 kDa, at most about 130 kDa, at most about 140 kDa, at most about 150 kDa, at most about 160 kDa, at most about 170 kDa, at most about 180 kDa, at most about 190 kDa, at most about 200 kDa, at most about 250 kDa, at most about 300 kDa, at most about 350 kDa, or at most about 400 kDa. In any of the above possibilities, molecular weight or molecular mass may be determined by any of the methods described herein.

[0170] In some embodiments, the ophthalmic article’s material can have an average molecular weight or average molecular mass (e.g., a number average molecular mass) of about 1 kDa, about 2 kDa, about 3 kDa, about 4 kDa, about 5 kDa, about 6 kDa, about 7 kDa, about 8 kDa, about 9 kDa, about 10 kDa, about 11 kDa, about 12 kDa, about 13 kDa, about 14 kDa, about 15 kDa, about 16 kDa, about 17 kDa, about 18 kDa, about 19 kDa, about 20 kDa, about 21 kDa, about 22 kDa, about 23 kDa, about 24 kDa, about 25 kDa, about 26 kDa, about 27 kDa, about 28 kDa, about 29 kDa, about 30 kDa, about 31 kDa, about 32 kDa, about 33 kDa, about 34 kDa, about 35 kDa, about 36 kDa, about 37 kDa, about 38 kDa, about 39 kDa, about 40 kDa, about 41 kDa, about 42 kDa, about 43 kDa, about 44 kDa, about 45 kDa, about 46 kDa, about 47 kDa, about 48 kDa, about 49 kDa, about 50 kDa, about 51 kDa, about 52 kDa, about 53 kDa, about 54 kDa, about 55 kDa, about 56 kDa, about 57 kDa, about 58 kDa, about 59 kDa, about 60 kDa, about 65 kDa, about 70 kDa, about 75 kDa, about 80 kDa, about 85 kDa, about 90 kDa, about 95 kDa, about 100 kDa, about 110 kDa, about 120 kDa, about 130 kDa, about 140 kDa, about 150 kDa, about 160 kDa, about 170 kDa, about 180 kDa, about 190 kDa, about 200 kDa, about 250 kDa, about 300 kDa, about 350 kDa, or about 400 kDa. In any of the above possibilities, molecular weight or molecular mass may be determined by any of the methods described herein.

[0171] In some embodiments, the ophthalmic article’s material can have an average molecular weight or average molecular mass of about 50 kDa to about 400 kDa. In some embodiments, the ophthalmic article’s material can have a number average molecular weight or average molecular mass of about 50 kDa to about 55 kDa, about 50 kDa to about 60 kDa, about 50 kDa to about 80 kDa, about 50 kDa to about 100 kDa, about 50 kDa to about 120 kDa, about 50 kDa to about 150 kDa, about 50 kDa to about 200 kDa, about 50 kDa to about 300 kDa, about 50 kDa to about 400 kDa, about 55 kDa to about 60 kDa, about 55 kDa to about 80 kDa, about 55 kDa to about 100 kDa, about 55 kDa to about 120 kDa, about 55 kDa to about 150 kDa, about 55 kDa to about 200 kDa, about 55 kDa to about 300 kDa, about 55 kDa to about 400 kDa, about 60 kDa to about 80 kDa, about 60 kDa to about 100 kDa, about 60 kDa to about 120 kDa, about 60 kDa to about 150 kDa, about 60 kDa to about 200 kDa, about 60 kDa to about 300 kDa, about 60 kDa to about 400 kDa, about 80 kDa to about 100 kDa, about 80 kDa to about 120 kDa, about 80 kDa to about 150 kDa, about 80 kDa to about 200 kDa, about 80 kDa to about 300 kDa, about 80 kDa to about 400 kDa, about 100 kDa to about 120 kDa, about 100 kDa to about 150 kDa, about 100 kDa to about 200 kDa, about 100 kDa to about 300 kDa, about 100 kDa to about 400 kDa, about 120 kDa to about 150 kDa, about 120 kDa to about 200 kDa, about 120 kDa to about 300 kDa, about 120 kDa to about 400 kDa, about 150 kDa to about 200 kDa, about 150 kDa to about 300 kDa, about 150 kDa to about 400 kDa, about 200 kDa to about 300 kDa, about 200 kDa to about 400 kDa, or about 300 kDa to about 400 kDa.

[0172] In some embodiments, the ophthalmic article can comprise one or more active agents and / or diagnostic agents in an amount to deliver an effective amount (e.g., therapeutically effective amount) or effective dose (e.g., therapeutically effective dose) of the one or more active agents and / or diagnostic agents to the eye (e.g., posterior segment of the eye) from the lens capsule. An effective amount or effective dose can vary depending on the particular active agent and / or diagnostic being employed in the polymeric material (e.g., biodegradable polymer matrix). Further, the effective amount or effective dose can vary depending on the severity of the condition or complication being treated. Nonetheless, the active agent and / or diagnostic agent can be present in an amount to facilitate delivery of the active agent and / or diagnostic agent (e.g., from the anterior segment of the eye (e.g. from the lens capsule) to the posterior segment of the eye.

[0173] In any of the various aspects, the at least one active agent and / or diagnostic described herein for use in various embodiments of the disclosure may be (e.g., found in the Orange Book published by the Food and Drug Administration) used for the diagnosis and / or treatment or prevention of infection, inflammation (e.g., postoperative inflammation), macular edema, neovascularization, age-related macular degeneration (neovascular form or atrophic form), glaucoma, diabetic retinopathy, retinopathy of prematurity, uveitis, corneal transplant rejection, fibrosis (e.g., capsular fibrosis), posterior capsule opacification, retinal vein occlusions, infections, and the like. For example, the ophthalmic article, for delivery or administration of the active agent to the eye, can comprise active ingredients for treatment or prevention of complications associated with cataract surgery. The function of the active agent (e.g., active ingredients) may be to impart pharmacologic properties upon release from the ophthalmic article. Active agent may be an agent or substance that has measurable specified or selected physiologic activity when administered to a subject in a significant or effective amount. The active agent may be a therapeutic agent. Diagnostic agents may be substances used to examine the body in order to detect impairment of its normal functions. In some cases, diagnostic agents may be pharmacological and non-pharmacological agents with a functional purpose, such as for use in the detection of ocular deformities, ailments, and pathophysiological aspects. For example, the diagnostic agent may be an important and effective diagnostic adjuvant, such as a dye (e.g., fluorescein dye, indocyanine green, trypan blue, a dark quencher such as a cyanine dye, an azo dye, an acridine, a fluorone, an oxazine, a phenanthridine, a naphthalimide, a rhodamine, a benzopyrone, a perylene, a benzanthrone, pra benzoxanthrone), to aid in visualization of ocular tissues. The diagnostic agent may comprise paramagnetic molecules, fluorescent compounds, magnetic molecules, radionuclides, x-ray imaging agents, and / or contrast media. In some embodiments, a diagnostic agent may include radiopharmaceuticals, contrast agents for use in imaging techniques, allergen extracts, activated charcoal, different testing strips (e.g., cholesterol, ethanol, and glucose), pregnancy test, breath test with urea 13C, and various stains / markers. In some embodiments, the labelling moiety is a fluorescent dye or a dark quencher, selected from the group consisting of a coumarin, a cyanine dye, an azo dye, an acridine, a fluorone, an oxazine, a phenanthridine, a naphthalimide, a rhodamine, a benzopyrone, a perylene, a benzanthrone, and a benzoxanthrone. In particular non-limiting embodiments, the fluorescent dye is or is the residue of a compound selected from the group consisting of Coumarin, Fluorescein, Cyanine 3 (Cy3), Cyanine 5 (Cy5), Cyanine 7 (Cy7), Alexa dyes, bodipy derivatives, (E)-2-(4-(phenyldiazenyl)phenoxy)acetic acid, 3-(3',3'-dimethyl-6-nitrospiro[chromene-2,2'-indolin]-l'-yl)propanoate (Spiropyran), 3,5-dihydroxybenzoate and (E)-2-(4-(phenyldiazenyl )phenoxy)acetic acid, or combinations thereof.

[0174] As used herein, the phrase "radionuclides" encompasses any chemical compound or moiety that includes one or more radioactive isotopes. A radioactive isotope is an element which emits radiation. Examples include a-radiation emitters, P-radiation emitters or y-radiation emitters. Suitable radionuclides for use as radioactive agents include, but are not limited to, Carbon-11, Fluorine-18, Bromine-76, or Iodine-123, and Iodine-124 and metallic radionuclides include Antimony-124, Antimony-125, Arsenic-74, Barium-103, Barium-140, Beryllium-7, Bismuth-206, Bismuth-207, Cadmium-109, Cadmium-115m, Calcium-45, Cerium-139, Cerium-141, Cerium-144, Cesium-137, Chromium-51, Cobalt-55, Cobalt-56, Cobalt-57, Cobalt-58, Cobalt-60, Cobalt-64, Copper-67, Erbium-169, Europium-152, Gallium-64, Gallium-68, Gadolinium-153, Gadolinium-157 Gold-195, Gold-199, Hafnium-175. Hafnium-175-181, Holmium-166, Indium-110, Indium-Ill, Iridium-192, Iron-55, Iron-59, Krypton-85, Lead-210, Manganese-54, Mercury-197, Mercury-203, Molybdenum-99, Neodymium-147, Neptunium-237, Nickel-63, Niobium-95, Osmium-185+191, Palladium-103, Platinum-195m, Praseodymium-143, Promethium-147, Protactinium-233, Radium-226, Rhenium-186, Rhenium-188, Rubidium-86, Ruthenium-103, Ruthenium-106, Scandium-44, Scandium-6, Selenium-75, Silver-110m, Silver-111, Sodium-22, Strontium-85, Strontium-89, Strontium-90, Sulfur-35, Tantalum-182, Technetium-99m, Tellurium-125, Tellurium-132, Thallium-204, Thorium-228, Thorium-232, Thallium-170, Tin-113, Tin-114, Tin-117m, Titanium-44, Tungsten-185, Vanadium-48, Vanadium-49, Ytterbium-169, Yttrium-86, Yttrium-88, Yttrium-90, Yttrium-91, Zinc-65, or Zirconium-95. In certain embodiments the radionuclide is selected from for example 99mTechnetium, 201Thalium, llllndium, 67Gallium, 90Yttrium, 177Lutetium, or 123Iodine.

[0175] Numerous active agents are known for the treatment or prophylaxis of various eye conditions or complications, such as infection, inflammation (e.g., postoperative inflammation), macular edema, neovascularization, age-related macular degeneration (neovascular form or atrophic form), glaucoma, diabetic retinopathy, retinopathy of prematurity, uveitis, corneal transplant rejection, fibrosis (e.g., capsular fibrosis), posterior capsule opacification, retinal vein occlusions, infections, and the like.

[0176] Categories of active agents that may be utilized for incorporation into the polymeric material can comprise anti-inflammatory agents, anti-vaso-proliferative agents, corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), interocular pressure (IOP) lowering agents, anti-infective drugs, antibiotics, anti-mitotic agents, antivirals, antifungals, antimetabolites, antifibrotic agents, glaucoma medications, anti-neovascular agents, integrins, integrin antagonists, complement antagonists, cytokines, cytokine inhibitors, antibody-blocking agents, angiogenesis inhibitors, vaccines, immunomodulatory agents, anticoagulants, anti-neoplastic agents, anesthetics, analgesics, adrenergic agonists or antagonists, cholinergic agonists or antagonists, enzymes, enzyme inhibitors, neuroprotective agents, cytoprotective agents, regenerative agents, antisense oligonucleotides, aptamers, antibodies, or combinations thereof.

[0177] The active agents may be comprised of proteins, peptides, lipids, carbohydrates, hormones, metals, radioactive elements and compounds, or combinations thereof.

[0178] In some embodiments, corticosteroids can comprise hydrocortisone, loteprednol, cortisol, cortisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, triamcinolone, aldosterone or fludrocortisone.

[0179] In some embodiments, NSAIDs can comprise diclofenac (e.g., diclofenac sodium), flubiprofen (e.g., flubiprofen sodium), ketorolac (e.g., ketorolac tromethamine), bromfenac, or nepafenac.

[0180] In some embodiments, IOP lowering agents and / or glaucoma medications can comprise prostaglandin analogs (e.g., bimatoprost, latanoprost, travoprost, or latanoprostene bunod), rho kinase inhibitor (e.g., netarsudil), adrenergic agonists (epinepherine or dipivefrin ), beta-adrenergic antagonists also known as beta blockers (e.g., timolol, levobunolol, metipranolol, carteolol, or betaxolol), alpha2-adrenergic agonists (e.g., apraclonidine, brimonidine, or brimonidine tartrate), carbonic anhydrase inhibitors (e.g., brinzolamide, di chlorphenamide, methazolamide acetazolamide, acetazolamide, or dorzolamide), pilocarpine, echothiophate, demercarium, physostigmine, and / or isofluorophate.

[0181] In some embodiments, anti-infective can comprise antibiotics comprising ciprofloxacin, tobramycin, erythromycin, ofloxacin, gentamicin, fluoroquinolone antibiotics, moxifloxacin, and / or gatifloxacin; antivirals comprising ganciclovir, idoxuridine, vidarabine, and / or trifluridine; and / or antifungals comprising amphotericin B, natamycin, voriconazole, fluconazole, miconazole, clotrimazole, ketoconazole, posaconazole, echinocandin, caspofungin, and / or micafungin.

[0182] In some embodiments, antimetabolites can comprise methotrexate, mycophenolate, or azathioprine.

[0183] In some embodiments, antifibrotic agents can comprise maitomycin C or 5-fluorouracil.

[0184] In some embodiments, angiogenesis inhibitors can comprise anti-VEGF agents (e.g., aflibercept, ranibizumab, bevacizumab), PDGF-B inhibitors (e.g., Fovista®), complement antagonists (e.g., eculizumab), tyrosine kinase inhibitors (e.g. sunitinib, axitinib), and / or integrin antagonists (e.g., natalizumab and vedolizumab).

[0185] In some embodiments, cytoprotective agents can comprise ebselen, sulforaphane, oltipraz or dimethyl fumarate.

[0186] In some embodiments, neuroprotective agents can comprise ursodiol, memantine or acetylcysteine.

[0187] In some embodiments, anesthetic agents can comprise lidocaine, proparacaine or bupivacaine.

[0188] In some embodiments, the active agent can be dexamethasone, ketorolac, diclofenac, vancomycin, moxifloxacin, gatifloxicin, besifloxacin, travoprost, 5-fluorouracil, methotrexate, mitomycin C, prednisolone, bevacizumab (Avastin®), ranibizumab (Lucentis®), sunitinib, pegaptanib (Macugen®), timolol, latanoprost, brimonidine, nepafenac, bromfenac, triamcinolone, difluprednate, fluocinolide, aflibercept, or combinations thereof. In some embodiments, the active agent may be dexamethasone, ketorolac, diclofenac, moxifloxacin, travoprost, 5-fluorouracil, or methotrexate. In some embodiments, the active agent is dexamethasone. In some embodiments, the active agent is ketorolac. In some embodiments, the active ingredient is dexamethasone.

[0189] In some embodiments, the ophthalmic article may comprise inactive agents (e.g., polymers). The function of the inactive ingredients may be to impart certain physical properties to the ophthalmic article, such as bulk, adhesion, firmness, flexibility, conformity, erosion, color and opacity, as well as to affect the rate of release of the inactive agents (e.g., inactive ingredients). Various inactive ingredients can be used with the ophthalmic article and in approved active agents (e.g., drug products) and may be biocompatible. In some embodiments, the ophthalmic article may also comprise a pigment to aid visualization by the surgeon.

[0190] In some embodiments, the ophthalmic article may also comprise one or more excipients and / or disintegrants. Excipients may be comprise preservatives, penetration enhancers, plasticizers, lubricants, emulsifying agents, solubilizing agents, suspending agents, stiffening agents, thickening agents, buffering agents, acidifying agents, alkalinizing agents, viscosityincreasing agents, colorants, release-modifying agents, controlled-release agents, opacifiers, stabilizing agents, gelling agents, antioxidants, dispersing agents, hydroxypropylcellulose, sodium carboxymethyl cellulose, croscarmellose sodium, hyaluronic acid, and / or albumin. Excipient may comprise one or more described by, for example, Raymond C. Rowe et al., Handbook of Pharmaceutical Excipients (6th Edition, 2009), which is incorporated by reference herein in its entirety.

[0191] Distintegrant can be a superdistintegrant. Non-limiting examples of suitable disintegrants can include crosslinked celluloses (e.g. croscarmellose, Ac-Di-Sol, Nymce ZSX, Primellose, SoluTab, VIVASOL), microcrystalline cellulose, alginates, crosslinked PVP (e.g. Crosspovidone, Kollidon, Polypiasdone), crosslinked starch, soy polysaccharides, calcium silicate, salts thereof, or the like.

[0192] For example, an excipient and / or disintegrant can be from 3 weight percentage (wt%) to 25 wt%, and in one case from 3 wt% to 20 wt% of the ophthalmic article. A disintegrant at greater than about 25 wt% can be useful for delivery times less than about 1 week, while less than about 3% can be useful for extended delivery times of greater than 6 to 9 months.

[0193] In some embodiments, the ophthalmic article may comprise from at least or up to about 0.1 wt% to 50 wt% of the excipient and / or disintegrant. In some embodiments, the ophthalmic article may comprise from about 0.5 wt% to 50 wt% of the excipient and / or disintegrant. In some embodiments, the ophthalmic article may comprise from about 1.0 wt% to 50 wt% of the excipient and / or disintegrant. In some embodiments, the ophthalmic article may comprise from about 5 wt% to 50 wt% of the excipient and / or disintegrant. In some embodiments, the ophthalmic article may comprise from about 10 wt% to 50 wt% of the excipient and / or disintegrant. In some embodiments, the ophthalmic article may comprise from about 15 wt% to 50 wt% of the excipient and / or disintegrant. In some embodiments, the ophthalmic article may comprise from about 20 wt% to 50 wt% of the excipient and / or disintegrant. In some embodiments, the ophthalmic article may comprise from 25 wt% to 50 wt% of the excipient and / or disintegrant. In some embodiments, the ophthalmic article may comprise from about 30 wt% to 50 wt% of the excipient and / or disintegrant. In some embodiments, the ophthalmic article may comprise from about 35 wt% to 50 wt% of the excipient and / or disintegrant. In some embodiments, the ophthalmic article may comprise from about 45 wt% to 50 wt% of the excipient and / or disintegrant. In some embodiments, the ophthalmic article may comprise from about 5 wt% to 40 wt% of the excipient and / or disintegrant. In some embodiments, the ophthalmic article may comprise from about 5 wt% to 35 wt% of the excipient and / or disintegrant. In some embodiments, the ophthalmic article may comprise from about 5 wt% to 30 wt% of the excipient and / or disintegrant. In some embodiments, the ophthalmic article may comprise from about 5 wt% to 25 wt% of the excipient and / or disintegrant. In some embodiments, the ophthalmic article may comprise from about 5 wt% to 20 wt% of the excipient and / or disintegrant. In some embodiments, the ophthalmic article may comprise from about 5 wt% to 15 wt% of the excipient and / or disintegrant. In some embodiments, the ophthalmic article may comprise from about 5 wt% to 10 wt% of the excipient and / or disintegrant.

[0194] In some embodiments, the ophthalmic article can be formed, for example, by mixing a polymeric material with a loading amount of active agent and / or diagnostic agent to form a matrix dispersion or solution. In some embodiments, the ophthalmic article can be formed using a biodegradable matrix and / or non-biodegradable materials.

[0195] In some embodiments, non-biodegradable materials may comprise methacrylates, acrylates and / or co-polymers thereof, silicone, and / or polymers and / or co-polymers of vinyl acetates, vinyl pyrrolidone and / or vinyl alcohol. Methacrylates may comprise poly(methyl acrylate) (PMA) or poly(methyl methacrylate) (PMMA). Vinyl acetates include vinyl acetate or ethylene vinyl acetate (EVA).

[0196] The active agent and / or diagnostic agent can be homogeneously dispersed as a solid, dissolved uniformly, or partially dissolved as long as uniformity and homogeneity is maintained. Thus, in some examples, the active agent and / or diagnostic agent can be homogenously combined with the polymer matrix such that the at least a portion (e.g., the entire) ophthalmic article is homogenous or substantially homogenous. For example, the homogeneity can extend throughout the entire ophthalmic article such that the ophthalmic article consists essentially of the homogeneously mixed matrix and active agent and / or diagnostic agent along with optional additives. The loading amount can be chosen to correspond to the desired dosage during diffusion. In some cases, the loading amount can take into consideration diffusion characteristics of the polymeric material and active agent and / or diagnostic agent, residual active agent and / or diagnostic agent, delivery time, and the like. The matrix dispersion can then be formed into the device shape using any suitable technique. For example, the matrix dispersion can be cast, sprayed and dried, extruded, stamped, or the like.

[0197] In some embodiments, the ophthalmic article (e.g., biocompatible and / or biodegradable matrix) can be configured to biodegrade or bioerode to provide release (e.g., controlled release) of the active agent (e.g., therapeutic agent) and / or diagnostic agent from the material (e.g., polymeric material). In some embodiments, the ophthalmic article (e.g., biocompatible and / or biodegradable matrix) can be configured to biodegrade or bioerode to provide release of the effective amount (e.g., therapeutically effective amount) of the active agent (e.g., therapeutic agent) and / or diagnostic agent from the polymeric material (e.g., polymer matrix) over a period of days, weeks, or months.

[0198] In some embodiments, the ophthalmic article for active agent (e.g., drug delivery) and / or diagnostic agent delivery to the eye may comprise bioerodible polymers, which may be any natural or synthetic polymers that spontaneously degrade when placed into a biologic environment. Mechanisms of bioerosion include ester hydrolysis, enzymatic degradation or reduction of a disulfide bond. Examples of bioerodible polymers may comprise polylactides, polyglycolides, polycaprolactone, poly(trimethylene carbonate), chitosan, polyethylene glycol, poly-beta-amino esters, poly-L-malic acid, hyaluronic acid, peptides, nucleic acids, or dextran-based polymers.

[0199] In some embodiments, the article for drug delivery to the eye can be designed to release drug over a short period of time (e.g. the first 24 to 48 hours after surgery). “Burst release” may be desirable to prevent immediate infection or inflammation following surgery. In other embodiments, the article for drug delivery to the eye might be designed to release drug over a longer period of time (e.g., many days to weeks or even months after surgery). Such sustained release would be desirable to treat more chronic conditions like glaucoma, posterior capsular opacification, or macular edema. In some embodiments, the ophthalmic article, described herein, can be targeted for a relatively short delivery duration, such as less than eight weeks. In some examples, the active agent and / or diagnostic agent has a delivery duration of from about one week to about six or eight weeks. In some examples, the active agent and / or diagnostic agent has a delivery duration of from about two weeks to about six or eight weeks. In some examples, the active agent and / or diagnostic agent has a delivery duration of from about three weeks to about six or eight weeks. In some examples, the active agent and / or diagnostic agent has a delivery duration of from about four weeks to about six or eight weeks. In some examples, the active agent and / or diagnostic agent has a delivery duration of from about one week to about 2 weeks. In some examples, the active agent and / or diagnostic agent has a delivery duration of from about one week to about 3 weeks. In some examples, the active agent and / or diagnostic agent has a delivery duration of from about one week to about 4 weeks. In some examples, the active agent and / or diagnostic agent has a delivery duration of from about one week to about 5 weeks. In some examples, the active agent and / or diagnostic agent has a delivery duration of from about one week to about 6 weeks. In some examples, the active agent and / or diagnostic agent has a delivery duration of from about one week to about 7 weeks. In some examples, the active agent and / or diagnostic agent has a delivery duration of from about one week to about 8 weeks.

[0200] In some embodiments, the material (e.g., biocompatible matrix) and the active agent (e.g., drug) and / or diagnostic agent may be selected to provide release for more than 7 days. In some embodiments, the active agent and / or diagnostic agent can be released from the biocompatible polymer matrix (e.g., the biocompatible copolymer matrix) over at least about 7 days. In some embodiments, the active agent and / or diagnostic agent is released from the biocompatible material (e.g., biocompatible polymer matrix) over from about 5-30 days, 5-21 days, 5-14 days, 5-10 days, 7-30 days, 7-21 days, 7-14 days, or 7-10 days.

[0201] In some embodiments, the active agent and / or diagnostic agent can be released from the biocompatible polymer matrix (e.g., the biocompatible copolymer matrix) over about 1 day up to about 36 months. In some embodiments, the active agent and / or diagnostic agent can be released from the biocompatible polymer matrix (e.g., the biocompatible copolymer matrix) over at least about 34 months, at least about 32 months, at least about 30 months, at least about 28 months, at least about 26 months, at least about 24 months, at least about 22 months, at least about 20 months, at least about 18 months, at least aboutl6 months, at least about 14 months, at least about 12 months, at least about 10 months, at least about 8 months, at least about 6 months, at least about 4 months, at least about 2 months, at least about 1 month, at least about 3 weeks, at least about 2 weeks, at least about 1 week, at least about 6 days, at least about 5 days, at least about 4 days, at least about 3 days, at least about 2 day, or at least about 1 day. In some embodiments, the active agent and / or diagnostic agent can be released from the biocompatible polymer matrix (e.g., the biocompatible copolymer matrix) over at least about 7 days. In some embodiments, the active agent and / or diagnostic agent can be released from the biocompatible polymer matrix (e.g., the biocompatible copolymer matrix) over at least about 14 days. In some embodiments, the active agent and / or diagnostic agent can be released from the biocompatible polymer matrix (e.g., the biocompatible copolymer matrix) over at least about 45 days. In some embodiments, the active agent and / or diagnostic agent can be released from the biocompatible polymer matrix (e.g., the biocompatible copolymer matrix) over at least about 90 days.

[0202] In some embodiments, the active agent and / or diagnostic agent can be released from the biocompatible polymer matrix (e.g., the biocompatible copolymer matrix) over about 1 day up to about 36 months. In some embodiments, the active agent and / or diagnostic agent can be released from the biocompatible polymer matrix (e.g., the biocompatible copolymer matrix) over at most about 34 months, at most about 32 months, at most about 30 months, at most about 28 months, at most about 26 months, at most about 24 months, at most about 22 months, at most about 20 months, at most about 18 months, at most aboutl6 months, at most about 14 months, at most about 12 months, at most about 10 months, at most about 8 months, at most about 6 months, at most about 4 months, at most about 2 months, at most about 1 month, at most about 3 weeks, at most about 2 weeks, at most about 1 week, at most about 6 days, at most about 5 days, at most about 4 days, at most about 3 days, at most about 2 day, or at most about 1 day. In some embodiments, the active agent and / or diagnostic agent can be released from the biocompatible polymer matrix (e.g., the biocompatible copolymer matrix) over at most about 7 days. In some embodiments, the active agent and / or diagnostic agent can be released from the biocompatible polymer matrix (e.g., the biocompatible copolymer matrix) over at most about 14 days. In some embodiments, the active agent and / or diagnostic agent can be released from the biocompatible polymer matrix (e.g., the biocompatible copolymer matrix) over at most about 45 days. In some embodiments, the active agent and / or diagnostic agent can be released from the biocompatible polymer matrix (e.g., the biocompatible copolymer matrix) over at most about 90 days.

[0203] In some embodiments, the active agent and / or diagnostic agent can be released from the biocompatible polymer matrix (e.g., the biocompatible copolymer matrix) over at about 1 week to about 36 months, about 1 week to about 34 months, about 1 week to about 32 months, about 1 week to about 30 months, about 1 week to about 30 months, about 1 week to about 28 months, about 1 week to about 26 months, about 1 week to about 24 months, about 1 week to about 22 months, about 1 week to about 20 months, about 1 week to about 18 months, about 1 week to about 16 months, about 1 week to about 14 months, about 1 week to about 12 months, about 1 week to about 10 months, about 1 week to about 8 months, about 1 week to about 6 months, about 1 week to about 4 months, about 1 week to about 2 months, about 1 week to about 1 month, about 1 week to about 3 weeks, or about 1 week to about 2 weeks. In some embodiments, the active agent and / or diagnostic agent can be released from the biocompatible polymer matrix (e.g., the biocompatible copolymer matrix) over about 1 day to about 7 days. In some embodiments, the active agent and / or diagnostic agent can be released from the biocompatible polymer matrix (e.g., the biocompatible copolymer matrix) over about 1 day to about 14 days. In some embodiments, the active agent and / or diagnostic agent can be released from the biocompatible polymer matrix (e.g., the biocompatible copolymer matrix) over about 1 day to about 45 days.

[0204] In an example, the therapeutically effective amount can be released over a period ranging from about 1 day to about 10 weeks. In other examples, the therapeutically effective amount can be released over a period ranging from about 1 day to about 3 weeks, from about 2 weeks to about 6 weeks, or from about 5 weeks to about 8 weeks. In some embodiments, the therapeutically effective amount can be released over at least about 1 day up to about 36 months.

[0205] In some embodiments, the therapeutically effective amount can be released over at least about 34 months, at least about 32 months, at least about 30 months, at least about 28 months, at least about 26 months, at least about 24 months, at least about 22 months, at least about 20 months, at least about 18 months, at least aboutl6 months, at least about 14 months, at least about 12 months, at least about 10 months, at least about 8 months, at least about 6 months, at least about 4 months, at least about 2 months, at least about 1 month, at least about 3 weeks, at least about 2 weeks, at least about 1 week, at least about 6 days, at least about 5 days, at least about 4 days, at least about 3 days, at least about 2 day, or at least about 1 day. In some embodiments, the therapeutically effective amount can be released over at least about 7 days. In some embodiments, the therapeutically effective amount can be released over at least about 14 days. In some embodiments, the therapeutically effective amount can be released over at least about 45 days. In some embodiments, the therapeutically effective amount can be released over at least about 90 days.

[0206] In some embodiments, the therapeutically effective amount can be released over at most about 34 months, at most about 32 months, at most about 30 months, at most about 28 months, at most about 26 months, at most about 24 months, at most about 22 months, at most about 20 months, at most about 18 months, at most about 16 months, at most about 14 months, at most about 12 months, at most about 10 months, at most about 8 months, at most about 6 months, at most about 4 months, at most about 2 months, at most about 1 month, at most about 3 weeks, at most about 2 weeks, at most about 1 week, at most about 6 days, at most about 5 days, at most about 4 days, at most about 3 days, at most about 2 day, or at most about 1 day. In some embodiments, the therapeutically effective amount can be released over at most about 7 days. In some embodiments, the therapeutically effective amount can be released over at most about 14 days. In some embodiments, the therapeutically effective amount can be released over at most about 45 days. In some embodiments, the therapeutically effective amount can be released over at most about 90 days.

[0207] In some embodiments, the therapeutically effective amount can be released over about 1 week to about 36 months, about 1 week to about 34 months, about 1 week to about 32 months, about 1 week to about 30 months, about 1 week to about 30 months, about 1 week to about 28 months, about 1 week to about 26 months, about 1 week to about 24 months, about 1 week to about 22 months, about 1 week to about 20 months, about 1 week to about 18 months, about 1 week to about 16 months, about 1 week to about 14 months, about 1 week to about 12 months, about 1 week to about 10 months, about 1 week to about 8 months, about 1 week to about 6 months, about 1 week to about 4 months, about 1 week to about 2 months, about 1 week to about 1 month, about 1 week to about 3 weeks, or about 1 week to about 2 weeks. In some embodiments, the therapeutically effective amount can be released over about 1 day to about 7 days. In some embodiments, the therapeutically effective amount can be released over about 1 day to about 14 days. In some embodiments, the therapeutically effective amount can be released over about 1 day to about 45 days. In some embodiments, the therapeutically effective amount can be released over about 1 day to about 90 days.

[0208] The effective amount (e.g., therapeutically effective amount) or effective dose (e.g., therapeutically effective dose) can range from about 1 micrograms (pg) to about 10 milligrams (mg). The effective amount or effective dose can depend on the active agent and / or diagnostic agent being employed and the severity of the condition or complication. In some embodiments, the effective amount or effective dose can range from about 50 pg to about 800 pg. In some embodiments, the effective amount or effective dose can range from about 50 pg to about 100 pg, from about 50 pg to about 150 pg, from about 50 pg to about 200 pg, from about 50 pg to about 250 pg, from about 50 pg to about 300 pg, from about 50 pg to about 350 pg, from about 50 pg to about 400 pg, from about 50 pg to about 450 pg, from about 50 pg to about 500 pg, from about 50 pg to about 550 pg, from about 50 pg to about 600 pg, from about 50 pg to about 650 pg, from about 50 pg to about 700 pg, from about 50 pg to about 750 pg, from about 50 pg to about 800 pg, from about 100 pg to about 150 pg, from about 100 pg to about 200 pg, from about 100 gg to about 250 gg, from about 100 gg to about 300 gg, from about 100 gg to about 350 gg, from about 100 gg to about 400 gg, from about 100 gg to about 450 gg, from about 100 gg to about 500 gg, from about 100 gg to about 550 gg, from about 100 gg to about 600 gg, from about 100 gg to about 650 gg, from about 100 gg to about 700 gg, from about 100 gg to about 750 gg, from about 100 gg to about 800 gg, from about 150 gg to about 200 gg, from about 150 gg to about 250 gg, from about 150 gg to about 300 gg, from about 150 gg to about 350 gg, from about 150 gg to about 400 gg, from about 150 gg to about 450 gg, from about 150 gg to about 500 gg, from about 150 gg to about 550 gg, from about 150 gg to about 600 gg, from about 150 gg to about 650 gg, from about 150 gg to about 700 gg, from about 150 gg to about 750 gg, from about 150 gg to about 800 gg, from about 200 gg to about 250 gg, from about 200 gg to about 300 gg, from about 200 gg to about 350 gg, from about 200 gg to about 400 gg, from about 200 gg to about 450 gg, from about 200 gg to about 500 gg, from about 200 gg to about 550 gg, from about 200 gg to about 600 gg, from about 200 gg to about 650 gg, from about 200 gg to about 700 gg, from about 200 gg to about 750 gg, from about 200 gg to about 800 gg, from about 250 gg to about 300 gg, from about 250 gg to about 350 gg, from about 250 gg to about 400 gg, from about 250 gg to about 450 gg, from about 250 gg to about 500 gg, from about 250 gg to about 550 gg, from about 250 gg to about 600 gg, from about 250 gg to about 650 gg, from about 250 gg to about 700 gg, from about 250 gg to about 750 gg, from about 250 gg to about 800 gg, from about 300 gg to about 350 gg, from about 300 gg to about 400 gg, from about 300 gg to about 450 gg, from about 300 gg to about 500 gg, from about 300 gg to about 550 gg, from about 300 gg to about 600 gg, from about 300 gg to about 650 gg, from about 300 gg to about 700 gg, from about 300 gg to about 750 gg, from about 300 gg to about 800 gg, from about 350 gg to about 400 gg, from about 350 gg to about 450 gg, from about 350 gg to about 500 gg, from about 350 gg to about 550 gg, from about 350 gg to about 600 gg, from about 350 gg to about 650 gg, from about 350 gg to about 700 gg, from about 350 gg to about 750 gg, from about 350 gg to about 800 gg, from about 400 gg to about 450 gg, from about 400 gg to about 500 gg, from about 400 gg to about 550 gg, from about 400 gg to about 600 gg, from about 400 gg to about 650 gg, from about 400 gg to about 700 gg, from about 400 gg to about 750 gg, from about 400 gg to about 800 gg, from about 450 gg to about 500 gg, from about 450 gg to about 550 gg, from about 450 gg to about 600 gg, from about 450 gg to about 650 gg, from about 450 gg to about 700 gg, from about 450 gg to about 750 gg, from about 500 gg to about 550 gg, from about 500 gg to about 600 gg, from about 500 gg to about 650 gg, from about 500 gg to about 700 gg, from about 500 gg to about 750 gg, from about 450 gg to about 800 gg, from about 550 gg to about 600 gg, from about 550 gg to about 650 gg, from about 550 gg to about 700 gg, from about 550 gg to about 750 gg, from about 550 gg to about 800 gg, from about 600 gg to about 650 gg, from about 600 gg to about 700 gg, from about 600 gg to about 750 gg, from about 650 gg to about 700 gg, from about 650 gg to about 750 gg, from about 600 gg to about 800 gg, from about 700 gg to about 750 gg, from about 700 gg to about 800 gg, or from about 750 gg to about 800 gg. In some embodiments, the effective amount or effective dose can range from about 50 gg to about 200 gg. In some embodiments, the effective amount or effective dose can range from about 50 gg to about 400 gg. In some embodiments, the effective amount or effective dose can range from about 50 gg to about 700 gg.

[0209] In some embodiments, the effective amount or effective dose can be at least about 50 gg, at least about 60 gg, at least about 70 gg, at least about 80 gg, at least about 90 gg, at least about 100 gg, at least about 150 gg, at least about 200 gg, at least about 250 gg, at least about 300 gg, at least about 350 gg, at least about 400 gg, at least about 450 gg, at least about 500 gg, at least about 600 gg, at least about 650 gg, at least about 700 gg, at least about 750 gg, at least about 800 gg, at least about 850 gg, at least about 900 gg, at least about 1 mg, at least about 2 mg, at least about 3 mg, at least about 4 mg, at least about 5 mg, at least about 6 mg, at least about 7 mg, at least about 8 mg, at least about 9 mg, or at least about 10 mg. In some embodiments, the effective amount or effective dose can be at least about 150 gg. In some embodiments, the effective amount or effective dose can be at least about 300 pg. In some embodiments, the effective amount or effective dose can be at least about 600 pg.

[0210] In some embodiments, the effective amount or effective dose can be at most about 50 pg, at most about 60 gg, at most about 70 gg, at most about 80 gg, at most about 90 gg, at most about 100 pg, at most about 150 gg, at most about 200 gg, at most about 250 gg, at most about 300 pg, at most about 350 gg, at most about 400 gg, at most about 450 gg, at most about 500 gg, at most about 600 gg, at most about 650 gg, at most about 700 gg, at most about 750 gg, at most about 800 pg, at most about 850 gg, at most about 900 gg, at most about 1 mg, at most about 2 mg, at most about 3 mg, at most about 4 mg, at most about 5 mg, at most about 6 mg, at most about 7 mg, at most about 8 mg, at most about 9 mg, or at most about 10 mg. In some embodiments, the effective amount or effective dose can be at most about 150 gg. In some embodiments, the effective amount or effective dose can be at most about 300 gg. In some embodiments, the effective amount or effective dose can be at most about 600 gg.

[0211] In some embodiments, the effective amount or effective dose can be about 50 gg, about 60 pg, about 70 gg, about 80 gg, about 90 gg, about 100 gg, about 150 gg, about 200 gg, about 250 gg, about 300 gg, about 350 gg, about 400 gg, about 450 gg, about 500 gg, about 600 pg, about 650 gg, about 700 gg, about 750 gg, about 800 gg, about 850 gg, about 900 gg, about 1 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, or about 10 mg. In some embodiments, the effective amount or effective dose can be about 150 pg. In some embodiments, the effective amount or effective dose can be about 300 gg. In some embodiments, the effective amount or effective dose can be about 600 gg.

[0212] In some examples, the ophthalmic article can release from about 1 pg to about 10 mg of active agent and / or diagnostic agent over a period of from about 1 week to about 36 months. In some additional examples, the ophthalmic article can release from about 1 pg to about 500 pg of active agent and / or diagnostic agent over a period of from about 1 week to about 12 weeks.

[0213] In some additional examples, the ophthalmic article can release from about 1 pg to about 500 pg of active agent and / or diagnostic agent over a period of from about 1 week to about 6 months. In some additional examples, the ophthalmic article can release from about 1 pg to about 500 pg of active agent and / or diagnostic agent over a period of from about 1 week to about 8 months. In some additional examples, the ophthalmic article can release from about 1 pg to about 500 pg of active agent and / or diagnostic agent over a period of from about 1 week to about 10 months. In some additional examples, the ophthalmic article can release from about 1 pg to about 500 pg of active agent and / or diagnostic agent over a period of from about 1 week to about 12 months. In some additional examples, the ophthalmic article can release from about 1 pg to about 500 pg of active agent and / or diagnostic agent over a period of from about 1 week to about 14 months. In some additional examples, the ophthalmic article can release from about 1 pg to about 500 pg of active agent and / or diagnostic agent over a period of from about 1 week to about 16 months. In some additional examples, the ophthalmic article can release from about 1 pg to about 500 pg of active agent and / or diagnostic agent over a period of from about 1 week to about 18 months. In some additional examples, the ophthalmic article can release from about 1 pg to about 500 pg of active agent and / or diagnostic agent over a period of from about 1 week to about 20 months. In some additional examples, the ophthalmic article can release from about 1 pg to about 500 pg of active agent and / or diagnostic agent over a period of from about 1 week to about 22 months. In some additional examples, the ophthalmic article can release from about 1 pg to about 500 pg of active agent and / or diagnostic agent over a period of from about 1 week to about 24 months. In some additional examples, the ophthalmic article can release from about 1 pg to about 500 pg of active agent and / or diagnostic agent over a period of from about 1 week to about 26 months. In some additional examples, the ophthalmic article can release from about 1 pg to about 500 pg of active agent and / or diagnostic agent over a period of from about 1 week to about 28 months. In some additional examples, the ophthalmic article can release from about 1 pg to about 500 pg of active agent and / or diagnostic agent over a period of from about 1 week to about 30 months. In some additional examples, the ophthalmic article can release from about 1 pg to about 500 pg of active agent and / or diagnostic agent over a period of from about 1 week to about 32 months. In some additional examples, the ophthalmic article can release from about 1 pg to about 500 pg of active agent and / or diagnostic agent over a period of from about 1 week to about 34 months. In some additional examples, the ophthalmic article can release from about 1 pg to about 500 pg of active agent and / or diagnostic agent over a period of from about 1 week to about 36 months.

[0214] In yet other examples, the ophthalmic article can release from about 100 pg to about 1000 pg of active agent and / or diagnostic agent over a period of from about 2 weeks to about 8 weeks. In still other examples, the ophthalmic article can release from about 100 pg to about 500 pg, or from about 200 pg to about 1000 pg of active agent and / or diagnostic agent over a period of from about 2 weeks to about 8 weeks. In another example, the ophthalmic article can release about 1 pg to about 300 pg over 2-3 weeks. In another example, the ophthalmic article can release 100 pg to about 600 pg over 6-8 weeks.

[0215] In some additional examples, the ophthalmic article can release from about 100 pg to about 500 pg, or from about 200 pg to about 1000 pg of active agent and / or diagnostic agent over a period of from about 1 week to about 6 months. In some additional examples, the ophthalmic article can release from about 100 pg to about 500 pg, or from about 200 pg to about 1000 pg of active agent and / or diagnostic agent over a period of from about 1 week to about 8 months. In some additional examples, the ophthalmic article can release from about 100 pg to about 500 pg, or from about 200 pg to about 1000 pg of active agent and / or diagnostic agent over a period of from about 1 week to about 10 months. In some additional examples, the ophthalmic article can release from about 100 pg to about 500 pg, or from about 200 pg to about 1000 pg of active agent and / or diagnostic agent over a period of from about 1 week to about 12 months. In some additional examples, the ophthalmic article can release from about 100 pg to about 500 pg, or from about 200 pg to about 1000 pg of active agent and / or diagnostic agent over a period of from about 1 week to about 14 months. In some additional examples, the ophthalmic article can release from about 100 pg to about 500 pg, or from about 200 pg to about 1000 pg of active agent and / or diagnostic agent over a period of from about 1 week to about 16 months. In some additional examples, the ophthalmic article can release from about 100 pg to about 500 pg, or from about 200 pg to about 1000 pg of active agent and / or diagnostic agent over a period of from about 1 week to about 18 months. In some additional examples, the ophthalmic article can release from about 100 pg to about 500 pg, or from about 200 pg to about 1000 pg of active agent and / or diagnostic agent over a period of from about 1 week to about 20 months. In some additional examples, the ophthalmic article can release from about 100 pg to about 500 pg, or from about 200 pg to about 1000 pg of active agent and / or diagnostic agent over a period of from about 1 week to about 22 months. In some additional examples, the ophthalmic article can release from about 100 pg to about 500 pg, or from about 200 pg to about 1000 pg of active agent and / or diagnostic agent over a period of from about 1 week to about 24 months. In some additional examples, the ophthalmic article can release from about 100 pg to about 500 pg, or from about 200 pg to about 1000 pg of active agent and / or diagnostic agent over a period of from about 1 week to about 26 months. In some additional examples, the ophthalmic article can release from about 100 pg to about 500 pg, or from about 200 pg to about 1000 pg of active agent and / or diagnostic agent over a period of from about 1 week to about 28 months. In some additional examples, the ophthalmic article can release from about 100 pg to about 500 pg, or from about 200 pg to about 1000 pg of active agent and / or diagnostic agent over a period of from about 1 week to about 30 months. In some additional examples, the ophthalmic article can release from about 100 pg to about 500 pg, or from about 200 pg to about 1000 pg of active agent and / or diagnostic agent over a period of from about 1 week to about 32 months. In some additional examples, the ophthalmic article can release from about 100 pg to about 500 pg, or from about 200 pg to about 1000 pg of active agent and / or diagnostic agent over a period of from about 1 week to about 34 months. In some additional examples, the ophthalmic article can release from about 100 pg to about 500 pg, or from about 200 pg to about 1000 pg of active agent and / or diagnostic agent over a period of from about 1 week to about 36 months.

[0216] In some examples, the ophthalmic article can deliver an average of from about 0.1 pg to about 1 pg per day of the active agent and / or diagnostic agent during a release period. In other examples, the ophthalmic article can deliver an average of from about 1 pg to about 10 pg per day of the active agent and / or diagnostic agent during a release period. In yet other examples, the ophthalmic article can deliver an average of from about 10 pg to about 50 pg per day of the active agent and / or diagnostic agent during a release period.

[0217] In yet other examples, the ophthalmic article can deliver an average of from about 10 pg to about 100 pg per day of the active agent and / or diagnostic agent during a release period. In yet other examples, the ophthalmic article can deliver an average of from about 10 pg to about 150 pg per day of the active agent and / or diagnostic agent during a release period. In yet other examples, the ophthalmic article can deliver an average of from about 10 pg to about 200 pg per day of the active agent and / or diagnostic agent during a release period. In yet other examples, the ophthalmic article can deliver an average of from about 10 pg to about 250 pg per day of the active agent and / or diagnostic agent during a release period. In yet other examples, the ophthalmic article can deliver an average of from about 10 pg to about 300 pg per day of the active agent and / or diagnostic agent during a release period. In yet other examples, the ophthalmic article can deliver an average of from about 10 pg to about 350 pg per day of the active agent and / or diagnostic agent during a release period. In yet other examples, the ophthalmic article can deliver an average of from about 10 pg to about 400 pg per day of the active agent and / or diagnostic agent during a release period. In yet other examples, the ophthalmic article can deliver an average of from about 10 pg to about 450 pg per day of the active agent and / or diagnostic agent during a release period. In yet other examples, the ophthalmic article can deliver an average of from about 10 pg to about 500 pg per day of the active agent and / or diagnostic agent during a release period. In yet other examples, the ophthalmic article can deliver an average of from about 10 pg to about 550 pg per day of the active agent and / or diagnostic agent during a release period. In yet other examples, the ophthalmic article can deliver an average of from about 10 pg to about 600 pg per day of the active agent and / or diagnostic agent during a release period. In yet other examples, the ophthalmic article can deliver an average of from about 10 pg to about 650 pg per day of the active agent and / or diagnostic agent during a release period. In yet other examples, the ophthalmic article can deliver an average of from about 10 pg to about 700 pg per day of the active agent and / or diagnostic agent during a release period. In yet other examples, the ophthalmic article can deliver an average of from about 10 pg to about 750 pg per day of the active agent and / or diagnostic agent during a release period. In yet other examples, the ophthalmic article can deliver an average of from about 10 pg to about 800 pg per day of the active agent and / or diagnostic agent during a release period. In yet other examples, the ophthalmic article can deliver an average of from about 10 pg to about 850 pg per day of the active agent and / or diagnostic agent during a release period. In yet other examples, the ophthalmic article can deliver an average of from about 10 pg to about 900 pg per day of the active agent and / or diagnostic agent during a release period. In yet other examples, the ophthalmic article can deliver an average of from about 10 pg to about 950 pg per day of the active agent and / or diagnostic agent during a release period. In yet other examples, the ophthalmic article can deliver an average of about 1 pg per day of the active agent and / or diagnostic agent during a release period. In yet other examples, the ophthalmic article can deliver an average of about 5 pg per day of the active agent and / or diagnostic agent during a release period. In yet other examples, the ophthalmic article can deliver an average of about 10 pg per day of the active agent and / or diagnostic agent during a release period. In yet other examples, the ophthalmic article can deliver an average of about 50 pg per day of the active agent and / or diagnostic agent during a release period. In yet other examples, the ophthalmic article can deliver an average of about 100 pg per day of the active agent and / or diagnostic agent during a release period. In yet other examples, the ophthalmic article can deliver an average of about 200 pg per day of the active agent and / or diagnostic agent during a release period. In yet other examples, the ophthalmic article can deliver an average of about 300 pg per day of the active agent and / or diagnostic agent during a release period. In yet other examples, the ophthalmic article can deliver an average of about 400 pg per day of the active agent and / or diagnostic agent during a release period. In yet other examples, the ophthalmic article can deliver an average of about 500 pg per day of the active agent and / or diagnostic agent during a release period. In yet other examples, the ophthalmic article can deliver an average of about 600 pg per day of the active agent and / or diagnostic agent during a release period. In yet other examples, the ophthalmic article can deliver an average of about 700 pg per day of the active agent and / or diagnostic agent during a release period. In yet other examples, the ophthalmic article can deliver an average of about 800 pg per day of the active agent and / or diagnostic agent during a release period. In yet other examples, the ophthalmic article can deliver an average of about 900 pg per day of the active agent and / or diagnostic agent during a release period. In yet other examples, the ophthalmic article can deliver an average of about 1,000 pg per day of the active agent and / or diagnostic agent during a release period.

[0218] In some embodiments, the active agent and / or diagnostic agent can be present in the ophthalmic article at a concentration of from about 5 weight percentage (wt%) to about 50 wt%. In some embodiments, the active agent and / or diagnostic agent can be present in the ophthalmic article at a concentration of from about 5 wt% to about 10 wt%, from about 5 wt% to about 15 wt%, from about 5 wt% to about 20 wt%, from about 5 wt% to about 25 wt%, from about 5 wt% to about 30 wt%, from about 5 wt% to about 35 wt%, from about 5 wt% to about 40 wt%, from about 5 wt% to about 45 wt%, from about 10 wt% to about 15 wt%, from about 10 wt% to about 20 wt%, from about 10 wt% to about 25 wt%, from about 10 wt% to about 30 wt%, from about 10 wt% to about 35 wt%, from about 10 wt% to about 40 wt%, from about 10 wt% to about 45 wt%, from about 10 wt% to about 50 wt%, from about 15 wt% to about 20 wt%, from about 15 wt% to about 25 wt%, from about 15 wt% to about 30 wt%, from about 15 wt% to about 35 wt%, from about 15 wt% to about 40 wt%, from about 15 wt% to about 45 wt%, from about 15 wt% to about 50 wt%, from about 20 wt% to about 25 wt%, from about 20 wt% to about 30 wt%, from about 20 wt% to about 35 wt%, from about 20 wt% to about 40 wt%, from about 20 wt% to about 45 wt%, from about 20 wt% to about 50 wt%, from about 25 wt% to about 30 wt%, from about 25 wt% to about 35 wt%, from about 25 wt% to about 40 wt%, from about 25 wt% to about 45 wt%, from about 25 wt% to about 50 wt%, from about 30 wt% to about 35 wt%, from about 30 wt% to about 40 wt%, from about 30 wt% to about 45 wt%, from about 30 wt% to about 50 wt%, from about 35 wt% to about 40 wt%, from about 35 wt% to about 45 wt%, from about 35 wt% to about 50 wt%, from about 40 wt% to about 45 wt%, from about 40 wt% to about 50 wt%, or from about 45 wt% to about 50 wt%. In some embodiments, the active agent and / or diagnostic agent can be present in the ophthalmic article at a concentration of from about 5 wt% to about 25 wt%. In some embodiments, the active agent and / or diagnostic agent can be present in the ophthalmic article at a concentration of from about 5 wt% to about 15 wt%. %. In some embodiments, the active agent and / or diagnostic agent can be present in the ophthalmic article at a concentration of at least about 5 wt%. In some embodiments, the active agent and / or diagnostic agent can be present in the ophthalmic article at a concentration of at least about 10 wt%. In some embodiments, the active agent and / or diagnostic agent can be present in the ophthalmic article at a concentration of at least about 20 wt%.

[0219] In some embodiments, the active agent and / or diagnostic agent can be present in the ophthalmic article at a concentration of at least about 5 wt%, at least about 10 wt%, at least about 15 wt%, at least about 20 wt%, at least about 25 wt%, at least about 30 wt%, at least about 35 wt%, at least about 40 wt%, at least about 45 wt%, at least about, or at least about 50 wt%.

[0220] In some embodiments, the active agent and / or diagnostic agent can be present in the ophthalmic article at a concentration of at most about 5 wt%, at most about 10 wt%, at most about 15 wt%, at most about 20 wt%, at most about 25 wt%, at most about 30 wt%, at most about 35 wt%, at most about 40 wt%, at most about 45 wt%, at most about, or at most about 50 wt%. In some embodiments, the active agent and / or diagnostic agent can be present in the ophthalmic article at a concentration of at most about 5 wt%. In some embodiments, the active agent and / or diagnostic agent can be present in the ophthalmic article at a concentration of at most about 10 wt%. In some embodiments, the active agent and / or diagnostic agent can be present in the ophthalmic article at a concentration of at most about 20 wt%.

[0221] In some embodiments, the active agent and / or diagnostic agent can be present in the ophthalmic article at a concentration of about 5 wt%, about 10 wt%, about 15 wt%, about 20 wt%, about 25 wt%, about 30 wt%, about 35 wt%, about 40 wt%, about 45 wt%, about, or about 50 wt%.

[0222] In some embodiments, the molecular weight, molecular mass, or molecular size of the active agent and / or diagnostic agent can affect delivery of the active agent and / or diagnostic agent to the eye (e.g., posterior segment of the eye). Thus, in some examples, the active agent and / or diagnostic agent can have a molecular weight or molecular mass of 250,000 daltons (Da) or less. In yet additional examples, the active agent and / or diagnostic agent can have a molecular weight or molecular mass of 200,000 Da or less. In yet additional examples, the active agent and / or diagnostic agent can have a molecular weight or molecular mass of 190,000 Da or less. In yet additional examples, the active agent and / or diagnostic agent can have a molecular weight or molecular mass of 180,000 Da or less. In yet other examples, the active agent and / or diagnostic agent can have a molecular weight or molecular mass of 170,000 Da or less. In yet other examples, the active agent and / or diagnostic agent can have a molecular weight or molecular mass of 160,000 Da or less. In yet other examples, the active agent and / or diagnostic agent can have a molecular weight or molecular mass of 150,000 Da or less. In yet other examples, the active agent and / or diagnostic agent can have a molecular weight or molecular mass of 140,000 Da or less. In yet other examples, the active agent and / or diagnostic agent can have a molecular weight or molecular mass of 130,000 Da or less. In yet other examples, the active agent and / or diagnostic agent can have a molecular weight or molecular mass of 120,000 Da or less. In yet other examples, the active agent and / or diagnostic agent can have a molecular weight or molecular mass of 110,000 Da or less. In yet other examples, the active agent and / or diagnostic agent can have a molecular weight or molecular mass of 100,000 Da or less. In yet other examples, the active agent and / or diagnostic agent can have a molecular weight or molecular mass of 90,000 Da or less. In yet other examples, the active agent and / or diagnostic agent can have a molecular weight or molecular mass of 80,000 Da or less. In yet other examples, the active agent and / or diagnostic agent can have a molecular weight or molecular mass of 70,000 Da or less. In yet other examples, the active agent and / or diagnostic agent can have a molecular weight or molecular mass of 60,000 Da or less. In yet other examples, the active agent and / or diagnostic agent can have a molecular weight or molecular mass of 50,000 Da or less. In yet other examples, the active agent and / or diagnostic agent can have a molecular weight or molecular mass of 40,000 Da or less. In yet other examples, the active agent and / or diagnostic agent can have a molecular weight or molecular mass of 30,000 Da or less. In yet other examples, the active agent and / or diagnostic agent can have a molecular weight or molecular mass of 20,000 Da or less. In yet other examples, the active agent and / or diagnostic agent can have a molecular weight or molecular mass of 10,000 Da or less. In yet other examples, the active agent and / or diagnostic agent can have a molecular weight or molecular mass of 5,000 Da or less. In yet other examples, the active agent and / or diagnostic agent can have a molecular weight or molecular mass of 1,000 Da or less. In yet additional examples, the active agent and / or diagnostic agent can have a molecular weight or molecular mass of 500 Da or less. In yet other examples, the active agent and / or diagnostic agent can have a molecular weight or molecular mass of 400 Da or less. In yet other examples, the active agent and / or diagnostic agent can have a molecular weight or molecular mass of 300 Da or less. In yet other examples, the active agent and / or diagnostic agent can have a molecular weight or molecular mass of 200 Da or less. In yet other examples, the active agent and / or diagnostic agent can have a molecular weight or molecular mass of 100 Da or less.

[0223] In some embodiments, one, two or more ophthalmic articles can be introduced or implanted per eye to achieve an effective amount (e.g., therapeutically effective amount) and / or an effective dose (e.g., therapeutically effective dose). In some embodiments, at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more ophthalmic articles can be introduced or implanted per eye. In some embodiments, at most about 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 ophthalmic articles can be introduced or implanted per eye. In some embodiments, at least about 1 ophthalmic articles can be introduced or implanted per eye. In some embodiments, at least about 2 ophthalmic articles can be introduced or implanted per eye. In some embodiments, at least about 3 ophthalmic articles can be introduced or implanted per eye. In some embodiments, at least about 4 ophthalmic articles can be introduced or implanted per eye. In some embodiments, at least about 5 ophthalmic articles can be introduced or implanted per eye.

[0224] In some embodiments, at most about 1 ophthalmic articles can be introduced or implanted per eye. In some embodiments, at most about 2 ophthalmic articles can be introduced or implanted per eye. In some embodiments, at most about 3 ophthalmic articles can be introduced or implanted per eye. In some embodiments, at most about 4 ophthalmic articles can be introduced or implanted per eye. In some embodiments, at most about 5 ophthalmic articles can be introduced or implanted per eye.

[0225] In some embodiments, about 1 ophthalmic articles can be introduced or implanted per eye. In some embodiments, about 2 ophthalmic articles can be introduced or implanted per eye. In some embodiments, about 3 ophthalmic articles can be introduced or implanted per eye. In some embodiments, about 4 ophthalmic articles can be introduced or implanted per eye. In some embodiments, about 5 ophthalmic articles can be introduced or implanted per eye

[0226] In any of the various aspects, the one or more ophthalmic articles described herein are engineered in size and / or shape, to provide maximal approximation of the ophthalmic article to a subject’s eye. The shape and / or size of ophthalmic articles (e.g., homogenous active agent and / or diagnostic agent delivery devices) for delivery or administration of the active agent and / or diagnostic agent to the eye can play an important role in the amount and rate of delivery of the active agent and / or diagnostic agent. For example, the shape and / or size of the ophthalmic articles (e.g., homogenous active agent and / or diagnostic agent delivery devices) can be designed to accommodate faster and / or slower release rates; and greater or smaller amounts of active agents and / or diagnostic agents released by the ophthalmic articles (e.g., homogenous active agent and / or diagnostic agent delivery devices) while maintaining suitable compositional parameters for a desired release profile.

[0227] In some embodiments, the shape of the ophthalmic article can be a prism with an open internal structure (e.g., a hole in the center) In some embodiments, the prism may be an extruded prism. The prism may be a round prism, a rectangular prism, a square prism, quadrilateral prism, pentagon prism, hexagon prism, heptagon prism, octagon prism, nonagon prism, decagon prism, undecagon prism, dodecagon prism, or a prism of another shape. In some embodiments, the prism may be a polyhedron. In some embodiments, the ophthalmic article may be an annulus, an extruded annulus, a torus, an extruded square, extruded quadrilateral, an extruded rectangle, extruded pentagon, an extruded hexagon, extruded heptagon, extruded octagon, extruded nonagon, extruded decagon, extruded undecagon, extruded dodecagon, an extruded polygon with an open internal structure (e.g., a hole in the center). In some embodiments, the polygon may comprise 3, 4, 5, 6, 7, 8, 9, or 10 sides.

[0228] In some embodiments, the shape of ophthalmic article may be disc, cylinder, nail-like-plug, rod, tablet, sphere, truncated cone with a bended axis, polymer wire rolled around a portion of an ocular device, and polymer sheet wrapped around a portion of an ocular device.

[0229] In some embodiments, the ophthalmic article may comprise an internal structure for associating with a portion of an ocular device. The internal structure may be a hole. For example, an ophthalmic article of any of the shapes disclosed herein may comprise a hole in the center for associating with an intraocular lens. In some embodiments, a shape of the ophthalmic article and / or internal structure may be the same as a shape of a portion of the ocular device (e.g., intraocular device) to which the ophthalmic article is associated. For example, the shape of the ophthalmic article and / or internal structure may be the same as a shape of a haptic of an intraocular lens. In some embodiments, a shape of the ophthalmic article and / or internal structure may be different from a shape of a portion of the ocular device (e.g., intraocular device) to which the ophthalmic article is associated. For example, the shape of the ophthalmic article and / or internal structure may be different than a shape of a haptic of an intraocular lens.

[0230] In some embodiments, the shape of the ophthalmic article can be manipulated to prevent obstruction of a line of sight in the eye. For example, in some cases, the ophthalmic article can have a crescent shape, an ellipsoid shape (e.g. a disc shape, a football shape, an egg shape, or the like), a rod shape, or the like, to allow the size to increase to a greater extent along one axis relative to a perpendicular axis so as to not obstruct a line of sight in the eye.

[0231] In some embodiments, where a polymeric material (e.g., biodegradable polymer matrix) is employed in the ophthalmic articles (e.g., homogenous active agent and / or diagnostic agent delivery devices), the polymeric material (e.g., biodegradable polymer matrix) can accommodate various amounts of active agents and / or diagnostic agents while maintaining a desirable biodegradation profile. The amount of active agents and / or diagnostic agents that a biodegradable matrix can release (e.g., controllably release) within a particular biodegradation profile may depend on both the composition of the polymeric matrix and the one or more active agents and / or diagnostic agents.

[0232] In some embodiments, a small or a large amount of an active agent and / or diagnostic agent can be required to provide an effective amount (e.g., therapeutically effective amount) to a subject to treat or diagnose a particular condition. The overall size of the ophthalmic article can be increased to accommodate a large amount of active agent and / or diagnostic agent. Conversely, as another example, the size of the ophthalmic article can be reduced where lesser amounts of the active agent and / or diagnostic agent are needed.

[0233] In some embodiments, the ophthalmic article may comprise an internal structure (e.g., a hole) for associating (e.g., attaching) around a portion of an ocular device (e.g., intraocular device). For example, the ophthalmic article may comprise a hole for associating around a geometric shape of a haptic of an intraocular lens. The hole may be round and the haptic can be circular or rectangular.

[0234] In some embodiments, a dimension or parameter of the internal structure (e.g., hole) may be less than, equal to, or greater than a corresponding dimension or parameter of a portion of the ocular device (e.g., intraocular device) to which the ophthalmic article associates. In some embodiments, a perimeter of the internal structure (e.g., hole) of the ophthalmic article may be less than or equal to a perimeter of a portion of the ocular device (e.g., intraocular device) to which the ophthalmic article associates. In some cases, a perimeter of the hole of the ophthalmic article may be less than or equal to a perimeter of the haptic on the intraocular lens to which the ophthalmic article associates. For example, when cross-sectional dimensions of a haptic of an IOL (e.g., Aurovue) is about 1.00 mm x 0.32 mm wide, the perimeter of the hole of the ophthalmic article can be less than or equal to 2.64 mm. In some embodiments, the perimeter of the hole of the ophthalmic article can be about 1.57 mm. In another example, when crosssectional dimensions of a haptic of an IOL (e.g., by Johnson & Johnson Surgical Vision foldable acrylic IOL Tecnis 1-piece) can be a rectangle about 0.72 x 0.46 mm wide, the perimeter of the hole of the ophthalmic article can be less than or equal to 2.36 mm.

[0235] In some embodiments, the perimeter of the hole of the ophthalmic article may be about 0.5 mm to about 6 mm. In some embodiments, the perimeter of the hole of the ophthalmic article may be about 0.5 mm to about 1 mm, about 0.5 mm to about 1.5 mm, about 0.5 mm to about 2 mm, about 0.5 mm to about 2.5 mm, about 0.5 mm to about 3 mm, about 0.5 mm to about 3.5 mm, about 0.5 mm to about 4 mm, about 0.5 mm to about 4.5 mm, about 0.5 mm to about 5 mm, about 0.5 mm to about 5.5 mm, about 0.5 mm to about 6 mm, about 1 mm to about 1.5 mm, about 1 mm to about 2 mm, about 1 mm to about 2.5 mm, about 1 mm to about 3 mm, about 1 mm to about 3.5 mm, about 1 mm to about 4 mm, about 1 mm to about 4.5 mm, about 1 mm to about 5 mm, about 1 mm to about 5.5 mm, about 1 mm to about 6 mm, about 1.5 mm to about 2 mm, about 1.5 mm to about 2.5 mm, about 1.5 mm to about 3 mm, about 1.5 mm to about 3.5 mm, about 1.5 mm to about 4 mm, about 1.5 mm to about 4.5 mm, about 1.5 mm to about 5 mm, about 1.5 mm to about 5.5 mm, about 1.5 mm to about 6 mm, about 2 mm to about 2.5 mm, about 2 mm to about 3 mm, about 2 mm to about 3.5 mm, about 2 mm to about 4 mm, about 2 mm to about 4.5 mm, about 2 mm to about 5 mm, about 2 mm to about 5.5 mm, about 2 mm to about 6 mm, about 2.5 mm to about 3 mm, about 2.5 mm to about 3.5 mm, about 2.5 mm to about 4 mm, about 2.5 mm to about 4.5 mm, about 2.5 mm to about 5 mm, about 2.5 mm to about 5.5 mm, about 2.5 mm to about 6 mm, about 3 mm to about 3.5 mm, about 3 mm to about 4 mm, about 3 mm to about 4.5 mm, about 3 mm to about 5 mm, about 3 mm to about 5.5 mm, about 3 mm to about 6 mm, about 3.5 mm to about 4 mm, about 3.5 mm to about 4.5 mm, about 3.5 mm to about 5 mm, about 3.5 mm to about 5.5 mm, about 3.5 mm to about 6 mm, about 4 mm to about 4.5 mm, about 4 mm to about 5 mm, about 4 mm to about 5.5 mm, about 4 mm to about 6 mm, about 4.5 mm to about 5 mm, about 4.5 mm to about 5.5 mm, about 4.5 mm to about 6 mm, about 5 mm to about 5.5 mm, about 5 mm to about 6 mm, or about 5.5 mm to about 6 mm.

[0236] In some embodiments, the perimeter of the hole of the ophthalmic article may be at least about 0.5 mm, at least about 1 mm, at least about 1.2 mm, at least about 1.3 mm, at least about 1.4 mm, at least about 1.5 mm, at least about 1.6 mm, at least about 1.7 mm, at least about 1.8 mm, at least about 1.9 mm, at least about 2 mm, at least about 2.1 mm, at least about 2.2 mm, at least about 2.3 mm, at least about 2.4 mm, at least about 2.5 mm, at least about 2.6 mm, at least about 2.7 mm, at least about 2.8 mm, at least about 2.9 mm, at least about 3 mm, at least about 3.2 mm, at least about 3.4 mm, at least about 3.6 mm, at least about 3.8 mm, at least about 4 mm, at least about 4.2 mm, at least about 4.4 mm, at least about 4.6 mm, at least about 4.8 mm, at least about 5 mm, at least about 5.2 mm, at least about 5.4 mm, at least about 5.6 mm, at least about 5.8 mm, at least about 6 mm, at least about 6.2 mm, at least about 6.4 mm, at least about 6.6 mm, at least about 6.8 mm, or at least about 7 mm.

[0237] In some embodiments, the perimeter of the hole of the ophthalmic article may be at most about 0.5 mm, at most about 1 mm, at most about 1.2 mm, at most about 1.3 mm, at most about 1.4 mm, at most about 1.5 mm, at most about 1.6 mm, at most about 1.7 mm, at most about 1.8 mm, at most about 1.9 mm, at most about 2 mm, at most about 2.1 mm, at most about 2.2 mm, at most about 2.3 mm, at most about 2.4 mm, at most about 2.5 mm, at most about 2.6 mm, at most about 2.7 mm, at most about 2.8 mm, at most about 2.9 mm, at most about 3 mm, at most about 3.2 mm, at most about 3.4 mm, at most about 3.6 mm, at most about 3.8 mm, at most about 4 mm, at most about 4.2 mm, at most about 4.4 mm, at most about 4.6 mm, at most about 4.8 mm, at most about 5 mm, at most about 5.2 mm, at most about 5.4 mm, at most about 5.6 mm, at most about 5.8 mm, at most about 6 mm, at most about 6.2 mm, at most about 6.4 mm, at most about 6.6 mm, at most about 6.8 mm, or at most about 7 mm.

[0238] In some embodiments, a widest dimension of the internal structure of the ophthalmic device may be less than or equal to a widest dimension of a portion of the ocular device (e.g., intraocular device) to which the ophthalmic article associates. For example, a widest dimension of the internal structure of the ophthalmic device may be less than or equal to a widest dimension of a haptic of the intraocular lens to which the ophthalmic article associates. The widest dimension of the haptic of a 1-piece foldable acrylic IOL may be around 0.7 mm to 1.0 mm, and the widest dimension of the haptic of a 3-piece foldable IOL may be around 0.1 mm to 0.2 mm. In some embodiments, a diameter of the internal structure of the ophthalmic device may be less than or equal to a diameter of a portion of the ocular device (e.g., intraocular device) to which the ophthalmic article associates. For example, a diameter of the internal structure of the ophthalmic device may be less than, equal to, or greater than a diameter of a haptic of the intraocular lens to which the ophthalmic article associates.

[0239] In some embodiments, the widest dimension of the haptic of any of the IOL herein may be about 0.01 mm to about 10 mm. In some embodiments, the widest dimension of the haptic of any of the IOL herein may be about 0.01 mm to about 0.05 mm, about 0.01 mm to about 0.1 mm, about 0.01 mm to about 0.5 mm, about 0.01 mm to about 1 mm, about 0.01 mm to about 1.5 mm, about 0.01 mm to about 2 mm, about 0.01 mm to about 3 mm, about 0.01 mm to about 4 mm, about 0.01 mm to about 5 mm, about 0.01 mm to about 10 mm, about 0.05 mm to about 0.1 mm, about 0.05 mm to about 0.5 mm, about 0.05 mm to about 1 mm, about 0.05 mm to about 1.5 mm, about 0.05 mm to about 2 mm, about 0.05 mm to about 3 mm, about 0.05 mm to about 4 mm, about 0.05 mm to about 5 mm, about 0.05 mm to about 10 mm, about 0.1 mm to about 0.5 mm, about 0.1 mm to about 1 mm, about 0.1 mm to about 1.5 mm, about 0.1 mm to about 2 mm, about 0.1 mm to about 3 mm, about 0.1 mm to about 4 mm, about 0.1 mm to about 5 mm, about 0.1 mm to about 10 mm, about 0.5 mm to about 1 mm, about 0.5 mm to about 1.5 mm, about 0.5 mm to about 2 mm, about 0.5 mm to about 3 mm, about 0.5 mm to about 4 mm, about 0.5 mm to about 5 mm, about 0.5 mm to about 10 mm, about 1 mm to about 1.5 mm, about 1 mm to about 2 mm, about 1 mm to about 3 mm, about 1 mm to about 4 mm, about 1 mm to about 5 mm, about 1 mm to about 10 mm, about 1.5 mm to about 2 mm, about 1.5 mm to about 3 mm, about 1.5 mm to about 4 mm, about 1.5 mm to about 5 mm, about 1.5 mm to about 10 mm, about 2 mm to about 3 mm, about 2 mm to about 4 mm, about 2 mm to about 5 mm, about 2 mm to about 10 mm, about 3 mm to about 4 mm, about 3 mm to about 5 mm, about 3 mm to about 10 mm, about 4 mm to about 5 mm, about 4 mm to about 10 mm, or about 5 mm to about 10 mm.

[0240] In some embodiments, the widest dimension of the haptic of any of the IOL herein may be at least about 0.01 mm, at least about 0.05 mm, at least about 0.1 mm, at least about 0.2 mm, at least about 0.3 mm, at least about 0.4 mm, at least about 0.5 mm, at least about 0.6 mm, at least about 0.7 mm, at least about 0.8 mm, at least about 0.9 mm, at least about 1 mm, at least about 1.1 mm, at least about 1.2 mm, at least about 1.3 mm, at least about 1.4 mm, at least about 1.5 mm, at least about 1.6 mm, at least about 1.7 mm, at least about 1.8 mm, at least about 1.9 mm, at least about 2 mm, at least about 3 mm, at least about 4 mm, at least about 5 mm, at least about 6 mm, at least about 7 mm, at least about 8 mm, at least about 9 mm, or at least about 10. In some embodiments, the widest dimension of the haptic of any of the IOL herein may be at least about 0.5 mm. In some embodiments, the widest dimension of the haptic of any of the IOL herein may be at least about 0.07 mm. In some embodiments, the widest dimension of the haptic of any of the IOL herein may be at least about 1 mm.

[0241] In some embodiments, the widest dimension of the haptic of any of the IOL herein may be at most about 0.01 mm, at most about 0.05 mm, at most about 0.1 mm, at most about 0.2 mm, at most about 0.3 mm, at most about 0.4 mm, at most about 0.5 mm, at most about 0.6 mm, at most about 0.7 mm, at most about 0.8 mm, at most about 0.9 mm, at most about 1 mm, at most about 1.1 mm, at most about 1.2 mm, at most about 1.3 mm, at most about 1.4 mm, at most about 1.5 mm, at most about 1.6 mm, at most about 1.7 mm, at most about 1.8 mm, at most about 1.9 mm, at most about 2 mm, at most about 3 mm, at most about 4 mm, at most about 5 mm, at most about 6 mm, at most about 7 mm, at most about 8 mm, at most about 9 mm, or at most about 10. In some embodiments, the widest dimension of the haptic of any of the IOL herein may be at most about 1.5 mm. In some embodiments, the widest dimension of the haptic of any of the IOL herein may be at most about 1 mm. In some embodiments, the widest dimension of the haptic of any of the IOL herein may be at most about 0.5 mm.

[0242] In some embodiments, a diameter of the internal structure of the ophthalmic device may be about 0.1 mm to 2.3 mm. In some embodiments, a diameter of the internal structure of the ophthalmic device may be about 0.1 mm to about 0.3 mm, about 0.1 mm to about 0.5 mm, about 0.1 mm to about 0.7 mm, about 0.1 mm to about 0.9 mm, about 0.1 mm to about 1.1 mm, about 0.1 mm to about 1.3 mm, about 0.1 mm to about 1.5 mm, about 0.1 mm to about 1.7 mm, about 0.1 mm to about 1.9 mm, about 0.1 mm to about 2.1 mm, about 0.1 mm to about 2.3 mm, about 0.3 mm to about 0.5 mm, about 0.3 mm to about 0.7 mm, about 0.3 mm to about 0.9 mm, about 0.3 mm to about 1.1 mm, about 0.3 mm to about 1.3 mm, about 0.3 mm to about 1.5 mm, about 0.3 mm to about 1.7 mm, about 0.3 mm to about 1.9 mm, about 0.3 mm to about 2.1 mm, about 0.3 mm to about 2.3 mm, about 0.5 mm to about 0.7 mm, about 0.5 mm to about 0.9 mm, about 0.5 mm to about 1.1 mm, about 0.5 mm to about 1.3 mm, about 0.5 mm to about 1.5 mm, about 0.5 mm to about 1.7 mm, about 0.5 mm to about 1.9 mm, about 0.5 mm to about 2.1 mm, about 0.5 mm to about 2.3 mm, about 0.7 mm to about 0.9 mm, about 0.7 mm to about 1.1 mm, about 0.7 mm to about 1.3 mm, about 0.7 mm to about 1.5 mm, about 0.7 mm to about 1.7 mm, about 0.7 mm to about 1.9 mm, about 0.7 mm to about 2.1 mm, about 0.7 mm to about 2.3 mm, about 0.9 mm to about 1.1 mm, about 0.9 mm to about 1.3 mm, about 0.9 mm to about 1.5 mm, about 0.9 mm to about 1.7 mm, about 0.9 mm to about 1.9 mm, about 0.9 mm to about 2.1 mm, about 0.9 mm to about 2.3 mm, about 1.1 mm to about 1.3 mm, about 1.1 mm to about 1.5 mm, about 1.1 mm to about 1.7 mm, about 1.1 mm to about 1.9 mm, about 1.1 mm to about 2.1 mm, about 1.1 mm to about 2.3 mm, about 1.3 mm to about 1.5 mm, about 1.3 mm to about 1.7 mm, about 1.3 mm to about 1.9 mm, about 1.3 mm to about 2.1 mm, about 1.3 mm to about 2.3 mm, about 1.5 mm to about 1.7 mm, about 1.5 mm to about 1.9 mm, about 1.5 mm to about 2.1 mm, about 1.5 mm to about 2.3 mm, about 1.7 mm to about 1.9 mm, about 1.7 mm to about 2.1 mm, about 1.7 mm to about 2.3 mm, about 1.9 mm to about 2.1 mm, about 1.9 mm to about 2.3 mm, or about 2.1 mm to about 2.3 mm. In some embodiments, a diameter of the internal structure of the ophthalmic device may be about 0.1 mm to about 1 mm. In some embodiments, a diameter of the internal structure of the ophthalmic device may be about 0.1 mm to about 0.7 mm.

[0243] In some embodiments, a diameter of the internal structure of the ophthalmic device may be at least about 0.1 mm, at least about 0.2 mm, at least about 0.25 mm, at least about 0.3 mm, at least about 0.35 mm, at least about 0.4 mm, at least about 0.45 mm, at least about 0.5 mm, at least about 0.55 mm, at least about 0.6 mm, at least about 0.65 mm, at least about 0.7 mm, at least about 0.75 mm, at least about 0.8 mm, at least about 0.85 mm, at least about 0.9 mm, at least about 0.95 mm, at least about 1 mm, at least about 1.05 mm, at least about 1.1 mm, at least about 1.15 mm, at least about 1.2 mm, at least about 1.25 mm, at least about 1.3 mm, at least about 1.35 mm, at least about 1.4 mm, at least about 1.45 mm, at least about 1.5 mm, at least about 1.55 mm, at least about 1.6 mm, at least about 1.65 mm, at least about 1.7 mm, at least about 1.75 mm, at least about 1.8 mm, at least about 1.85 mm, at least about 1.9 mm, at least about 1.95 mm, at least about 2 mm, at least about 2.05 mm, at least about 2.1 mm, at least about 2.15 mm, at least about 2.2 mm, at least about 2.25 mm, or at least about 2.3. In some embodiments, a diameter of the internal structure of the ophthalmic device may be at least about 0.1 mm. In some embodiments, a diameter of the internal structure of the ophthalmic device may be at least about 0.5 mm.

[0244] In some embodiments, a diameter of the internal structure of the ophthalmic device may be at most about 0.1 mm, at most about 0.2 mm, at most about 0.25 mm, at most about 0.3 mm, at most about 0.35 mm, at most about 0.4 mm, at most about 0.45 mm, at most about 0.5 mm, at most about 0.55 mm, at most about 0.6 mm, at most about 0.65 mm, at most about 0.7 mm, at most about 0.75 mm, at most about 0.8 mm, at most about 0.85 mm, at most about 0.9 mm, at most about 0.95 mm, at most about 1 mm, at most about 1.05 mm, at most about 1.1 mm, at most about 1.15 mm, at most about 1.2 mm, at most about 1.25 mm, at most about 1.3 mm, at most about 1.35 mm, at most about 1.4 mm, at most about 1.45 mm, at most about 1.5 mm, at most about 1.55 mm, at most about 1.6 mm, at most about 1.65 mm, at most about 1.7 mm, at most about 1.75 mm, at most about 1.8 mm, at most about 1.85 mm, at most about 1.9 mm, at most about 1.95 mm, at most about 2 mm, at most about 2.05 mm, at most about 2.1 mm, at most about 2.15 mm, at most about 2.2 mm, at most about 2.25 mm, or at most about 2.3. In some embodiments, a diameter of the internal structure of the ophthalmic device may be at most about 0.5 mm. In some embodiments, a diameter of the internal structure of the ophthalmic device may be at most about 1 mm. In some embodiments, a diameter of the internal structure of the ophthalmic device may be at most about 1.5 mm.

[0245] In some embodiments, a diameter of the internal structure of the ophthalmic device maybe about 0.1 mm, about 0.2 mm, about 0.25 mm, about 0.3 mm, about 0.35 mm, about 0.4 mm, about 0.45 mm, about 0.5 mm, about 0.55 mm, about 0.6 mm, about 0.65 mm, about 0.7 mm, about 0.75 mm, about 0.8 mm, about 0.85 mm, about 0.9 mm, about 0.95 mm, about 1mm, about 1.05 mm, about 1.1 mm, about 1.15 mm, about 1.2 mm, about 1.25 mm, about 1.3 mm, about 1.35 mm, about 1.4 mm, about 1.45 mm, about 1.5 mm, about 1.55 mm, about 1.6 mm, about 1.65 mm, about 1.7 mm, about 1.75 mm, about 1.8 mm, about 1.85 mm, about 1.9 mm, about 1.95 mm, about 2 mm, about 2.05 mm, about 2.1mm, about 2.15 mm, about 2.2 mm, about 2.25 mm, or about 2.3. In some embodiments, a diameter of the internal structure of the ophthalmic device may be about 0.5 mm.

[0246] Fig. 1A and Fig. IB schematically illustrate examples of various shaped ophthalmic articles (e.g., active agent and / or diagnostic agent delivery devices) 100. The ophthalmic article 100 may comprise an internal structure (e.g., a hole) 110. In some figures, the ophthalmic article 100 may be an annulus (e.g., extruded annulus) shaped ophthalmic article 101 and / or a toroid shaped ophthalmic article 106. Fig. 1A illustrates a perspective view of an annulus (e.g., extruded annulus) shaped ophthalmic article 101. Fig. IB illustrates a perspective view of a toroid shaped ophthalmic article 106. In some figures, the internal structure (e.g., a hole) 110 may be a circular hole 120 of the annulus (e.g., extruded annulus) shaped ophthalmic article 101. In some figures, the internal structure (e.g., a hole) 110 may be a circular hole 130 of the toroid shaped ophthalmic article 106.

[0247] Fig. 2A, Fig. 2B, Fig. 2C, Fig. 2D, Fig. 2E, Fig. 2F, Fig. 2G, and Fig. 2H schematically illustrate other views (e.g., plan view, cross-sectional view) of examples of various shaped ophthalmic articles (e.g., active agent and / or diagnostic agent delivery devices) 100. The ophthalmic article 100 may comprise an internal structure (e.g., hole) 110 with an inner diameter or side edge 240. The ophthalmic article 100 may also comprise an outer diameter or outer edge 230, cross-sectional thickness 250, and / or a wall thickness 260.

[0248] Fig. 2A illustrates a plan view of an annulus (e.g., extruded annulus) shaped ophthalmic article 101. Fig. 2B illustrates a cross-sectional view of the annulus shaped ophthalmic article 101. The annulus shaped ophthalmic article 101 comprises an internal structure 110 which is a circular hole 120. The internal structure 110 comprises an inner diameter or side edge 240. The inner diameter or side edge 240 may be inner diameter 204. The annulus shaped ophthalmic article 101 may also comprise an outer diameter or outer edge 230, a crosssectional thickness 250, and / or a wall thickness 260. The outer diameter or outer edge 230 may be outer diameter 203. The cross-sectional thickness 250 may be cross-sectional thickness 205. The wall thickness 260 may be wall thickness 216.

[0249] Fig. 2C illustrates a plan view of a toroid shaped ophthalmic article 106. Fig. 2D illustrates a cross-sectional view of the toroid shaped ophthalmic article 106. The toroid shaped ophthalmic article 106 comprises an internal structure 110 which is a circular hole 130. The internal structure 110 comprises an inner diameter or side edge 240. The inner diameter or side edge 240 may be inner diameter 209. The toroid shaped ophthalmic article 106 may also comprise an outer diameter or outer edge 230, a cross-sectional thickness 250, and / or a wall thickness 260. The outer diameter or outer edge 230 may be outer diameter 208. The crosssectional thickness 250 may be cross-sectional thickness 210. The wall thickness 260 may be wall thickness 217.

[0250] In some figures, the ophthalmic article 100 may be a square shaped (e.g., extruded square shaped) ophthalmic article 211. Fig. 2E illustrates a plan view of a square shaped (e.g., extruded square shaped) ophthalmic article 211. Fig. 2F illustrates a cross-sectional view of a square shaped (e.g., extruded square shaped) ophthalmic article 211. The square shaped (e.g., extruded square shaped) ophthalmic article 211 may comprise an internal structure (e.g., a hole) 110 that can be a square hole 255. The internal structure 110 comprises an inner diameter or side edge 240. The inner diameter or side edge 240 may be side edge 214. The square shaped ophthalmic article 211 may also comprise an outer diameter or outer edge 230, cross-sectional thickness 250, and / or a wall thickness 260. The outer diameter or outer edge 230 may be outer edge 213. The cross-sectional thickness 250 may be cross-sectional thickness 215. The wall thickness 260 may be wall thickness 218.

[0251] In some figures, the ophthalmic article 100 may be an octagon shaped ophthalmic article 270. Fig. 2G illustrates a plan view of an octagon shaped ophthalmic article 270. Fig. 2H illustrates a cross-sectional view of an octagon shaped ophthalmic article 270. The octagon shaped ophthalmic article 270 may comprise an internal structure (e.g., a hole) 110 that can be an octagon shaped hole 272. The internal structure 110 comprises an inner diameter or side edge 240. The inner diameter or side edge 240 may be an inner diameter 274. The octagon shaped ophthalmic article 270 may also comprise an outer diameter or outer edge 230, cross-sectional thickness 250, and / or a wall thickness 260. The outer diameter or outer edge 230 may be outer edge 276. The cross-sectional thickness 250 may be cross-sectional thickness 278. The wall thickness 260 may be wall thickness 280.

[0252] In some embodiments, the inner diameter 240 (e.g., inner diameter 204, inner diameter 209, inner diameter 274) or an inner side length 240 (e.g., inner diameter 214) may be from about 0.05 millimeters (mm) to 6 mm.

[0253] In some embodiments, the inner diameter 240 or an inner side length 240 may be from about 0.05 mm to 6 mm. In some embodiments, the inner diameter 240 or an inner side length 240 may be about 0.05 mm to about 0.5 mm, about 0.05 mm to about 0.1 mm, about 0.05 mm to about 1.5 mm, about 0.05 mm to about 2 mm, about 0.05 mm to about 2.5 mm, about 0.05 mm to about 3 mm, about 0.05 mm to about 3.5 mm, about 0.05 mm to about 4 mm, about 0.05 mm to about 4.5 mm, about 0.05 mm to about 5 mm, about 0.05 mm to about 5.5 mm, about 0.05 mm to about 6 mm, about 0.5 mm to about 0.1 mm, about 0.5 mm to about 1.5 mm, about 0.5 mm to about 2 mm, about 0.5 mm to about 2.5 mm, about 0.5 mm to about 3 mm, about 0.5 mm to about 3.5 mm, about 0.5 mm to about 4 mm, about 0.5 mm to about 4.5 mm, about 0.5 mm to about 5 mm, about 0.5 mm to about 5.5 mm, about 0.5 mm to about 6 mm, about 0.1 mm to about 1.5 mm, about 0.1 mm to about 2 mm, about 0.1 mm to about 2.5 mm, about 0.1 mm to about 3 mm, about 0.1 mm to about 3.5 mm, about 0.1 mm to about 4 mm, about 0.1 mm to about 4.5 mm, about 0.1 mm to about 5 mm, about 0.1 mm to about 5.5 mm, about 1 mm to about 6 mm, about 1.5 mm to about 2 mm, about 1.5 mm to about 2.5 mm, about 1.5 mm to about 3 mm, about 1.5 mm to about 3.5 mm, about 1.5 mm to about 4 mm, about 1.5 mm to about 4.5 mm, about 1.5 mm to about 5 mm, about 1.5 mm to about 5.5 mm, about 1.5 mm to about 6 mm, about 2 mm to about 2.5 mm, about 2 mm to about 3 mm, about 2 mm to about 3.5 mm, about 2 mm to about 4 mm, about 2 mm to about 4.5 mm, about 2 mm to about 5 mm, about 2 mm to about 5.5 mm, about 2 mm to about 6 mm, about 2.5 mm to about 3 mm, about 2.5 mm to about 3.5 mm, about 2.5 mm to about 4 mm, about 2.5 mm to about 4.5 mm, about 2.5 mm to about 5 mm, about 2.5 mm to about 5.5 mm, about 2.5 mm to about 6 mm, about 3 mm to about 3.5 mm, about 3 mm to about 4 mm, about 3 mm to about 4.5 mm, about 3 mm to about 5 mm, about 3 mm to about 5.5 mm, about 3 mm to about 6 mm, about 3.5 mm to about 4 mm, about 3.5 mm to about 4.5 mm, about 3.5 mm to about 5 mm, about 3.5 mm to about 5.5 mm, about 3.5 mm to about 6 mm, about 4 mm to about 4.5 mm, about 4 mm to about 5 mm, about 4 mm to about 5.5 mm, about 4.5 mm to about 5 mm, about 4.5 mm to about 5.5 mm, about 4.5 mm to about 6 mm, about 5 mm to about 5.5 mm, about 5 mm to about 6 mm, or about 5.5 mm to about 6 mm.

[0254] In some embodiments, the inner diameter 240 or an inner side length 240 of the ophthalmic device may be at least about 0.05 mm, at least about 0.1 mm, at least about 0.15 mm, at least about 0.2 mm, at least about 0.25 mm, at least about 0.3 mm, at least about 0.35 mm, at least about 0.4 mm, at least about 0.45 mm, at least about 0.5 mm, at least about 0.55 mm, at least about 0.6 mm, at least about 0.65 mm, at least about 0.7 mm, at least about 0.75 mm, at least about 0.8 mm, at least about 0.85 mm, at least about 0.9 mm, at least about 0.95 mm, at least about 1 mm, at least about 1.05 mm, at least about 1.1 mm, at least about 1.15 mm, at least about 1.2 mm, at least about 1.25 mm, at least about 1.3 mm, at least about 1.35 mm, at least about 1.4 mm, at least about 1.45 mm, at least about 1.5 mm, at least about 1.55 mm, at least about 1.6 mm, at least about 1.65 mm, at least about 1.7 mm, at least about 1.75 mm, at least about 1.8 mm, at least about 1.85 mm, at least about 1.9 mm, at least about 1.95 mm, at least about 2 mm, at least about 2.05 mm, at least about 2.1 mm, at least about 2.15 mm, at least about 2.2 mm, at least about 2.25 mm, at least about 2.3 mm, at least about 2.4 mm, at least about 2.5 mm, at least about 2.6 mm, at least about 2.7 mm, at least about 2.8 mm, at least about 2.9 mm, at least about 3 mm, at least about 3.5 mm, at least about 4 mm, at least about 4.5 mm, at least about 5 mm, at least about 5.5 mm, or at least about 6 mm. In some embodiments, the inner diameter 240 or an inner side length 240 of the ophthalmic device may be at least about 0.1 mm. In some embodiments, the inner diameter 240 or an inner side length 240 of the ophthalmic device may be at least about 0.5 mm.

[0255] In some embodiments, the inner diameter 240 or an inner side length 240 of the ophthalmic device may be at most about 0.05 mm, at most about 0.1 mm, at most about 0.15 mm, at most about 0.2 mm, at most about 0.25 mm, at most about 0.3 mm, at most about 0.35 mm, at most about 0.4 mm, at most about 0.45 mm, at most about 0.5 mm, at most about 0.55 mm, at most about 0.6 mm, at most about 0.65 mm, at most about 0.7 mm, at most about 0.75 mm, at most about 0.8 mm, at most about 0.85 mm, at most about 0.9 mm, at most about 0.95 mm, at most about 1 mm, at most about 1.05 mm, at most about 1.1 mm, at most about 1.15 mm, at most about 1.2 mm, at most about 1.25 mm, at most about 1.3 mm, at most about 1.35 mm, at most about 1.4 mm, at most about 1.45 mm, at most about 1.5 mm, at most about 1.55 mm, at most about 1.6 mm, at most about 1.65 mm, at most about 1.7 mm, at most about 1.75 mm, at most about 1.8 mm, at most about 1.85 mm, at most about 1.9 mm, at most about 1.95 mm, at most about 2 mm, at most about 2.05 mm, at most about 2.1 mm, at most about 2.15 mm, at most about 2.2 mm, at most about 2.25 mm, at most about 2.3 mm, at most about 2.4 mm, at most about 2.5 mm, at most about 2.6 mm, at most about 2.7 mm, at most about 2.8 mm, at most about 2.9 mm, at most about 3 mm, at most about 3.5 mm, at most about 4 mm, at most about 4.5 mm, at most about 5 mm, at most about 5.5 mm, or at most about 6 mm. In some embodiments, the inner diameter 240 or an inner side length 240 of the ophthalmic device may be at most about 0.5 mm. In some embodiments, the inner diameter 240 or an inner side length 240 of the ophthalmic device may be at most about 1 mm. In some embodiments, the inner diameter 240 or an inner side length 240 of the ophthalmic device may be at most about 1.5 mm.

[0256] In some embodiments, the inner diameter 240 or an inner side length 240 of the ophthalmic device may be about 0.05 mm, about 0.1 mm, about 0.15 mm, about 0.2 mm, about 0.25 mm, about 0.3 mm, about 0.35 mm, about 0.4 mm, about 0.45 mm, about 0.5 mm, about 0.55 mm, about 0.6 mm, about 0.65 mm, about 0.7 mm, about 0.75 mm, about 0.8 mm, about 0.85 mm, about 0.9 mm, about 0.95 mm, about 1 mm, about 1.05 mm, about 1.1 mm, about 1.15 mm, about 1.2 mm, about 1.25 mm, about 1.3 mm, about 1.35 mm, about 1.4 mm, about 1.45 mm, about 1.5 mm, about 1.55 mm, about 1.6 mm, about 1.65 mm, about 1.7 mm, about 1.75 mm, about 1.8 mm, about 1.85 mm, about 1.9 mm, about 1.95 mm, about 2 mm, about 2.05 mm, about 2.1 mm, about 2.15 mm, about 2.2 mm, about 2.25 mm, about 2.3 mm, about 2.4 mm, about 2.5 mm, about 2.6 mm, about 2.7 mm, about 2.8 mm, about 2.9 mm, about 3 mm, about 3.1 mm, about 3.2 mm, about 3.3 mm, about 3.4 mm, about 3.5 mm, about 3.6 mm, about 3.7 mm, about 3.8 mm, about 3.9 mm, about 4 mm, about 4.1 mm, about 4.2 mm, about 4.3 mm, about 4.4 mm, about 4.5 mm, about 4.6 mm, about 4.7 mm, about 4.8 mm, about 4.9 mm, about 5 mm, about 5.1 mm, about 5.2 mm, about 5.3 mm, about 5.4 mm, about 5.5 mm, about 5.6 mm, about 5.7 mm, about 5.8 mm, about 5.9 mm, or about 6 mm. In some embodiments, the inner diameter 240 or an inner side length 240 of the ophthalmic device may be about 0.5 mm.

[0257] In some embodiments, a wall thickness 260 (e.g., wall thickness 216, wall thickness 217, wall thickness 218, wall thickness 280) of the ophthalmic article may be from about 0.001 mm to 3 mm. In some embodiments, a wall thickness of the ophthalmic article may be about 0.001 mm to about 0.01 mm, about 0.001 mm to about 0.1 mm, about 0.001 mm to about 0.2 mm, about 0.001 mm to about 0.3 mm, about 0.001 mm to about 0.4 mm, about 0.001 mm to about 0.5 mm, about 0.001 mm to about 1 mm, about 0.001 mm to about 1.5 mm, about 0.001 mm to about 2 mm, about 0.001 mm to about 2.5 mm, about 0.001 mm to about 3 mm, about 0.01 mm to about 0.1 mm, about 0.01 mm to about 0.2 mm, about 0.01 mm to about 0.3 mm, about 0.01 mm to about 0.4 mm, about 0.01 mm to about 0.5 mm, about 0.01 mm to about 1 mm, about 0.01 mm to about 1.5 mm, about 0.01 mm to about 2 mm, about 0.01 mm to about 2.5 mm, about 0.01 mm to about 3 mm, about 0.1 mm to about 0.2 mm, about 0.1 mm to about 0.3 mm, about 0.1 mm to about 0.4 mm, about 0.1 mm to about 0.5 mm, about 0.1 mm to about 1 mm, about 0.1 mm to about 1.5 mm, about 0.1 mm to about 2 mm, about 0.1 mm to about 2.5 mm, about 0.1 mm to about 3 mm, about 0.2 mm to about 0.3 mm, about 0.2 mm to about 0.4 mm, about 0.2 mm to about 0.5 mm, about 0.2 mm to about 1 mm, about 0.2 mm to about 1.5 mm, about 0.2 mm to about 2 mm, about 0.2 mm to about 2.5 mm, about 0.2 mm to about 3 mm, about 0.3 mm to about 0.4 mm, about 0.3 mm to about 0.5 mm, about 0.3 mm to about 1 mm, about 0.3 mm to about 1.5 mm, about 0.3 mm to about 2 mm, about 0.3 mm to about 2.5 mm, about 0.3 mm to about 3 mm, about 0.4 mm to about 0.5 mm, about 0.4 mm to about 1 mm, about 0.4 mm to about 1.5 mm, about 0.4 mm to about 2 mm, about 0.4 mm to about 2.5 mm, about 0.4 mm to about 3 mm, about 0.5 mm to about 1 mm, about 0.5 mm to about 1.5 mm, about 0.5 mm to about 2 mm, about 0.5 mm to about 2.5 mm, about 0.5 mm to about 3 mm, about 1 mm to about 1.5 mm, about 1 mm to about 2 mm, about 1 mm to about 2.5 mm, about 1 mm to about 3 mm, about 1.5 mm to about 2 mm, about 1.5 mm to about 2.5 mm, about 1.5 mm to about 3 mm, about 2 mm to about 2.5 mm, about 2 mm to about 3 mm, or about 2.5 mm to about 3 mm. In some embodiments, a wall thickness of the ophthalmic article may be about 0.1 mm to about 1 mm. In some embodiments, a wall thickness of the ophthalmic article may be about 0.1 mm to about 1.5 mm.

[0258] In some embodiments, a wall thickness of the ophthalmic article may be at least about 0.001 mm, at least about 0.005 mm, at least about 0.01 mm, at least about 0.02 mm, at least about 0.03 mm, at least about 0.04 mm, at least about 0.05 mm, at least about 0.06 mm, at least about 0.07 mm, at least about 0.08 mm, at least about 0.09 mm, at least about 0.1 mm, at least about 0.15 mm, at least about 0.2 mm, at least about 0.25 mm, at least about 0.3 mm, at least about 0.35 mm, at least about 0.4 mm, at least about 0.45 mm, at least about 0.5 mm, at least about 0.55 mm, at least about 0.6 mm, at least about 0.65 mm, at least about 0.7 mm, at least about 0.75 mm, at least about 0.8 mm, at least about 0.85 mm, at least about 0.9 mm, at least about 0.95 mm, at least about 1 mm, at least about 1.2 mm, at least about 1.4 mm, at least about 1.6 mm, at least about 1.8 mm, at least about 2 mm, at least about 2.2 mm, at least about 2.4 mm, at least about 2.6 mm, at least about 2.8 mm, or at least about 3 mm. In some embodiments, a wall thickness of the ophthalmic article may be at least about 0.1 mm. In some embodiments, a wall thickness of the ophthalmic article may be at least about 0.5 mm. In some embodiments, a wall thickness of the ophthalmic article may be at least about 1 mm.

[0259] In some embodiments, a wall thickness of the ophthalmic article may be at most about 0.001 mm, at most about 0.005 mm, at most about 0.01 mm, at most about 0.02 mm, at most about 0.03 mm, at most about 0.04 mm, at most about 0.05 mm, at most about 0.06 mm, at most about 0.07 mm, at most about 0.08 mm, at most about 0.09 mm, at most about 0.1 mm, at most about 0.15 mm, at most about 0.2 mm, at most about 0.25 mm, at most about 0.3 mm, at most about 0.35 mm, at most about 0.4 mm, at most about 0.45 mm, at most about 0.5 mm, at most about 0.55 mm, at most about 0.6 mm, at most about 0.65 mm, at most about 0.7 mm, at most about 0.75 mm, at most about 0.8 mm, at most about 0.85 mm, at most about 0.9 mm, at most about 0.95 mm, at most about 1 mm, at most about 1.2 mm, at most about 1.4 mm, at most about 1.6 mm, at most about 1.8 mm, at most about 2 mm, at most about 2.2 mm, at most about 2.4 mm, at most about 2.6 mm, at most about 2.8 mm, or at most about 3 mm. In some embodiments, a wall thickness of the ophthalmic article may be at most about 0.5 mm. In some embodiments, a wall thickness of the ophthalmic article may be at most about 1 mm. In some embodiments, a wall thickness of the ophthalmic article may be at most about 1.5 mm.

[0260] In some embodiments, a wall thickness of the ophthalmic article may be about 0.001 mm, about 0.005 mm, about 0.01 mm, about 0.02 mm, about 0.03 mm, about 0.04 mm, about 0.05 mm, about 0.06 mm, about 0.07 mm, about 0.08 mm, about 0.09 mm, about 0.1 mm, about 0.11 mm, about 0.12 mm, about 0.13 mm, about 0.14 mm, about 0.15 mm, about 0.16 mm, about 0.17 mm, about 0.18 mm, about 0.19 mm, about 0.2 mm, about 0.21 mm, about 0.22 mm, about 0.23 mm, about 0.24 mm, about 0.25 mm, about 0.26 mm, about 0.27 mm, about 0.28 mm, about 0.29 mm, about 0.3 mm, about 0.31 mm, about 0.32 mm, about 0.33 mm, about 0.34 mm, about 0.35 mm, about 0.36 mm, about 0.37 mm, about 0.38 mm, about 0.39 mm, about 0.4 mm, about 0.41 mm, about 0.42 mm, about 0.43 mm, about 0.44 mm, about 0.45 mm, about 0.46 mm, about 0.47 mm, about 0.48 mm, about 0.49 mm, about 0.5 mm, about 0.51 mm, about 0.52 mm, about 0.53 mm, about 0.54 mm, about 0.55 mm, about 0.56 mm, about 0.57 mm, about 0.58 mm, about 0.59 mm, about 0.6 mm, about 0.61 mm, about 0.62 mm, about 0.63 mm, about 0.64 mm, about 0.65 mm, about 0.66 mm, about 0.67 mm, about 0.68 mm, about 0.69 mm, about 0.7 mm, about 0.71 mm, about 0.72 mm, about 0.73 mm, about 0.74 mm, about 0.75 mm, about 0.76 mm, about 0.77 mm, about 0.78 mm, about 0.79 mm, about 0.8 mm, about 0.81 mm, about 0.82 mm, about 0.83 mm, about 0.84 mm, about 0.85 mm, about 0.86 mm, about 0.87 mm, about 0.88 mm, about 0.89 mm, about 0.9 mm, about 0.91 mm, about 0.92 mm, about 0.93 mm, about 0.94 mm, about 0.95 mm, about 0.96 mm, about 0.97 mm, about 0.98 mm, about 0.99 mm, about 1 mm, about 1.1 mm, about 1.2 mm, about 1.3 mm, about 1.4 mm, about 1.5 mm, about 1.6 mm, about 1.7 mm, about 1.8 mm, about 1.9 mm, about 2 mm, about 2.1 mm, about 2.2 mm, about 2.3 mm, about 2.4 mm, about 2.5 mm, about 2.6 mm, about 2.7 mm, about 2.8 mm, about 2.9 mm, or about 3 mm. In some embodiments, a wall thickness of the ophthalmic article may be about 0.7 mm.

[0261] In some embodiments, the ophthalmic article extends no more than about 0.32 mm beyond a portion of the ocular device (e.g., the haptic of an I0L) once the ophthalmic article is associated (e.g., attached) with the portion of the ocular device (e.g., the haptic of an I0L). In some embodiments, the ophthalmic article extends beyond a portion of the ocular device (e.g., the haptic of an I0L), once the ophthalmic article is associated (e.g., attached) with the portion (e.g., haptic) of the ocular device (e.g., I0L), of at most about 3 mm, 2.9 mm, 2.8 mm, 2.7 mm, 2.6 mm, 2.5 mm, 2.4 mm, 2.3 mm, 2.2 mm, 2.1 mm, 2 mm, 1.9 mm, 1.8 mm, 1.7 mm, 1.6 mm, 1.5 mm, 1.4 mm, 1.3 mm, 1.2 mm, 1.1 mm, 1 mm, 0.9 mm, 0.8 mm, 0.7 mm, 0.6 mm, 0.5 mm, 0.4 mm, 0.3 mm, 0.2 mm, 0.1 mm, or less.

[0262] In some embodiments, the ophthalmic article extends beyond a portion (e.g., haptic) of the ocular device (e.g., I0L), once the ophthalmic article is associated (e.g., attached) with the portion (e.g., haptic) of the ocular device (e.g., IOL), of at least about 0.1 mm, 0.2 mm, 0.3 mm, 0.4 mm, 0.5 mm, 0.6 mm, 0.7 mm, 0.8 mm, 0.9 mm, 1 mm, 1.1 mm, 1.2 mm, 1.3 mm, 1.4 mm, 1.5 mm, 1.6 mm, 1.7 mm, 1.8 mm, 1.9 mm, 2 mm, 2.1 mm, 2.2 mm, 2.3 mm, 2.4 mm, 2.5 mm, 2.6 mm, 2.7 mm, 2.8 mm, 2.9 mm, 3 mm, or more.

[0263] In some embodiments, the ophthalmic article extends beyond a portion (e.g., haptic) of the ocular device (e.g., IOL), once the ophthalmic article is associated (e.g., attached) with the portion (e.g., haptic) of the ocular device (e.g., IOL), of about 0.1 mm, about 0.2 mm, about 0.3 mm, about 0.4 mm, about 0.5 mm, about 0.6 mm, about 0.7 mm, about 0.8 mm, about 0.9 mm, about 1 mm, about 1.1 mm, about 1.2 mm, about 1.3 mm, about 1.4 mm, about 1.5 mm, about 1.6 mm, about 1.7 mm, about 1.8 mm, about 1.9 mm, about 2 mm, about 2.1 mm, about 2.2 mm, about 2.3 mm, about 2.4 mm, about 2.5 mm, about 2.6 mm, about 2.7 mm, about 2.8 mm, about 2.9 mm, or about 3 mm.

[0264] In some embodiments, a cross-sectional thickness 250 (e.g., cross-sectional thickness 205, cross-sectional thickness 210, cross-sectional thickness 215, cross-sectional thickness 278) of the ophthalmic article may be from about 0.05 mm to 3 mm.

[0265] In some embodiments, the cross-sectional thickness of the ophthalmic article may be about 0.01 mm to about 4 mm. In some embodiments, the cross-sectional thickness of the ophthalmic article may be about 0.01 mm to about 0.05 mm, about 0.01 mm to about 0.1 mm, about 0.01 mm to about 0.5 mm, about 0.01 mm to about 1 mm, about 0.01 mm to about 1.5 mm, about 0.01 mm to about 2 mm, about 0.01 mm to about 2.5 mm, about 0.01 mm to about 3 mm, about 0.01 mm to about 3.5 mm, about 0.01 mm to about 4 mm, about 0.05 mm to about 0.1 mm, about 0.05 mm to about 0.5 mm, about 0.05 mm to about 1 mm, about 0.05 mm to about 1.5 mm, about 0.05 mm to about 2 mm, about 0.05 mm to about 2.5 mm, about 0.05 mm to about 3 mm, about 0.05 mm to about 3.5 mm, about 0.05 mm to about 4 mm, about 0.1 mm to about 0.5 mm, about 0.1 mm to about 1 mm, about 0.1 mm to about 1.5 mm, about 0.1 mm to about 2 mm, about 0.1 mm to about 2.5 mm, about 0.1 mm to about 3 mm, about 0.1 mm to about 3.5 mm, about 0.1 mm to about 4 mm, about 0.5 mm to about 1 mm, about 0.5 mm to about 1.5 mm, about 0.5 mm to about 2 mm, about 0.5 mm to about 2.5 mm, about 0.5 mm to about 3 mm, about 0.5 mm to about 3.5 mm, about 0.5 mm to about 4 mm, about 1 mm to about 1.5 mm, about 1 mm to about 2 mm, about 1 mm to about 2.5 mm, about 1 mm to about 3 mm, about 1 mm to about 3.5 mm, about 1 mm to about 4 mm, about 1.5 mm to about 2 mm, about 1.5 mm to about 2.5 mm, about 1.5 mm to about 3 mm, about 1.5 mm to about 3.5 mm, about 1.5 mm to about 4 mm, about 2 mm to about 2.5 mm, about 2 mm to about 3 mm, about 2 mm to about 3.5 mm, about 2 mm to about 4 mm, about 2.5 mm to about 3 mm, about 2.5 mm to about 3.5 mm, about 2.5 mm to about 4 mm, about 3 mm to about 3.5 mm, about 3 mm to about 4 mm, or about 3.5 mm to about 4 mm. In some embodiments, the cross-sectional thickness of the ophthalmic article may be about 0.1 mm to about 1 mm.

[0266] In some embodiments, the cross-sectional thickness of the ophthalmic article may be at least about 0.01 mm, at least about 0.05 mm, at least about 0.1 mm, at least about 0.5 mm, at least about 1 mm, at least about 1.5 mm, at least about 2 mm, at least about 2.5 mm, at least about 3 mm, at least about 3.5 mm, or at least about 4 mm. In some embodiments, the crosssectional thickness of the ophthalmic article may be at least about 0.1 mm. In some embodiments, the cross-sectional thickness of the ophthalmic article may be at least about 0.5 mm.

[0267] In some embodiments, the cross-sectional thickness of the ophthalmic article may be at most about 0.01 mm, at most about 0.05 mm, at most about 0.1 mm, at most about 0.5 mm, at most about 1 mm, at most about 1.5 mm, at most about 2 mm, at most about 2.5 mm, at most about 3 mm, at most about 3.5 mm, or at most about 4 mm. In some embodiments, the cross sectional thickness of the ophthalmic article may be at most about 1 mm. In some embodiments, the cross-sectional thickness of the ophthalmic article may be at most about 1.5 mm.

[0268] In some embodiments, the outer diameter 230 (e.g., outer diameter 203, outer diameter 208, outer diameter 276) or an outer edge 230 (e.g., outer diameter 213) of may be from about 0.1 millimeters (mm) to 6 mm. In some embodiments, the outer diameter or an outer edge of the ophthalmic article may be about 0.1 mm to about 1.5 mm, about 0.1 mm to about 2 mm, about 0.1 mm to about 2.5 mm, about 0.1 mm to about 3 mm, about 0.1 mm to about 3.5 mm, about 0.1 mm to about 4 mm, about 0.1 mm to about 4.5 mm, about 0.1 mm to about 5 mm, about 0.1 mm to about 5.5 mm, about 1 mm to about 6 mm, about 1.5 mm to about 2 mm, about 1.5 mm to about 2.5 mm, about 1.5 mm to about 3 mm, about 1.5 mm to about 3.5 mm, about 1.5 mm to about 4 mm, about 1.5 mm to about 4.5 mm, about 1.5 mm to about 5 mm, about 1.5 mm to about 5.5 mm, about 1.5 mm to about 6 mm, about 2 mm to about 2.5 mm, about 2 mm to about 3 mm, about 2 mm to about 3.5 mm, about 2 mm to about 4 mm, about 2 mm to about 4.5 mm, about 2 mm to about 5 mm, about 2 mm to about 5.5 mm, about 2 mm to about 6 mm, about 2.5 mm to about 3 mm, about 2.5 mm to about 3.5 mm, about 2.5 mm to about 4 mm, about 2.5 mm to about 4.5 mm, about 2.5 mm to about 5 mm, about 2.5 mm to about 5.5 mm, about 2.5 mm to about 6 mm, about 3 mm to about 3.5 mm, about 3 mm to about 4 mm, about 3 mm to about 4.5 mm, about 3 mm to about 5 mm, about 3 mm to about 5.5 mm, about 3 mm to about 6 mm, about 3.5 mm to about 4 mm, about 3.5 mm to about 4.5 mm, about 3.5 mm to about 5 mm, about 3.5 mm to about 5.5 mm, about 3.5 mm to about 6 mm, about 4 mm to about 4.5 mm, about 4 mm to about 5 mm, about 4 mm to about 5.5 mm, about 4.5 mm to about 5 mm, about 4.5 mm to about 5.5 mm, about 4.5 mm to about 6 mm, about 5 mm to about 5.5 mm, about 5 mm to about 6 mm, or about 5.5 mm to about 6 mm. In some embodiments, the outer diameter or an outer edge of the ophthalmic article may be about 0.1 mm to about 1.5 mm. In some embodiments, the outer diameter or an outer edge of the ophthalmic article may be about 0.5 mm to about 1.5 mm. In some embodiments, the outer diameter or an outer edge of the ophthalmic article may be about 0.5 mm to about 2 mm.

[0269] In some embodiments, the outer diameter or an outer edge of the ophthalmic article may be at least about 0.1 mm, at least about 0.15 mm, at least about 0.2 mm, at least about 0.25 mm, at least about 0.3 mm, at least about 0.35 mm, at least about 0.4 mm, at least about 0.45 mm, at least about 0.5 mm, at least about 0.55 mm, at least about 0.6 mm, at least about 0.65 mm, at least about 0.7 mm, at least about 0.75 mm, at least about 0.8 mm, at least about 0.85 mm, at least about 0.9 mm, at least about 0.95 mm, at least about 1 mm, at least about 1.05 mm, at least about 1.1 mm, at least about 1.15 mm, at least about 1.2 mm, at least about 1.25 mm, at least about 1.3 mm, at least about 1.35 mm, at least about 1.4 mm, at least about 1.45 mm, at least about 1.5 mm, at least about 1.55 mm, at least about 1.6 mm, at least about 1.65 mm, at least about 1.7 mm, at least about 1.75 mm, at least about 1.8 mm, at least about 1.85 mm, at least about 1.9 mm, at least about 1.95 mm, at least about 2 mm, at least about 2.05 mm, at least about 2.1 mm, at least about 2.15 mm, at least about 2.2 mm, at least about 2.25 mm, at least about 2.3 mm, at least about 2.4 mm, at least about 2.5 mm, at least about 2.6 mm, at least about 2.7 mm, at least about 2.8 mm, at least about 2.9 mm, at least about 3 mm, at least about 3.5 mm, at least about 4 mm, at least about 4.5 mm, at least about 5 mm, at least about 5.5 mm, or at least about 6 mm. In some embodiments, the outer diameter or an outer edge of the ophthalmic article may be at least about 0.5 mm. In some embodiments, the outer diameter or an outer edge of the ophthalmic article may be at least about 1 mm. In some embodiments, the outer diameter or an outer edge of the ophthalmic article may be at least about 1.5 mm.

[0270] In some embodiments, the outer diameter or an outer edge of the ophthalmic article may be at most about 0.1 mm, at most about 0.15 mm, at most about 0.2 mm, at most about 0.25 mm, at most about 0.3 mm, at most about 0.35 mm, at most about 0.4 mm, at most about 0.45 mm, at most about 0.5 mm, at most about 0.55 mm, at most about 0.6 mm, at most about 0.65 mm, at most about 0.7 mm, at most about 0.75 mm, at most about 0.8 mm, at most about 0.85 mm, at most about 0.9 mm, at most about 0.95 mm, at most about 1 mm, at most about 1.05 mm, at most about 1.1 mm, at most about 1.15 mm, at most about 1.2 mm, at most about 1.25 mm, at most about 1.3 mm, at most about 1.35 mm, at most about 1.4 mm, at most about 1.45 mm, at most about 1.5 mm, at most about 1.55 mm, at most about 1.6 mm, at most about 1.65 mm, at most about 1.7 mm, at most about 1.75 mm, at most about 1.8 mm, at most about 1.85 mm, at most about 1.9 mm, at most about 1.95 mm, at most about 2 mm, at most about 2.05 mm, at most about 2.1 mm, at most about 2.15 mm, at most about 2.2 mm, at most about 2.25 mm, at most about 2.3 mm, at most about 2.4 mm, at most about 2.5 mm, at most about 2.6 mm, at most about 2.7 mm, at most about 2.8 mm, at most about 2.9 mm, at most about 3 mm, at most about 3.5 mm, at most about 4 mm, at most about 4.5 mm, at most about 5 mm, at most about 5.5 mm, or at most about 6 mm. In some embodiments, the outer diameter or an outer edge of the ophthalmic article may be at most about 2 mm. In some embodiments, the outer diameter or an outer edge of the ophthalmic article may be at most about 1 mm.

[0271] In some embodiments, the outer diameter or an outer edge of the ophthalmic article may be about 0.1 mm, about 0.15 mm, about 0.2 mm, about 0.25 mm, about 0.3 mm, about 0.35 mm, about 0.4 mm, about 0.45 mm, about 0.5 mm, about 0.55 mm, about 0.6 mm, about 0.65 mm, about 0.7 mm, about 0.75 mm, about 0.8 mm, about 0.85 mm, about 0.9 mm, about 0.95 mm, about 1 mm, about 1.05 mm, about 1.1 mm, about 1.15 mm, about 1.2 mm, about 1.25 mm, about 1.3 mm, about 1.35 mm, about 1.4 mm, about 1.45 mm, about 1.5 mm, about 1.55 mm, about 1.6 mm, about 1.65 mm, about 1.7 mm, about 1.75 mm, about 1.8 mm, about 1.85 mm, about 1.9 mm, about 1.95 mm, about 2 mm, about 2.05 mm, about 2.1 mm, about 2.15 mm, about 2.2 mm, about 2.25 mm, about 2.3 mm, about 2.4 mm, about 2.5 mm, about 2.6 mm, about 2.7 mm, about 2.8 mm, about 2.9 mm, about 3 mm, about 3.1 mm, about 3.2 mm, about 3.3 mm, about 3.4 mm, about 3.5 mm, about 3.6 mm, about 3.7 mm, about 3.8 mm, about 3.9 mm, about 4 mm, about 4.1 mm, about 4.2 mm, about 4.3 mm, about 4.4 mm, about 4.5 mm, about 4.6 mm, about 4.7 mm, about 4.8 mm, about 4.9 mm, about 5 mm, about 5.1 mm, about 5.2 mm, about 5.3 mm, about 5.4 mm, about 5.5 mm, about 5.6 mm, about 5.7 mm, about 5.8 mm, about 5.9 mm, or about 6 mm. In some embodiments, the outer diameter or an outer edge of the ophthalmic article may be about 1.5 mm. In some embodiments, the outer diameter or an outer edge of the ophthalmic article may be about 1.3 mm.

[0272] In some embodiments, the shape of the ophthalmic article can also affect the active agent and / or diagnostic agent release rate for the homogenous delivery device. For example, in some cases, a thinner homogenous delivery device can biodegrade more quickly than a thicker homogenous delivery device, resulting in a faster active agent and / or diagnostic agent release profile. Additionally, in some examples, the perimeter edges or other sections of the ophthalmic article can be made thinner and / or rougher than other parts of the ophthalmic article to provide an initial burst of active agent and / or diagnostic agent followed by a near zero order release profile. Further, in some examples, the overall geometrical shape alone of the homogenous delivery device can affect the release rate of the active agent and / or diagnostic agent. For example, exposed surface area to volume ratio can be increased to increase release rate and degradation.

[0273] In one example, efficacy can be provided for treatment of uveitis and post-operative cataract surgery inflammation. For example, dexamethasone can be dispersed within a biodegradable polymeric matrix. Although dexamethasone dosage amounts can vary, generally from about 100 pg to about 1000 pg can be effective. In some cases, a subject may be categorized as low risk while another subject can be categorized as high risk due to various factors such as age, secondary complications, pre-existing conditions. A low risk patient can benefit from a low dosage of about 100 pg to about 500 pg. In contrast, a high risk individual can be administered a high dosage of about 500 pg to about 1000 pg. The ophthalmic articles can be specifically designed and tested for the various conditions and treatments (e.g., treatment of postoperative surgery inflammation) disclosed herein, and can deliver an active agent (e.g., pharmaceutical active agent) up to or about 2 weeks or more. In other examples, other ophthalmic articles (e.g., biodegradable active agent delivery devices) can be designed and tested for the treatment of postoperative surgery inflammation and uveitis and can deliver active agent up to or about 4 weeks or more. In some examples, depending on the severity of the condition (e.g., inflammation), one, two, more implants (e.g., ophthalmic article and / or ocular device) can be administered per eye during surgery.

[0274] In some embodiments, each eye may...

Claims

1. An ophthalmic delivery system, comprising:(i) an ophthalmic article, comprising:a. a biocompatible matrix comprising poly(lactide-co-caprolactone); andb. an active agent or a diagnostic agent; and(ii) an intraocular lens (IOL) comprising a haptic,wherein said ophthalmic article comprises an internal structure configured to associate to said haptic of said IOL, and wherein a perimeter or widest dimension of said internal structure is less than a perimeter or widest dimension of said haptic of said IOL,wherein said ophthalmic delivery system is formed by (x) stretching said ophthalmic article beyond a largest cross-sectional perimeter of said haptic, (y) positioning said ophthalmic article at a region on said haptic, and (z) securing said ophthalmic article to said region by compressively associating said ophthalmic article to said region such that said ophthalmic article encloses contiguously around an outer surface of said haptic at said region.

2. The ophthalmic delivery system of claim 1, wherein said poly(lactide-co-caprolactone) comprises about 20 wt% to about 60 wt% of caprolactone monomer and from about 40 wt% to 80 wt% of lactide monomer.

3. The ophthalmic delivery system according to claim 1 or 2, wherein said poly(lactide-co-caprolactone) comprises about 40 wt% of caprolactone monomer and about 60 wt% of lactide monomer.

4. The ophthalmic delivery system of claim 1, wherein said poly(lactide-co-caprolactone comprises a random copolymer.

5. The ophthalmic delivery system of claim 1, wherein said active agent is dexamethasone, ketorolac, diclofenac, moxifloxacin, travoprost, 5-fluorouracil, or methotrexate.2020302924   16 Sep 20266. The ophthalmic delivery system according to claim 1 or 2, wherein said ophthalmic article has a glass transition temperature of at most about 24°C as measured by differential scanning calorimetry.

7. The ophthalmic delivery system according to claim 1 or 2, wherein said ophthalmic article has an elasticity modulus of at most about 3 MPa.

8. The ophthalmic delivery system according to claim 1 or 2, wherein said ophthalmic article has an elongation at break of at least about 100% as measured by tensile testing.

9. The ophthalmic delivery system according to claim 1 or 2, wherein the region of the haptic comprises a notch, valley, indent, groove, narrowing, or protrusion for securing the ophthalmic article to the region.

10. The ophthalmic delivery system according to claim 1 or 2, wherein said ophthalmic article is toroid shaped.

Images